Design, Synthesis and Evaluation of Iron(III) Selective Ligands for Biostatic Application by Hunter, Michael
Citation:  Hunter,  Michael  (2013)  Design,  Synthesis  and  Evaluation  of  Iron(III)  Selective 
Ligands for Biostatic Application. Doctoral thesis, University of Northumbria. 
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/21428/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to 
access the University’s research output. Copyright © and moral rights for items on NRL are 
retained by the individual author(s) and/or other copyright owners.  Single copies of full items 
can be reproduced,  displayed or  performed,  and given to third  parties  in  any format  or 
medium for personal research or study, educational, or not-for-profit purposes without prior 
permission or charge, provided the authors, title and full bibliographic details are given, as 
well  as a hyperlink and/or URL to the original metadata page. The content  must not be 
changed in any way. Full items must not be sold commercially in any format or medium 
without  formal  permission  of  the  copyright  holder.   The  full  policy  is  available  online: 
http://nrl.northumbria.ac.uk/policies.html
  
Design, Synthesis and Evaluation of 
Iron(III) Selective Ligands for Biostatic 
Application 
 
 
Michael Hunter 
 
PhD  
 
 
 
2013 
 
 
 
 
 
 
 
 
Design, Synthesis and Evaluation of Iron(III) 
Selective Ligands for Biostatic Application 
 
 
 
Michael Hunter MChem (Hons in Chemistry) 
 
 
 
 
A thesis submitted in partial fulfilment 
of the requirements of Northumbria 
University for the degree of 
Doctor of Philosophy 
 
 
Research undertaken in the 
Faculty of Health and Life Sciences 
 
 
September 2013 
i 
 
Abstract 
Bacterial pathogens, such as MRSA (methicillin-resistant Staphylococcus aureus) and VRE 
(vancomycin-resistant Enterococcus) give rise to nosocomial infections, especially to the 
immunodeficient.  Disinfection of a surface is rarely 100% effective; microbes are almost always 
present on a surface, just in significantly reduced numbers.  After disinfection, microbial 
repopulation to potentially dangerous levels on surfaces can be rapid if a nutrient source is made 
available e.g. soil or blood. With the exception of some lactic acid bacteria iron is ubiquitous 
among microbes as being necessary for growth and development within an environment.  The 
implementation of a chelating agent, to restrict nutrient iron availability has been shown to reduce 
the rate of microbial repopulation post-disinfection.     
The synthesis and characterisation of novel Fe(III) chelators is presented.  Novel hexadentate 
chelators have been successfully synthesised utilising the previously assessed 1,3,5-
tris(aminomethyl)-2,4,6-triethylbenzene core molecular scaffold; the 3,2-HOPO, 1,2-HOPO and 
3,4-HOPO binding moieties have been explored in these ligands.  In addition, two novel 
cyclotriguaiacylene (CTG) and two novel tris(piperazin-1-yl)-1,3,5-triazine based chelators have 
been produced; the 3,2-HOPO and 1,2-HOPO moieties have been explored for these cores.  
Furthermore, two novel tris(2-aminoethyl)amine (TREN) based chelators have been synthesised, 
which provide structural variation of literature compounds previously accessed.  For comparison, 
literature compounds: EMECAM (pFe(III) = 32.6), CP130 (pFe(III) = 27.6) and TRENCAM 
(pFe(III) = 27.8) have been synthesised.   
The MIC data shows three principal ligand candidates that display an inhibitory effect across the 
panel of microbes.  The CTG-1,2-HOPO molecule, the TEB-1,2-HOPO molecule and TEB-R-3,2-
HOPO molecule all inhibit growth at relatively low concentrations i.e. <500µM, with the exception 
of TEB-R-3,2-HOPO on K. pneumoniae which showed an MIC of 964µM.  The kinetic assays 
performed have shown some of the ligands induce a desirable ‘lag time’ in the growth of organisms 
with respect to a control sample.     
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Aims 
The research presented here aims to expand the current hydroxypyridinone-based (HOPO) chelator 
technology with the thought to target Fe3+ binding.     
This work will be focussed upon the design and synthesis of novel ligands that create restriction of 
nutrient Fe3+ in microbial systems, at low concentrations.   
The ligands will be based upon new and previous core scaffolds and have incorporated a variety of 
HOPO moieties so as to provide a comparative study of the effect of these novel compounds on 
microbial systems.  In addition, some literature based ligands will be synthesised so as to provide a 
basis for comparison of the efficacy of microbial growth inhibition of literature Fe3+ chelators with 
respect to the novel compounds.       
The response of microbes which have current clinical relevance to these ligands will be assessed 
through microbiological MIC assays.  In addition, an analysis of the growth profiles of these 
microbes will be provided, as a preliminary assessment of the longevity of any bacteriostatic effect 
produced.   
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1 Introduction 
1.1 The Atmosphere, Early Life and Iron Availability  
 
The composition of Earth’s surface before 4 billion years ago is thought to have been dominated 
primarily by reductive species.  The especially high concentrations of H2(g) and its compounds H2O 
and H2S were greatly significant and are thought to have controlled the chemical composition of 
the atmosphere and the planetary surface, particularly metallic species.  Those metals whose sulfide 
compounds are largely insoluble, such as: Zn, Cu and Mo were scarcely available, especially 
within aqueous environments.  By contrast elements such as: Na, K, Mg, Ca, Cl, P, S, C, H, N, O, 
Fe, Mn, V and W however, were readily available.  The surface layers of the Earth were subject to 
thermal irradiation from the Earth’s core and, in addition without an ozone layer (which developed 
sometime later), the surface was also subject to irradiation from the sun, both thermal and 
photonic.1      
When exposed to high levels of this radiation liquid H2O was subjected to photolysis, liberating 
molecular oxygen.  In the still largely reductant-laden atmosphere the oxygen was highly reactive.  
As the oxygen generating process continued, over a period of around 4 billion years, the land, air 
and sea became deposited with oxidised species.2  By this stage it is thought the atmosphere had 
altered dramatically and was now mostly comprised of N2(g), CO2(g) and O2(g).   
With the elements available to early life, it is thought that C, H, N, O and S as well as, in small part 
P, were essential components of the earliest organic life.  When primitive biosystems were 
developing, some 4 billion years ago, trace elements became important in various bioprocesses.  
Na, K, Cl, Fe, Ni and Cu were thought to be important in these bioprocesses due to their 
incorporation into essential biosynthetic pathways in life today.  In addition, there are several 
biological pathways thought to be conserved throughout evolution, the vast majority of these 
containing a necessary Fe component to undoubtedly facilitate redox processes.  Fe is also an 
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element thought to be conserved within organisms leading back to primitive anaerobic 
prokaryotes.3   
Throughout the evolution of an oxidising atmosphere, it is thought chelating agents became 
necessary for metal solubilisation and the acquisition of nutrients.   Accessible forms of: Mg, Fe, 
Co and Ni were available in such low abundance that those organisms that evolved primitive 
chelating systems would gain an advantage.  Elaboration on these early systems is thought to have 
developed the complex systems now present in eukaryotic life, e.g. haem, ferritin, cobalamin.1,3   
Microbes, plants and fungi have over time developed sophisticated Fe3+ regulatory systems to cope 
with the ever increasing O2(g) concentrations that limit Fe
3+ availability.  The release of molecules 
called siderophores (from the Greek meaning ‘iron carrier’) promotes solubilisation, uptake and the 
regulation of Fe3+ within these organisms.4     
Within a biological system Fe2+ can react via the Fenton mechanism (initiation step shown below) 
to produce reactive oxygen species and so the biological Fe3+ concentration is kept at a constant 
level through regulatory proteins (homeostasis) such as ferritin, to avoid the potential damaging 
effects of such species within biological systems.5   
 
Fe2+ +  H2O2    Fe
3+ + HO- + HO. 
 
1.1.1 The Roles of Iron in the Bacterial Cell 
 
Iron has several vital roles within bacterial cells.  The metal is involved in metabolic and enzymatic 
processes which are required for cell proliferation.  A summary of bacterial cell iron requirements 
is given in Table 1.1.6   
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Table 1.1 Summary of the role of iron within bacterial cells.  Reproduced from: Biochemical 
Education, 1983, 11, 2, 54-63 
Affected Area Effects 
Cell composition 
Iron deficiency can cause: growth inhibition, decrease in 
RNA and DNA production, inhibition of sporulation, 
morphological alteration to cells 
Intermediary metabolism 
Processes requiring iron: tricarboxylic acid cycle, electron 
transport, oxidative phosphorylation, nitrogen fixation and 
aromatic biosynthesis. 
Metabolic products 
Products regulated by iron: porphyrins, toxins, vitamins, 
antibiotics, hydroxamates, cytochromes, pigments, 
siderophores, aromatic compounds, DNA and RNA 
Proteins and enzymes requiring 
iron 
Enzymes: Peroxidase, superoxide dismutase, nitrogenase, 
hydrogenase, glutamate synthase.  Proteins: Cytochromes, 
ferridoxins, flavoproteins, ferritin. 
 
Table 1.1 highlights the integral part iron plays within the processes required for bacterial cell 
proliferation and, those effects an iron deficiency would impart upon the cell.  It is shown that a 
deficiency of iron would prevent the cells from functioning normally; a consequence of the 
detrimental impact such a deficiency would impose upon the enzymatic and protein-based 
processes.   
 
1.1.2 Iron Bioavailability 
 
The increase in oxidation state of metal centres such as iron from Fe(II) to Fe3+ generates a metal 
centre of higher Lewis acidity, due to increased electrophilicity.  Fe3+ has an equilibrium 
concentration in water of  around 10-18M  at pH 7, which even by diffusional processes is too low 
to sustain life at a microbial level.7   
The insolubility of Fe3+ stems from the hard Lewis-acidic metal centre withdrawing electron 
density from solvating water molecules, causing the dissociation of protons from these complexes.8  
This generates insoluble Fe(OH)3 or polymeric species, the process is shown in Figure 1.1.
9 
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Figure 1.1 Equations describing the dissociation of protons from solvated Fe3+ and the associated 
pKa values. 
 
Siderophores are defined as low molecular weight chelating agents which have a very high specific 
affinity for Fe3+.  Their function is to mediate Fe3+ transport to cells.   Approximately 500 known 
compounds fall under this definition of siderophore.4   
The selectivity for ferric iron and the binding potency that these molecules display is dependent on 
a number of contributing factors.  Firstly, the denticity of the ligand and the binding moiety have a 
large impact on the strength of chelation and on the metal selectivity.  In addition, the arrangement 
of the binding moieties; attached to or included within a core backbone, impacts the selectivity of 
such ligands.4  The factors effecting siderophore binding affinity will be addressed later within this 
chapter. 
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1.2 Siderophore Discovery 
 
By the mid-1960s a range of molecules had been discovered and determined through 
experimentation to be important growth factors for microorganisms.  These molecules were found 
to contain hydroxamic acid groups when the molecular structures were elucidated.   
   
Figure 1.2 Molecular structures of ferrichrome (left) and of ferrichrome A (right) 
This work began in 1952 where Neilands isolated an ‘Organo-iron Pigment’ from a rust fungus 
Ustilago sphaerogena and named the compound ‘ferrichrome’, Figure 1.2.10  After further work in 
the area, a key observation was made in 1955 by Garibaldi and Neilands.  It was shown that 
ferrichrome A production (Figure 1.2) by Ustilago sphaerogena was increased when the microbe 
was subject to iron limitation.11  This led to the eventual eludication of the structure of ferrichrome 
and ferrichrome A, which were published in 1961 by Emery and Neilands.12   
Around the same time in 1954, Snow et al., knowing the empirical formula of mycobactin, 
attempted to elucidate the structure through assessing the properties of products after performing 
degradation reactions, such as hydrolysis.13  In addition, in 1954 Snow performed a set of 
experiments to define the coordinative groups of mycobactin, and did so correctly as the 
hydroxamic acid moiety.  For mycobactin it was found that the addition of ferric chloride to 
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ethanolic solutions of the 'mycobactin acid' produced changes in the UV absorbance spectra which 
were consistent with Fe binding.14   
It was in the late 1950s when catecholate-type moieties were beginning to be characterised and 
recognised as important structures in the regulation of iron in microbes.  In 1958, Neilands and Ito 
isolated glycine and 2,3-dihydroxybenoic acid from an extract of Bacillus subtilis cultured under 
iron limiting conditions.  These two products were the result of the hydrolysis of the parent 
compound, 2,3-dihydroxybenzoylglycine.  Therefore, showing that under iron limitation Bacillus 
subtilis secretes this catecholate molecule.15   
 
           
 Figure 1.3 – Structures of 2,3-dihydroxybenzoylglycine (left) 2,3-dihydroxybenzoylserine (right)  
 
Post discovery of the 2,3-dihydroxybenzoylglycine secretion, in 1966 Brot, Goodwin and Fales 
found that when cultures of E. coli  were in their stationary growth phase the media in which they 
grew became red in colour.  The attempted isolation of the compound responsible for the colour led 
to the identification of serine and iron, as well as the catechol moiety being present.  When in an 
iron deficient media, a pale yellow compound could be isolated from the culture, which upon the 
addition of iron turned red.  They concluded that E. coli was secreting compounds in response to 
iron limitation, capable of chelating iron.   The group surmised that the compound was 2,3-
dihydroxybenzoylserine (Figure 1.3), which mirrored the findings of the glycine conjugate by 
Neilands and Ito.15,16   
Later, in 1970, O’Brien and Gibson correctly elucidated the structure of the tris-catecholate 
enterobactin (enterochelin) from the degradation products of molecules isolated from E. coli 
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cultures.17  The compound was also independently isolated and characterised by Pollock and 
Neilands from Salmonella typhimurium in the same year.18   
 
Figure 1.4 - Structure of enterobactin 
 
Enterobactin was found to have an exocyclic structure (Figure 1.4, Figure 1.5), based on a triserine 
core scaffold bearing three arms.  Coordination of iron occurs through three catecholate units to 
facilitate hexadentate binding.  
 
 
 
 
Figure 1.5 Representation of Fe3+ binding by enterobactin.  (Left) Computer generated structure of 
uncomplexed enterobactin displaying H-binding network, (Right) structure of the V(IV)-
enterobactin complex as a model for the Fe3+ complex.  Reproduced from PNAS, 2003, 100, 7, 
3584-3558.19 
 
The core structure of enterobactin allows for the binding catecholate moieties to move minimally in 
order for iron complexation to take place (preorganised for iron binding), this reduces a 
disfavoured entropic contribution to the Gibb’s Free Energy for the reaction and is the one reason 
for its remarkable affinity for Fe3+, which will be discussed later in 1.5.1.   
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1.2.1 Ligand Denticity   
 
Siderophores have been found to have a variety of denticities where; bidentate, tetradentate and 
hexadentate are the most common.  However due to the thermodynamic considerations of metal-
ligand complex formation, in general, siderophores which satisfy the octahedral arrangement i.e. 
hexadentate ligands, will form more stable Fe3+-siderophore complexes.  A general trend of ligand 
denticity and Fe3+-ligand formation constant is displayed in Table 1.2.20   
 
Table 1.2 Binding affinity for a range of ligands for Fe3+, displayed in descending order of pFe3+ – 
data reproduced from Nat. Prod. Rep., 2010, 27, 637  
Ligand Denticity Logβ (Fe3+) pFe3+ 
Enterobactin 6 49.0 35.5 
MECAM 6 45.9 29.1 
Ferrioxamine E 6 32.5 26.6 
Amonabactin 4 34.5 26.0 
Ferrichrome A 6 32.0 25.2 
Ferrioxamine B 6 30.5 25.0 
Ferrichrome 6 29.1 25.0 
EDTA 6 25.1 23.4 
Rhodotorulic acid 4 31.2 22.0 
Rhizoferrin 6 25.3 20.0 
N,N-Dimethyl-2,3-dihydroxybenzene 2 40.2 15.0 
Acetohydroxamic acid 2 28.3 14.8 
Hydroxide anion 1 11.7 14.6 
 
It is shown that, with some exceptions, generally the higher the denticity of the ligand the stronger 
and more stable the Fe3+-ligand complex, as denoted by the logβ Fe3+ and also the more efficient at 
scavenging Fe3+, denoted by the pFe3+ value, discussed in 1.5.1.   
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A concentration effect is also apparent when we consider different denticities of ligands and those 
of higher denticity are favoured.   
 
 
 
 
Figure 1.6 Equations displaying the equilibrium constants for bi-, tetra- and hexadentate Fe3+-ligand 
complexation 
 
The increased denticity of the hexadentate ligand, reduces the concentration requirement for that 
ligand to produce the fully saturated Fe3+ metal ion, in general this leads to a higher metal complex 
formation constant.4,20      
In addition to a concentration effect we can also rationalise the trend displayed in Table 1.2 
partially through the chelate effect.  The chelate effect is the observed increase in complex stability 
for higher dentate ligands (polydentate) when compared to ligands of lower denticity with 
analogous binding sites (mono- or bidentate).8   
There are a few apparent exceptions to the trend which links increased denticity and complex 
stability, both within natural and synthetic siderophores.  An interesting illustration is provided by 
the synthetic molecules CP130 and its bidentate analogue 2-(3-hydroxy-2-oxo-1,2-dihydropyridin-
1-yl)acetic acid.  The compound named CP130 was first reported by Hider and coworkers in 1990 
and was the first hexadentate 3,2-HOPO containing tripodal chelator.21 
 
Hexadentate 
Tetradentate 
Bidentate 
  β110=  [FeL]/[Fe3+][L3-] 
β320 =  [Fe2L3]/[Fe3+]2[L-]3 
β310  =  [FeL3]/[Fe3+][L-]3 
Kf 
β2 
β3 
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Figure 1.7 Structures of CP130 (left) and the bidentate unit (right) 
 
The bidentate analogue has a reported logβ310 of 32.3 whereas the subsequent incorporation of three 
bidentate units onto the TREN (tris(2-aminoethyl)amine) core produces the hexadentate chelator 
with a logβ110 value of 28.8.22  This drop in binding affinity has been attributed to disfavoured 
interactions when the hexadentate species forms a complex with Fe3+, most likely the core scaffold 
influence.  However, as the comparison is made between systems which vary in their 
stoichiometry, this conclusion is not strictly true.  A better measure of binding affinity is the pFe3+ 
value which will be discussed in 1.5.1.  
 
1.2.2 Arrangement of Binding Moieties 
 
To achieve the hexadenticity required to saturate the coordination sphere of Fe3+ and hence produce 
strong Fe3+ chelation, the binding moieties of the most powerful siderophores can be incorporated 
within or around a core molecular scaffold.23   
Siderophores have a diverse range of structures but the main families of architectural structures for 
hexadentate siderophores are displayed in Figure 1.8. The inclusion of; hydroxamate, catecholate 
or α-hydroxycarboxylic acid into the architectures displayed in  Figure 1.8 is common in natural 
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siderophores.  It is the incorporation of these groups into these arrangements, either mixed or the 
same type which has led to such a diverse library of natural siderophores.  
 
 
Figure 1.8 Common siderophore architectures. (i)top left, linear (ii) top right, tripodal (iii)bottom 
left, exocyclic (iv) bottom right, endocyclic.  Orange denotes binding site, black lines are ligand 
scaffold. 
 
Microbial siderophores adopt: linear, exocyclic and endocyclic architectures, examples to illustrate 
these are displayed in Figure 1.9.4  Researchers designing synthetic analogues, such as  CP130, 
have introduced the tripodal architecture.24   
 
Figure 1.9 Examples of natural siderophore architectures; desferrioxamine B (left, linear) 
desferrioxamine E (middle, endocyclic) and deferriferrichrome (right, exocyclic) 
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By way of example from natural siderophore molecules, as can be derived from Figure 1.9 that 
desferrioxamine E (logβ110Fe3+ = 32.5, pFe3+ = 29.7) has a higher affinity for Fe3+ than the linear 
desferrioxamine B (logβ110Fe3+ = 30.6, pFe3+ = 28.6).  The marginally higher affinity may be 
attributed to the preorganisation  towards binding Fe3+ achieved with desferrioxamine E, through 
having an endocyclic structure as opposed to the linear arrangement of the desferrioxamine B 
binding moieties.20  Deferriferrichrome (logβ110 = 29.1, pFe3+ = 25.2) has a lower affinity than both, 
this could be attributed to strain within the macrocycle core when Fe3+ binding occurs, or an 
insufficient organisation of the binding moieties towards the chelation of Fe3+.25  
The effect can also be noted when a comparison is made between the thermodynamic stability of 
the ferric complexes of enterobactin and the mono-hydrolysed linear enterobactin.   
 
 
Figure 1.10 Structure of linear enterobactin 
 
Enterobactin (logβ310 = 1049) displays a remarkably higher thermodynamic stability and therefore 
selectivity for Fe3+ over linear enterobactin (logβ310 = 1043).  As the only difference between the 
two structures is the nature of the core scaffold (linear vs cyclic) the distortion in the stability 
constant is easily attributed to change in ligand architecture.26    
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1.2.3 Binding Moieties  
 
Fe3+ has a high charge density and an ionic radius of around 0.64Å.27  This creates a non-
polarisable metal centre and therefore classifies ferric iron as a hard Lewis acid.  With this 
realisation it is therefore not surprising that within natural siderophores, there is preferential 
incorporation of oxygen and nitrogen donor atoms into siderophore scaffolds.  This can be seen as 
being the case with the natural siderophore examples shown in Figure 1.9.  In addition, a five-
membered chelate ring, producing a bite angle of approximately 69°, will be favoured over a six-
membered ring because of the relatively large ionic radius of Fe3+.8    Despite the diversity of 
siderophore structures discovered in nature, there are a number of binding moieties that are 
conserved throughout the majority of siderophores.  The catechol, hydroxamic acid and α-
hydroxycarboxylic acid groups are the three groups found displayed most widely in natural 
siderophores, Figure 1.11.28   
 
 
Figure 1.11 Examples of Fe3+ binding to common siderophore moieties (top) catechol (middle) 
hydroxamic acid and (bottom) α-hydroxycarboxylic acid 
 
The catechol binding moiety is common throughout natural siderophores, most notably within the 
most powerful natural siderophore thus far discovered, enterobactin.  There are also examples of 
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catecholic siderophores isolated from Gram-positive bacteria, such as bacillibactin (BB), isolated 
from Bacillus subtilis as well as related species B. anthracis and B. cereus.29   
 
Figure 1.12 Structure of bacillibactin (BB) 
 
There are many examples of the hydroxamic acid (Figure 1.11, middle) group within natural 
siderophores, the most well-known of which were displayed previously in Figure 1.9 within the 
desferrioxamine E and desferrioxamine B structures.20,30  The α-hydroxycarboxylic acid group is 
most notably displayed within the marine siderophore families.  Examples of which are displayed 
in Figure 1.13.   
                        
Figure 1.13 Structure of (left) aerobactin and (right) achromobactin displaying the α-
hydroxycarboxylic acid binding group (red), structures reproduced from; Coordination Chemistry 
Reviews, 2010, 254, 288–296 
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Siderophores containing the α-hydroxycarboxylic acid moiety are susceptible to photolysis.  UV 
photo-irradiation leads to the release of CO2 and in turn reduction of the Fe
3+ site to Fe2+.  This 
undoubtedly produces a less stable complex, as usually the Fe(II)-siderophore complexes have 
markedly lower formation constants and pFe(II) values, sometimes of up to 20 order of magnitude 
lower.  This has been suggested as one of the possible iron release mechanisms utilised by marine 
bacteria.31   
 
1.3 The hydroxypyridinone (HOPO) Moiety 
 
In addition to the more common binding moieties discovered in the natural siderophore population 
i.e. hydroxamate, catecholate, there is another binding moiety found so far in only a few natural 
siderophores.  The hydroxypyridinone (HOPO) moiety, one such example of this group isolated 
from nature is taken from the siderophore cepabactin (Figure 1.14) first isolated from Burkholderia 
cepacia.
32
   
 
Figure 1.14 Structures of cepabactin (left)  and mimosine (right), examples of the HOPO moiety 
found in nature 
 
The HOPOs are very powerful Fe3+ ligands, stronger even than the catechol binding unit, Figure 
1.15.  They exist as three structural isomers, the 1,2-HOPO, 3,2-HOPO and the 3,4-HOPO (Figure 
1.16).28   
The HOPO groups are monoprotic acids and therefore form neutral complexes with trivalent metal 
cations,33 the preferential affinity for the harder tribasic metal centres over the dibasic can be noted 
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through comparison of pFe3+ vs pFe2+ values.  The limited abundance of the HOPO within the 
natural siderophore library could indicate that higher denticity ligands based upon these groups 
may be too powerful to be safely biosynthesised, stored or utilised by microorganisms.  This maybe 
a mechanism by which recognition could be avoided by microbial uptake systems.  
    
 
Figure 1.15 Table displaying relative binding affinity for some bidentate units 
 
As an example deferiprone, a 3,4-HOPO chelator has a logβ for Fe3+ of 37.2 where the 
corresponding Fe2+ logβ is 12.1, displaying the preference for hard cations.34    Of the three 
isomers, the 3,4-HOPO displays the highest pFe3+ value.35  In addition, the HOPO group is 
isoelectronic with catechol33 and due to the zwitterionic nature of the HOPOs, they are bioisoteric 
with the catechol group, Figure 1.16.36,37    
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Figure 1.16 pKa values and structures of catechol and HOPO groups 
 
1.3.1 Medicinal application of HOPOs 
 
The HOPO moiety has current applications in medicine, deferiprone Figure 1.17 is an orally active 
3,4-HOPO compound used in the treatment of iron overload.  Deferiprone is an effective treatment 
for this condition, which can be brought on through iron supplementation following anaemia, as the 
properties of the 3,4-HOPO moiety lend well to the chelation of excess Fe3+ in vivo.38   
 
Figure 1.17 Structure of deferiprone 
 
In particular, the affinity for the desired metal species i.e. Fe3+ over other metals within the 
biological system is highly desired when applying a chelator for this purpose in a biological 
system.  Deferiprone is favoured amongst other treatments, such as DFO(B) due to its oral activity, 
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stability and low toxicity.  However, some studies have shown links between deferiprone and 
patient hepatic fibrosis, which cast doubts on its continued usage in this area.39  
 
1.3.2 Previous synthetic HOPO-based chelators  
 
Hydroxypyridinone containing chelators have been accessed for a variety of: HOPO isomers, 
denticities and on several core molecular scaffolds.  One of the earliest reported synthetic chelators 
containing the HOPO moiety (Figure 1.18), specifically the 1,2-HOPO moiety was reported in 
1985 by Raymond et al.40  The molecule presented contained features similar to that of 
rhodotorulic acid (section 1.8) and, as was discovered, both rhodotorulic acid and the HOPO 
compound were dianionic and tetradentate.  Resulting from the tetradenticity, the ligand forms an 
Fe2L3 complex, as was shown for rhodotorulic acid.
41   
   
Figure 1.18 Complex structure for Fe2L3 (left) Structure of 1,2-HOPO tetradentate molecule 
reported in 1985 by Raymond et al (right) 
 
The HOPO group has also been incorporated successfully into ligands designed for potential use as 
MRI contrasts agents, in particular targeting Gd(III) binding.  The HOPO group, due to its affinity 
for trivalent metal cations was an obvious choice in this area of research.  Examples in the literature 
include those of 1,2-HOPO and retro-3,2-HOPO containing ligands, Figure 1.19.42-44 
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Figure 1.19 Structures of HOPO containing molecules designed for MRI contrast agents: H(2,2)-
1,2-HOPO (top left), TREN-Me-3,2-HOPOTAM (top right) and TREN-1,2-HOPO (bottom) 
 
In addition to MRI contrast agents, the HOPO moiety has been accommodated onto fluorescent 
probes for cell imaging purposes.  The molecule in Figure 1.20 was published in 2010 by Hider et 
al.  
 
Figure 1.20 Fluorescent hexadentate Fe3+ chelator 
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The fluorescent probe was successful in allowing the intracellular compartments to which the 
chelator accumulated to be imaged.  The fluorophore molecule was also shown to have an 
inhibitory effect on the growth of Mycobacterium avium.45   
More recently, in 2011 Hider et al. published an article containing 3,4-HOPO containing chelators 
which were based upon tris(2-aminoethyl)amine and amine-triacid core scaffolds.   
   
Figure 1.21 3,4-HOPO hexadentate chelators based upon amine-triacid core scaffolds 
 
These compounds were tested for their antimicrobial properties with reference to DTPA (pFe3+ = 
24.6).  It was found that the compounds display antimicrobial activity against both Gram-positive 
and Gram-negative bacteria.  The levels to which the antimicrobial activity was displayed are, with 
reference to molar concentration of the chelators, much lower than those of DTPA.  Approximately 
25/50% of the concentration of the HOPO containing chelators with respect to DTPA was required 
to induce inhibition.  The inhibitory effect the molecules displayed was surmised to be attributed to 
their ability to disrupt bacterial iron absorption.46   
There has been wide variety of tris-amide/amine based chelators which are tripodal in structure.  
However, HOPO containing chelators which are based upon more sophisticated core structures are 
less common throughout the literature, examples are given in Figure 1.22.   
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Figure 1.22 HOPO containing chelators based upon sophisticated core molecular scaffolds.  Retro-
3,2-HOPObactin (top left) 1,2-HOPObactin (top centre) KEMPPr(3,4-HP)3 (n = 3); KEMPBu(3,4-
HP)3 (n = 4) (top right). N3(etLH)3 (bottom left), 4(N),10(N)-Bis[2-(3-hydroxy-2-oxo-2H-pyridin-
1-yl)ethyl]-1,7-dimethyl-1,4,7,10-tetraazacyclododecane (bottom right).     
 
Of those chelators displayed in Figure 1.22 the two HOPObactin analogues (top left and top centre) 
are those whose structures are the most similar to that of enterobactin.39,47  The stability constant 
and pFe3+ have not been assessed for the 1,2-HOPObactin analogue as yet due to the inability  to 
afford the deprotected ligand.  However, for the retro-3,2-HOPObactin the results show that there 
is a significant loss of stability for this analogue with respect to enterobactin.  Where we see 
enterobactin has a pFe3+ = 34.3 the HOPObactin analogue has a pFe3+ = 27.439,48  It is clear from 
these figures that the core scaffold, unlike in enterobactin, does not provide the increased stability 
for these pendant HOPO moieties which we see for the catecholate within the natural siderophore.   
For the ligands KEMPPr(3,4-HP)3 (n = 3); KEMPBu(3,4-HP)3 (n = 4) (top right) the pFe
3+ values 
are 28 and 26.8 respectively.49  Despite the 3,4-HOPO moiety possessing the highest pFe3+ value in 
its bidentate state, this molecule does not reach some of the higher pFe3+ values we have seen for 
some other synthetic siderophores.  This could be attributed to either inherent strain arising from an 
imperfect predisposition of the binding groups by the core scaffold, or that the para-situated 
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attachment (with respect to the carbonyl-functionality) of the binding groups to the scaffold 
interferes with stability, as an ortho-attachment has been shown to be important in some 
instances.34   
There are but a few examples of macrocyclic core scaffolds bearing HOPO functionality.  Those 
shown in Figure 1.22 (bottom left and right) were produced through similar synthetic methodology.  
The core scaffolds in these cases display an increased stability over a wide pH range, avoiding 
hydrolysis, unlike those based upon a hydrolysable core scaffold such as enterobactin and its 
analogues based upon the trilactone core.  The introduction of secondary amine functionality into 
the core also improves the aqueous solubility of the chelators.39  
 
1.4 Thermodynamic Considerations of Complex Formation 
 
Complex stability can be considered as being the result of a series of contributing thermodynamic 
factors.  Governing the thermodynamics of complex stability is the equation describing the Gibbs 
free energy of a reaction ΔGo.        
 
 
Highly charged ions in solution can be thought of as imposing order upon the molecules 
surrounding them e.g. solvent molecules, brought on by imposed dipole interactions.  This 
imposition upon the surrounding molecules can be considered to be thermodynamically 
unfavourable in terms of the entropic contribution, ΔS°.   Therefore, the formation of complexes 
involving charged species would result in partial or complete cancellation of those charges in 
solution.  This results in an increase in entropy for the system overall and provides a favourable 
contribution to the entropic considerations within the free energy of the system.   
The total or partial cancellation of charges in solution has also a favourable enthalpic contribution, 
as the combination of oppositely charged species in solution and hence the partial or complete 
ΔGo = ΔHo - TΔSo 
Figure 1.23 Equation for the Gibbs free energy of reaction (kJ mol-1), ΔHo is the standard enthalpy of 
reaction (Jmol-1), T is the temperature (K) and ΔSo is the standard entropy of reaction (JK-1mol-1) 
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cancellation of charges, in general, holds a significantly negative ΔHo, favoured in terms of Gibbs 
free energy. 
In addition, polydenticity in ligands has an impact on the thermodynamic favourability of complex 
formation.  The chelate effect, as previously discussed will have enthalpic and entropic 
contributions to stability also.  For example, a stabilising enthalpic contribution of the chelate effect 
would be the inductive contribution of electron density gained from atoms adjacent to the ligating 
sites.  This will increase the donor strength of binding sites and increase the stability of the 
complex.   
The overall entropic contribution stems from two major contributing factors.  Firstly, the entropy 
surrounding metal-ligand complex formation is often more favoured for reactions in which the 
ligands are polydentate.  This is because the polydentate ligands often displace several solvating 
molecules, leaving more free species on the product side of a reaction.  This type of interaction 
leads to an increase in entropy of the system and thus increased thermodynamic favourability, 
Figure 1.24.      
 
 
Figure 1.24 Reaction scheme for a hexadentate siderophore (H3Sid) species displacing solvent 
molecules from ferric iron centre 
 
Furthermore, polydentate ligands have an increased probability of complex formation due to the 
‘branches’ of the complexed ligand directing the binding of the non-complexed ‘branches’.  The 
complexed binding sites hold the ligand in place making it more likely the other sites will bind.8   
 
1.5 Expressing the Stability of Fe
3+
-siderophore complexes 
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In order for many siderophores to bind Fe3+ the dissociation of protons from the ligand is 
necessary.  This creates a competition between the Lewis acids Fe3+ and H+ for the ligands binding 
sites.  This competition between the two has to therefore be accounted for when calculating 
equilibrium constants for Fe3+-siderophore complex formation, Figure 1.25.50,51   
 
 
Figure 1.25 Equations displaying the stepwise addition of a monoprotic bidentate ligand (L) to Fe 
after proton dissociation 
 
To simplify the expression of these stepwise stability constants it is often the case that these are  
often expressed as the product of the overall stability constant β, Figure 1.26.51   
 
Figure 1.26 Reaction scheme for the overall stability constant defined for the addition of a bidentate 
monoprotic ligand L to Fe 
With siderophore overall stability constants when the reaction involves multiple ligands of the 
same type (denticity and structure) the β values are displayed along with subscript notations in the 
form of βLMH where, L = number of the same ligand involved, M = number of metal centres 
involved and H = number of protons involved in the stoichiometry of the equilibrium expression.    
Figure 1.26 displays the case for monoprotic bidentate ligands, however the most powerful 
chelators are usually hexadentate.  For these ligands the overall stability constant would take the 
form β110 for the fully deprotonated triprotic hexadentate ligand, .   
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Figure 1.27 Equations displaying the stepwise deprotonation steps for a triprotic hexadentate ligand 
and the overall stability constant of such a ligand binding Fe 
 
The presence of the competition between the Lewis acidic centres means that the equilibrium 
conditions for the reactions will be pH dependent.  However, when we look at siderophore 
equilibrium constants it is often simpler to measure the conditions for the proton-free reaction, that 
is the β measured for the fully deprotonated ligand.   
The overall stability constant does not account for the Lewis acid competition between H+ and Fe3+ 
which would often be present in biological systems.  For this reason it allows for the direct 
comparison only for ligands that are of the same denticity, which would give the same 
stoichiometry for the Fe3+-ligand complex at equilibrium.20   
1.5.1 pFe
3+
 as a measure of ligand binding efficiency  
 
An alternative measurement of complex stability is to measure the equilibrium concentration of 
free Fe3+ in solution.  This value is the pFe3+ and it is analogous to pH, in that it is defined as;  
 
The pFe3+ value is usually defined for pH = 7.4, [Fe3+]tot = 1µM and [Chelator] = 10µM.  The 
values obtained for the pFe3+ are dependent upon the pH, [Fe]tot and [Che]tot and as a result only 
those measurements taken using the same defined conditions are comparable.  The Lewis acid 
competition of dissociated protons, ligand denticity and basicity as well as differences in metal-
ligand stoichiometry is accounted for by the pFe3+ value and hence it is a more acceptable measure 
pFe3+ = -log10[Fe
3+]free 
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of the ability of a ligand to bind Fe3+.  The [Fe3+]free is understood as the non-complexed Fe
3+ left in 
solution.  The measurement was first realised by Raymond et al. in 1979 in order to characterise 
the Fe3+-aerobactin complex.  This value allows for the direct comparison of chelator strength as 
long as the conditions in which the measurements are taking are conserved in both cases, the one 
with the highest value of pFe3+ will be the stronger chelator.52   
Enterobactin has an affinity for Fe3+ which is notable as being the strongest natural siderophore 
ever discovered with a logβ110 = 49 and pFe3+ of 34.3. 8,9   
Previous work has described the possibility of stronger iron chelators to be synthesised than 
enterobactin, as the core unit still holds some inherent strain, shown through molecular modelling.  
This study highlighted that the β110 has a connection with the inherent strain in the molecule and if 
this was brought to a minimum a theoretical maximum of β110 of ~1057 +/- 5 which would equate to 
108 +/- 5 higher than that of enterobactin.53    
 
1.5.2 Kinetic Considerations of ferri-siderophore Complexes 
 
Generally, rate of ligand exchange for ferri-siderophore complexes is slow due to the 
overwhelming affinity of the siderophore for the Fe3+. This ensures Fe3+ binding even at minute 
concentrations.20  The dissociation of a siderophore from the complex has been investigated and 
found to be assisted by lowering the pH.  For hydroxamate siderophores, the data suggests both 
multiple species and pathways are present in the dissociation of tris-chelated dihydroxamate 
complexes.54   
The lability of ligands in general decreases with either increasing denticity or level of organisation 
towards the metal centre and so the bidentate and tetradentate siderophores show faster rates of 
dissociation and ligand exchange kinetics than the hexadentate analogues.  This has been 
hypothesised to be associated with Fe3+ delivery to the cell in that, the bi- and tetradentate ligands 
would primarily bind the metal and then these would release the Fe3+ to the more powerful 
hexadentate siderophores, due to their lability.34  As an example to illustrate, Raymond et al. 
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determined through 55Fe3+ labelling studies that the exchange of the metal between ferrioxamine B 
and ferrichrome A is 50% complete after 220 hours at pH 7.4.  The exchange is therefore quite 
slow but again this rate can be increased through lowering pH.55   
 
1.5.3 Kinetic Vs Thermodynamic Considerations 
 
In the design of novel synthetic chelators for bacteriostatic applications there will be consideration 
given to both the thermodynamic and kinetic factors which affect the binding of Fe3+ by a ligand.   
 
Figure 1.28 Diagram to represent effective routes to Fe3+ bacteriostasis by synthetic chelator (Che) 
with respect to natural siderophore Fe assimilation by bacteria (Sid). (i) Siderophore production 
and release (ii) ferri-siderophore complex formation and formation of equilibrium with (Che) (iii) 
diffusion of ferri-siderophore complex to bacterial cell (iv) competition of ferri-siderophore 
complex with synthetic chelator (Che) (v) Competition of ferri-(Che) complex with natural 
siderophore (Sid) (vi) depletion of the environmental Fe pool via (Che)   
 
The design of new Fe3+ selective ligands will encompass those features which will produce 
thermodynamic complex stability as discussed in section 1.5.  However, these will be in 
competition with the microbial systems (Figure 1.28).  Depending on the rate of complex formation 
from the environmental Fe pool, different pathways to Fe3+ starvation must be addressed.   
 If complexation of the environmental Fe by the new ligands (Che) is achieved at a faster rate than 
that of the bacterium’s own siderophore (Sid) released into the extracellular environment (i) then 
the competition for the metal should be thermodynamic between the (Sid) and the [Fe-Che] (v).    
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Alternatively, if the complexation of Fe by the (Che) occurs at a slower rate than that of the natural 
(Sid) (ii) then the thermodynamic competition will be between [Fe-Sid] and (Che), (iv).  This 
competition is represented by the equilibrium in Figure 1.28.    Though the competition for 
complex formation would not be mutually exclusive between the competing processes, one may 
dominate based on more favourable thermodynamic or kinetic properties.   
As previously stated, the proposed high affinity Fe3+ ligands to be synthesised will incorporate 
design features to improve their likelihood in forming thermodynamically stable complexes 
however; little is known regarding the effect ligand structure has on creating kinetically favourable 
complex formation.  Therefore, the thermodynamic factors which contribute to the design of high 
affinity Fe3+ chelators need to be addressed in the first instance to ensure that the ligands achieve 
the primary project aim.   After these factors have been addressed the kinetic factors which 
contribute to Fe3+ binding can be studied further.  Ideally, the rate of [Fe-Che] formation will be 
rapid to produce a kinetically viable ligand as well as the thermodynamic stability of the complex 
being favoured over the [Fe-Sid] complex.   
The lability of the formed complex and rate of metal exchange between natural and synthetic 
competing ligands will become important if the bacterial response to Fe3+ starvation includes the 
secretion of large quantities of (Sid).  It may be the case that there is a window in which the applied 
synthetic ligands function but are eventually overcome by far higher concentrations of (Sid) being 
introduced to the extracellular environment by the microbes.  Literature suggests that the exchange 
kinetics between chelators of this nature are generally slow, therefore if the initial complexation of 
environmental iron by (Che) is rapid the exchange with (Sid) should be slow and the desired 
bacteriostasis should be observed.  This effect may be measurable as a delayed response in 
bacterial growth over time with reference to cultures lacking (Che) i.e. a repopulation ‘lag time’ 
should be observable.  However, if the opposing situation arises that of the [Fe-Sid] complex 
formation is more kinetically viable then this lag time may not be observed on a measurable 
timescale.56   
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1.6 Iron Uptake and Intracellular Release in Bacteria 
1.6.1 Siderophore Mediated Fe
3+
 Acquisition in Bacteria 
 
As described by Crumbliss et al. siderophore mediated Fe3+ acquisition in bacteria follows the 
general pathway displayed in Figure 1.29.  Firstly the siderophore is biosynthesised and released by 
the cell into the surrounding environment.  Then the siderophore forms a complex with iron, which 
is followed by diffusion of the complex to a cell’s surface.  Specific ferri-sideorphore receptor 
proteins on the surface of the cell recognise the Fe3+-siderophore complex and facilitate transport of 
the complex into the cell’s interior where finally the iron is released from the complex for use in 
microbial metabolic processes.4 
 
Figure 1.29 Diagram representing pathway for sideorphore mediated Fe3+ acquisition in bacteria; 
diagram from Hakim Boukhalfa & Alvin L. Crumbliss; BioMetals, 2002, 15,325–339 
 
The generalised overview of siderophore-mediated iron acquisition is well established.  It requires 
a high affinity receptor to capture and effectively concentrate the micronutrient at the cell surface.  
The ferri-siderophore complex is actively dissociated from the receptor and transported to the 
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interior of the cell where the iron is then downloaded from the complex by a reductive process to a 
less stable ferro-siderophore from which the metal can be readily exchanged.     
The specific intricacies and differences between bacteria and their acquisition mechanisms have 
been studied.  A simple classification of bacteria distinguishes Gram-positive and Gram-negative 
genera.  The most conspicuous difference between these two groups is their distinctive cell 
envelope architecture; the variations herein have implications for the pathway for iron uptake.  The 
following briefly relates these architectural differences and the structural biology solutions that 
have evolved to assure the efficient supply of iron.      
 
1.6.2 Gram-negative Bacteria 
 
The main structural difference seen in the cell envelope of the Gram-negative bacteria is their 
possession of an additional outer membrane that limits a secure periplasmic space in which a 
thinner layer of murein resides.  The outer membrane affords the underlying bacterium some 
protection from toxins, degradative enzymes and detergents.  Some passive diffusion of 
macronutrients across this membrane is facilitated through the relatively non-specific water-filled 
channels in porin proteins.  This system is not adequate to support the uptake of scarce 
micronutrients such as ferri-siderophores and cobalamin.  In these cases the necessary high-affinity 
receptor proteins are located within this outer membrane.   The outer membrane has no ATP-
binding cassette proteins to allow for an energy transfer to facilitate movement of the Fe3+-
siderophore complexes through the outer membrane, like we see in the cytoplasmic membrane.  It 
has been suggested the energy to do this stems from interaction of the outer membrane receptor 
with the TonB system (TonB, ExbB and ExbD).57,58   
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Figure 1.30 Diagram representing the biology of Fe3+-siderophore complexes in Gram-negative 
bacteria – taken from Biochimica et Biophysica Acta, 2008,  1778, 1781–1804  
 
The binding of the ferri-siderophore to the receptor must be strong and requires active dissociation 
in a structure that affords influx of the chelate to the periplasmic space.  Crystal structures have 
been determined for the outer-membrane receptors FhuA (hydroxamate) FecA (citrate) and FepA 
(enterobactin) in E. coli.  Also, FpvA (pyoverdine) and FptA (pyochelin) in P. aeruginosa.59,60  
These outer membrane receptors have a barrel and plug construction.  The transmembrane channel 
is formed by a β-barrel protein domain that resembles the non-specific open channels of the porin 
diffusion channels.  In this case the channel is blocked by a globular ‘plug’ or ‘cork’ domain that 
fills the channel and controls the movement of molecules through it.  It is this domain that binds the 
ferri-siderophore complex.  This binding event initiates a rearrangement of a part of the plug 
domain that faces the periplasmic space.  The rearrangement allows the receptors’ recognition by 
the periplasmic TonB protein which transduces energy to drive the translocation of the complex to 
that location via further rearrangement of the plug domain.61   
The periplasmic binding proteins then interact with ATP-binding cassette proteins and permeases 
to facilitate movement of the complex through the plasma membrane.  Not all bacteria have the 
three systems shown in Figure 1.30; haemoglobin, transferrin and lactoferrin and siderophore.  
Most have a combination of these systems.   
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1.6.3 Gram-positive Bacteria 
 
Gram-positive bacteria present the least complex pathway for ferri-siderophore uptake.  Their key 
outer structures are the cell wall and plasma membrane.  The cell wall of Gram-positive bacteria is 
made up of primarily murein, polysaccharides, teichoic acid and cell wall-associated proteins.  The 
murein is the major structural component forming a single macromolecular boundary to the cell.  In 
order to support mass transfer of materials across the cell’s margins, it has a well-hydrated and 
highly porous structure.  Ferri-siderophores passively diffuse through the thick murein layer.  Their 
active uptake commences when they encounter high-affinity cognate binding proteins that are 
anchored in the plasma membrane via a lipid modification.  These receptor proteins intimately 
interact with permease and ATP-binding cassette proteins embedded in the plasma membrane to 
facilitate transport across the membrane, Figure 1.31.  On sensing a ferri-siderophore loaded 
receptor, these ATP-binding cassette proteins transduce energy derived from the hydrolysis of ATP 
to affect the transport of the ferri-sidrophore complex through the integral transmembrane channel 
of the permease.  One such example of this uptake system comes from Bacillus anthracis and 
related strains and is the uptake the ferri-siderophore complex ferribacillibactin.29,62  Initial binding 
of the complex by the membrane protein receptor is followed by active uptake of the complex, 
mediated by the FeuA receptor protein.57   
 
Figure 1.31 Diagram representing the Fe3+-siderophore uptake in Gram-positive bacteria -  taken 
from Biochimica et Biophysica Acta, 2008, 1778, 1781–1804  
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1.7 Siderophore Recognition 
 
In terms of ferri-enterobactin uptake by E. coli, Raymond et al. discovered several important 
structural features, thought to be crucial in enterobactin to facilitate uptake and recognition of the 
ferri-siderophore complex.63  The group synthesised enterobactin analogues to investigate which 
features of the natural molecules were necessary for molecular recognition and eventual uptake of 
the complex.   
The amide functionality adjacent to the catechol rings appear to be necessary for recognition by the 
outer membrane receptor for Fe3+-ent.  However, the molecular structure of the nitrogen atom of 
the amide linkage is not significant for recognition.  Both secondary and tertiary nitrogens in this 
position can be utilised as substrates for the receptor.  Additionally, minor structural alterations to 
the binding unit were shown to reverse activity.  No uptake was observed when substitution of the 
ring by methyl- or sulphate had occurred.   
 
Figure 1.32 Highlighting the domains investigated by Raymond et al. from J. Am. Chem. Soc., 
1988, 110, 2451-2464 
 
In other examples, the configuration of the groups at the metal centre has been found to be 
important in siderophore recognition.  Rhodoturulic acid is a tetradentate dihydroxamic acid 
siderophore. It accomplishes full saturation of the iron coordination sphere through forming the 
L3M2 ligand to metal stoichiometry.
26  
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Figure 1.33 Structure of rhodotorulic acid (left) and enantiorhodotorulic acid (right) 
 
The absolute configuration is ∆ (right handed propeller) for ferri-rhodoturulic acid complex at the 
metal centre, opposite to that of ferrichrome. The enantiomeric derivative therefore has a ᴧ-
configuration (enantiorhodotorulic acid) at the metal centre and it is this enantiomer which is 
successful in mediating iron transport to E. coli. It was concluded that this is a consequence of the 
receptor recognising the configuration at the metal centre, Figure 1.34. 
 
 
Figure 1.34 Diagram to show sterochemical configuration of enantiomers in octahedral Fe 
complexes (ᴧ-configuration right structure.  ∆-configuration left structure) 
 
In contrast, a recent study of the enzymatic hydrolysis of the ferric- enterobactin and bacillibactin 
trilactone backbones was performed by Albergel et al. in order to discover where particular chiral 
recognition occurs in the uptake of these complexes.62  It was discovered that, in terms of 
enzymatic hydrolysis in vivo of these complexes, it is the trilactone backbone and not the 
configuration of the binding groups at the metal centre which is important for recognition.  This 
was concluded from producing the enantiomeric forms of the complexes, which by definition have 
the alternate stereochemistry at the metal centre and seeing the effect this has on uptake.  The 
enantiomeric complexes were able to be uptaken by the membrane receptors; however enzymatic 
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cleavage of the backbone within the periplasmic space could not be achieved, therefore leading to 
the conclusion that the chirality of this complex is recognised once uptake has occurred.   
This suggests a different recognition pattern for chirality, contrasting with what has been observed 
for rhodotorulic acid and highlighting the differences in hydroxamate and catecholate uptake 
pathways.        
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1.8 Mechanisms of Fe
3+
 Release  
1.8.1 Reductive Release  
 
Several mechanisms for the release of Fe3+ from bacterial siderophore complexes have been 
proposed.  For hydroxamate-containing siderophores, such as ferrioxamine B, the release 
mechanism is thought to be relatively simple and involves the reduction of the metal centre from 
Fe3+ to Fe2+.  This process significantly reduces the ligand’s affinity for the metal centre and 
therefore the complex stability.  The iron can now be more readily removed from the complex 
through exchange with other intracellular ligands.  This general mechanism has been shown to be 
the case for several hydroxamate siderophore producing organisms.64   
A reductive mechanism of iron release allows for the reutilisation of the siderophore,65 and 
therefore poses a lesser metabolic penalty to the microbe.  Biological reducing agents such as 
NADH hold reduction potentials of around -320mV and so are able to reduce ferri-siderophore 
complex which fall into this range such as the hydroxamate-based rhodotorulic acid, E1/2 = -359mv. 
However catecholate siderophores, in particular tris-catecholate siderophores such as enterobactin 
possess much lower reductive potentials, E1/2 = -750mV for ferri-enterobactin.
4  Therefore these are 
out of the range of biological reductants and so other mechanisms for iron release are thought to be 
necessary.  However the reduction potential can alter with respect to the [H+] and so an increase in 
acidity may lead to iron release via a reductive pathway.     
 
1.8.2  Enzymatic Release 
 
Although the ferri-enterobactin complex has been the most studied in terms of its iron release 
mechanism, there is no consensus on one mechanism for the release of the iron to the bacterial cell; 
several opposing theories have been put forward.   
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The Fes esterase enzyme that operates within the cytoplasm of the Gram-negative bacterium E. coli 
was found to be specific for the Fe3+-enterobactin complex.  A mechanism that involves the 
enzymatic hydrolysis of the enterobactin ligand by this enzyme leading to the eventual release of 
Fe3+ has been proposed.62   
The enzyme can hydrolyse both the apo- and ferri- forms of the siderophore.  Hydrolysis by Fes 
leads to the generation of dihydroxylbenzoylserine monomeric units binding Fe3+.26  The reduction 
potential of these monomeric units lies within the range of biological reducing agents and hence the 
process promotes Fe3+ release.   
This hypothesis has some strong supporting evidence as mutant organisms lacking the Fes esterase 
enzyme turn pink due to an accumulation of Fe3+-ent complex.  The inability to release intracellular 
Fe3+ without the esterase would suggest that it is vital for the release of Fe3+.65  However, once 
hydrolysed the monomeric units can no longer be utilised as siderophores, this poses a significant 
metabolic cost to the organism and thus has become one of the main opposing opinions to the 
enzymatic release proposal.66  However, it is worth considering that a lower concentration of 
enterobactin may be required to deliver sufficient iron to the cell in comparison to other, less potent 
siderophores.   
Alternatively, protonation of the Fe3+-ent complex leading to reduced stability of the complex or a 
conformation switch from the catecholate to salicylate binding mode has been suggested.  The 
salicyclate mode requires the protonation of the Fe3+-ent complex at the most basic catecholic site 
on each binding unit.64,66   
 
Figure 1.35 Diagram displaying the conformational shift due to protonation of a catecholate binding 
mode of iron to the salicylate mode 
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In addition, altering the lipophilicity of the complex environment or having a large concentration of 
Fe(II) chelant surrounding the Fe3+-ent complex have both been proposed as possible mechanisms 
by which seemingly irreducible complexes by biological means may be reduced in vivo.  These 
might promote a reductive, rather than enzymatic, release of iron to the bacterial cell.64   
The primary function of the Fes esterase in this latter scenario would be the degradation of the apo-
siderophore to limit the reformation of the of the ferri-siderophore complex.  The subtle difference 
here is that the Fes esterase is not required for the removal of iron from the complex but it is 
required for effective utilisation of the enterobactin-delivered iron.    
It is however still unclear as to which mechanism, or indeed combination of mechanisms under 
different conditions facilitates the release of Fe3+ from the Fe3+-ent complex in vivo.   
 
1.9 Synthetic Chelators 
1.9.1  Fe
3+
 Affinity  
 
There are now numerous examples of synthetic siderophores, some of which have stability 
constants and pFe3+ values approaching those of enterobactin, some well-studied examples are 
displayed in Figure 1.36.   
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Figure 1.36 Examples of literature chelators.  EMECAM (top left) carbocyclic triscatecholate 
(top right) TRENTAM (bottom left) TACN-MeHP (bottom right) 
 
EMECAM (Figure 1.36) is a triscatecholate siderophore mimic; the ethyl- groups were included to 
probe the hypothesis that bulky groups would promote the preorganisation of the catecholate 
moieties towards Fe3+ binding.67  When comparison is made between EMECAM, the methyl 
derivative MMECAM and MECAM (Table 1.3); we can see the larger the groups the more 
preorganisation towards chelation and in turn the higher the logKFe
3+ and pFe3+ values.53   
Table 1.3 Table displaying stability constants and pFe3+ values for synthetic chelators EMECAM, 
MMECAM and MECAM and natural siderophore enterobactin 
Ligand Logβ110 (FeL) pFe3+ 
Enterobactin 49 34.3 
EMECAM 47.1(3) 32.6 
MMECAM 45.8(5) 31.2 
MECAM 43 29.4 
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The increase in the stability as larger groups are added has been attributed to an entropic 
contribution to the thermodynamic stability i.e. the binding moieties have to perturb less to bind 
Fe3+.  This allows for the increase of 104 in the logβ110 and a 103 fold decrease in [Fe3+]free, almost 
approaching the pFe3+ for enterobactin itself.   
The triscatecholate carbocyclic molecule (top right, Figure 1.36) is an example of an incredibly 
high LogKFe
3+ value of 48.8 which approaches that of enterobactin (1049, Table 1.3).68  The 
molecule was designed to probe the role of core rigidity with respect to Fe3+ binding.  The 
carbocyclic structure displays some resemblance to the core scaffold of enterobactin in that it is in 
essence a 12 membered ring.  However, the carbon bridges it features serve to enhance the rigidity 
in the molecule, causing some preorganisation of the binding motifs towards Fe3+ chelation.   
TACN-MeHP (bottom right, Figure 1.36) is a hexadentate chelator comprised of a 
triazamacrocyclic core with bound functionalised pyridine rings.  Fe3+ is bound through a 
combination of the core scaffold and the hydroxyl functionality of the pyridine moieties.69,70  The 
pFe3+ of 40.3 exhibited by TACN-MeHP is the highest so far recorded for a chelator of synthetic or 
natural origin.  However, this molecule is not as closely related to siderophore mimics as the other 
molecules due to its different binding mode and so does not serve as a viable comparison in this 
project.  Although it displays an affinity for Fe3+ which is so far unrivalled its metal selectivity is 
significantly relaxed.  Consequently issues relating to TACN-MeHP toxicity, thought to be due to 
its binding of other metal ions such as Zn(II) in vivo have already emerged.  If applied to a bacterial 
culture, the bacteriostasis might arise through several contributing factors and a specific 
mechanism could be difficult to discern.71      
TRENTAM (bottom left, Figure 1.36) was originally designed to probe whether the integration of 
more terephthalamide groups onto the TREN core would lead to an increase in Fe3+ affinity of the 
ligand.72  TRENTAM possesses a pFe3+ of 34.2.  Only enterobactin (pFe3+ = 34.3), a macrobicyclic 
compound and TACN-MeHP have ever been reported to surpass this value.   
Analysis of the ligands discussed above have provided insights into design features that make an 
important contribution to powerful Fe3+ chelation.  The ligands mostly contain: hard Lewis-base 
donor groups (with the exception of TACN-MeHP), are hexadentate and the core unit itself or the 
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groups attached to the core serve to preorganise the binding moieties towards iron chelation.  It is 
these principles which therefore should be further explored in the design of new ligands in order to 
produce new synthetic chelators with improved Fe3+ binding properties compared to those 
described in the literature.   
 
1.9.2  Antimicrobial activity 
 
Inducing bacteriostasis through the application of a chelating agent has been a popular area of 
research for several years.  It is known that the virulence of pathogenic bacteria has been linked to 
their ability to acquire Fe3+ from their environment.  The application of a ligand which targets the 
binding of Fe3+  to bacterial populations should allow for restriction of nutrient iron and inhibit or 
distort the growth of the bacteria as a result.73   
There are several examples in the literature of successful inhibition of bacterial growth through the 
application of chelators.  These molecules tend to be high affinity Fe3+ ligands and are therefore 
said to be siderophore mimics.  However, several mechanisms of bacterial iron acquisition have 
been targeted.   
There are examples of siderophore mimics which restrict the extracellular Fe3+ availability and 
therefore reduce the growth rate of bacteria.  By way of example in 1983 Bergeron et al. tested a 
series of catecholamide iron, Figure 1.37.56   
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Figure 1.37 Structure of catecholamide chelators tested against organisms: E. coli, P. aeruginosa, 
C. albicans and S. aureus 
 
These ligands (Figure 1.37) were capable of inhibiting the growth of the bacteria E. coli, P. 
aeruginosa, S. aureus as well as the dimorphic fungus C. albicans.  In most cases the bacteria 
displayed an extended ‘lag’ period before growth was detected and they also failed to match the 
biomass yield achieved by untreated cultures.  However, it was noted that in some cases after an 
extended lag period rapid growth ensued.  This observation would be consistent with the bacteria 
secreting large quantities of their own siderophores competing for the available iron pool and 
overcoming the bacteriostasis imposed by the exogenous chelator treatment.   
Furthermore, in 1985 compounds such as EDTA, DTPA and HBED (Figure 1.38) were tested on a 
range of mastitis causing bacteria for their antimicrobial/bacteriostatic properties.  The research 
showed that the compounds were effective inhibitors of certain bacteria relating to this problematic 
infection.  The effect seemed to be more marked against Gram-positive bacteria, especially in the 
case for EDTA which was much less effective against E. coli than Staphylococcus aureus.73   
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Figure 1.38 Structures of EDTA (top left) DTPA (top right) and HBED (bottom) 
 
In addition, there are examples of synthetic siderophores, or toxic metal complexes of natural 
siderophores, which target the Fe3+ uptake systems of bacteria; through the blockage of the 
receptors necessary for ferri-siderophore uptake, growth inhibition can be induced.  One example 
of such is that of the Sc(III)- enterobactin complex.  In 1982 Rogers et al. described Sc(III) and 
In(III) enterobactin complexes as having a growth inhibitory effect on E. coli and K. pneumoniae.74  
They attributed this to competitive inhibition between the In(III)/Sc(III)-enterobactin complex and 
Fe3+-enterobactin uptake systems.   Evidence was presented that the Sc(III)-enterobactin complex 
even exerted a therapeutic effect on E. coli infected mice.   
An alternative method to target bacterial growth has been the ‘trojan horse’ approach.  The premise 
behind this method is the attachment of a molecule or antibiotic to a compound which is known to 
be taken up by the target organism.  Once inside, the bioactivation of the compound results in the 
release of the active antibiotic and, in turn, produces the inhibition.  This type of system has been 
shown to be effective against some mycobacteria and was reported in 2012 by Miller at al.75  In this 
case mycobactins were synthetically altered to accommodate an antibiotic agent such as 
artemisinin.  The mycobactin-artemisinin conjugate proved an effective inhibitor of 
Mycobacterium tuberculosis and also to four strains of Plasmodium falciparum (causative agent in 
malaria).  The siderophore-drug conjugates were ineffective against a panel of bacteria, showing 
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mycobactin has limited potential as a broad host range delivery device but could prove useful 
against two of the three most prevalent infectious diseases of our age.  
Of the three methods described (i) extracellular Fe3+ restriction (ii) Fe3+ receptor blocking and (iii) 
siderophore-drug conjugates; the extracellular Fe3+ restriction would seem to have the widest 
applications for use as a bacteriostatic approach.  Reasoned by, assuming the Fe3+-chelator 
complexes were not able to be metabolised or utilised by bacteria due to their ‘alien’ nature then 
the approach should target all bacteria which require Fe3+.  Whereas approach (ii) would be able to 
target certain uptake systems; however as previously discussed, bacteria have varied Fe3+ 
acquisition systems which cover a number of receptors, many of which are not characterised.  It 
would be therefore difficult to target a wide range of bacteria with this approach.  In addition, the 
use of metal complexes such as in the literature described, Sc(III) or In(III)  would be unsuitable 
for widespread usage throughout areas which require disinfection due to their toxicity.  The 
siderophore-drug conjugate approach would be an effective solution again to target specific 
organisms as the antibiotic agents required for the inhibitory effect are often specific to their target.  
This approach has the disadvantage to possibly promote resistance to the siderophore-drug 
conjugate and render the target immune to the compound.  As antibiotic resistance is a universal 
issue facing the healthcare services, this approach could be problematic in this area.   
An environment in which bacteriostasis induction would be of particular use is within hospitals.  
Over the past few decades the rise of cases of infection resulting from the hospital environment i.e. 
nosocomial and also involving those bacteria which are particularly virulent e.g. MRSA or VRE 
has been extensive.  The application of a bacteriostatic agent to the hospital environment may serve 
to reduce the number, or the population recovery time after disinfection of a surface.  This 
reduction in the growth of virulent organisms may serve to reduce the potential for the contraction 
of a nosocomial infection.   
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1.10 Scope of the Project 
 
The project aims to develop novel chelators which are strong and selective for binding Fe3+.  The 
chelators will be designed to be applied to previously disinfected surfaces to prolong the period of 
microbiological disinfection though restriction of nutrient Fe3+.     
The literature data suggests that, as the HOPO moiety provides powerful Fe3+ binding with 
synthetically accessible derivatives that are able to be incorporated into a core molecular scaffold to 
produce hexadentate ligands, this group is ideal to attempt to achieve nutrient Fe3+ restriction.   
The synthetic work within this project will involve the synthesis of novel hexadentate ligands based 
upon new and known core molecular scaffolds, which will be modified to include 
hydroxypyridinone binding moieties.      
The strategy will incorporate molecules that will probe synthetic space in order to optimise: core 
size and rigidity, spacer length and rigidity and HOPO isomer to produce strong Fe3+ chelation i.e. 
via modulating entropic and thermodynamic contributions to complex formation.  The core 
scaffolds and ligands themselves ideally should be resistant to biodegradative processes by, for 
example avoiding the incorporation of ester linkages within the core scaffold.  Additionally, the 
core scaffolds utilised in these ligands should not be biomimetic of known siderophore core 
scaffolds in the hope to avoid recognition and possible uptake of the ferric-ligand complexes.    
Once accessed synthetically the ligands will then be subject to microbiological testing.  The 
efficacy of the chelators to create a bacteriostatic effect will be assessed through assay of minimum 
inhibitory concentration (MIC).  The ligands will be tested on a diverse panel of clinically relavent 
microorganisms that differ in Gram-positive and Gram-negative species with differing iron 
acquisition systems.   
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Design and Synthesis of Novel Selective 
Fe3+ Chelators Based Upon 
Cyclotriguaiacylene Bearing 
hydroxypyridinone Moieties 
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2 Chapter Aims 
 
This chapter aims to introduce cyclotriguaiacylene (CTG) as a viable choice for a core molecule, 
on which to base Fe3+ chelators.  In addition, the chapter aims to provide the synthetic methodology 
required to produce the hexadentate chelators as shown in Figure 2.1.   
 
   
Figure 2.1 CTG based HOPO containing chelators 
  
The synthetic methodology will be provided for the core molecule as based on literature 
procedures.   The synthetic methodology for the HOPO units synthesised for attachment to the core 
will be given, based on literature procedures.  The 3,2-HOPO and 1,2-HOPO bidentate molecules 
have been the focussed upon due to their accessible derivatives which allowing for attachment to 
the core scaffold.   
The preparation of the protected hexadentate chelators and the subsequent deprotection methods 
are provided.    
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2.1 Introduction to CTG 
 
Cyclotriveratrylene (CTV, Figure 2.2) is a cone shaped, rigid, lipophilic molecule.  CTV is 
comprised of three substituted benzene rings, bridged by methylene groups, attributing the 
molecule with three-fold rotational symmetry.  Primarily, chemistry surrounding the molecule has 
focussed upon complexation of small ionic molecules e.g. MeNH4
+, within the ‘bowl’ molecular 
cavity.   It has since become popular as a scaffold on which to build supramolecular arrays.76   As a 
core scaffold unit itself, CTV cannot be directly functionalised to host the desired three bidentate 
ligands necessary to bind iron.  Therefore, there is a need for a synthetically accessible derivative 
of CTV which can be functionalised in such a way as to incorporate three units on its structure.    
 
Figure 2.2 Structure of CTV 
 
Such a molecule can be found in CTG (cyclotriguaiacylene, Figure 2.3);  CTG retains its cone 
shaped structure but has three hydroxyl groups in replacement of three methoxy groups on the rings 
of CTV.77  The rigidity and the three dimensional structure of CTG lend themselves favourably to 
the desired features previously discussed for strong chelation.  That is, the molecule has the 
potential to be functionalised with three units, in our case the HOPO moiety, forming a hexadentate 
ligand.  Also, the rigidity and the ‘cone’ or ‘bowl’ shape qualities of CTG may lend favourably to 
reducing the entropic penalty of metal complexation, by partially organising the binding moieties 
towards each other, as is observed for enterobactin (Figure 2.3).  Additionally, as a core scaffold 
CTG would be resistant to enzymatic processes such as hydrolysis, which have been surmised to be 
integral in the release of iron to the bacterial cell.  For example Fes enzyme in E. coli which breaks 
down the core unit of enterobactin to facilitate intracellular iron release, as discussed previously.    
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Figure 2.3 Structure of CTG (left).  Tube rendered models of crystallographic data (middle and 
right) displaying C3v symmetry (middle) and bowl like character (right).78 
 
Previously, CTG has been utilised as a scaffold on which to build Fe2+ and Fe3+ chelators.79,80  
These molecules contained: catecholate, hydroxamic acid and pyridine based binding moieties, 
tailoring their binding towards the Lewis acidity of the metal centre.  Examples of these molecules 
which have previously been accessed for the binding of iron and based upon CTG are shown in 
Figure 2.4 (2.3-2.5). 
 
Figure 2.4 Examples of literature Fe2+/Fe3+ chelators based on CTG scaffold 
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It can be noted that the positions of the phenolic -OH functionality and the –OMe are not randomly 
distributed but are in an alternating array around the molecule.  This attributes the CTG scaffold 
with C3 symmetry which should allow for functionalization to be concerted at all three positions.   
The literature data suggests that the core unit is accessible in multigram quantities, from 
commercially available starting materials,81 which is a desired quality for any synthetic 
undertaking.  To date, no known Fe3+ chelators have been produced based upon the CTG core 
which contain HOPO moieties as the binding motif.  In light of this and the qualities CTG 
possesses in relation to the core scaffold requirements, the molecule presents itself as a viable 
scaffold onto which HOPO groups can be coupled to facilitate Fe3+ binding.   
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2.2 Results and Discussion 
2.3 Ligand Synthesis 
2.3.1 Preparation of CTG (2.2) 
From literature sources, the trimerization of 3,4-substituted benzyl alcohols is an effective route to 
the desired core scaffold CTG.81  In particular the use of vanillyl alcohol (4-hydroxy-3-
methoxybenzyl alcohol (2.6), (Figure 2.5) would allow for the production of the compound on 
multigram scale.81,82   
 
Figure 2.5 Structure of vanillyl alcohol 
The synthesis of CTG by this route (Scheme 2.1) began with the allyl protection of vanillyl alcohol.  
The literature method was achieved successfully in yields of ~90%, using K2CO3 and allylbromide 
in acetone at reflux temperature.  The oligomerization of the allyl-vanillyl alcohol was then 
attempted and it was found that as described a 2:1 methanol:70% HClO4 would produce the tris-
allyl-CTG (2.8) in yields 27-60%.  A 10:1 ratio was attempted at first to limit the use of the acid 
however this failed to give the product.  Subsequent deprotection of this allyl-CTG with Pd/C 
under acidic conditions in ethanol-dioxane (2:1) gave the desired CTG in yields up to around 60% 
(but as low as 20% in some instances).     
  
Scheme 2.1 Synthetic route for CTG. Reagents and Conditions: (i) allyl bromide, K2CO3, acetone 
(ii)70% HClO4 in MeOH (iii) Pd/C, 70% HClO4, EtOH, dioxane 
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As an aside, another method which promised a solvent free route to the allyl-protected CTG,83 was 
also attempted, Scheme 2.2.  It involved the grinding together of the allyl-vanillyl alcohol (2.7) 
with paratoluenesulfonic acid, without solvent and thus was attractive for its potential ‘green’ 
chemistry implications.  However, unfortunately this did not produce the tris-allyl CTG as 
described and was subsequently abandoned in view of the less green but ultimately more effective 
method previously described.   
 
Scheme 2.2 Solvent free synthesis of 2.8.  Reagents and condition: (i) p-TsOH, pestle and mortar 
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2.3.2  Synthesis of 3-Benzyloxy-1-(2-chloroethyl)-1H-pyridin-2-one (2.13) 
 
A diverse range of HOPOs are now synthetically achievable for all three positional isomers within 
the greater HOPO family (1,2-HOPO, 3,2-HOPO and 3,4-HOPO).  Many of these HOPO moieties 
have the capabilities to be attached to the core molecules realised herein.  However, the 3,2-HOPO 
has some of the most established chemistry.  The 3,2-HOPO can be manipulated to incorporate 
various alkyl chains on the N-position of the ring, hence lending favourably to try and create 
molecules with various chain length as previously mentioned.   
The 3,2-HOPO was therefore chosen as the isomer of HOPO to attempt and attach first to CTG.  
The synthetic route taken to reach 3-Benzyloxy-1-(2-chloroethyl)-1H-pyridin-2-one, a benzyl 
protected 3,2-HOPO with possible attachment point on the haloalkane chain, as has been 
previously shown, is depicted in Scheme 2.3.   
 
Scheme 2.3 Synthetic route to 2.13.  Reagents and conditions: (i) ethyl bromoacetate, 155°C, 48 
hours (ii) 90% MeOH, NaOHaq (4M), BnBr/BnCl, reflux 8hours (iii) borane-THF, dry THF, rt (iv) 
TsCl, Et3N, dry DCM/DCM, SOCl2 reflux 
 
The preparation of  3-benzyloxy-1-(2-chloroethyl)-1H-pyridin-2-one began with the synthesis of 1-
[(ethoxycarbonyl)methyl]-3-hydroxy-2(1H)-pyridinone (2.10) from 2,3-dihydroxypyridine (2.9) 
and ethyl bromoacetate under reflux for 48 hours.21  The reaction produces the pure compound in 
25-50% yield (lit. 77%).  Due to the large excess of ethyl bromoacetate required for this first step 
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(5 equiv.) it was briefly investigated whether this reaction could be made more economical, with 
respect to limiting the amount of this toxic reagent.  The use of dyglyme as a high boiling point 
solvent with sodium iodide catalyst, in the presence of equimolar amounts of 2,3-
dihydroxypyridine and ethyl bromoacetate was tried.  The reaction was stirred at 140-150°C for 48 
hours; unfortunately the only recovered product from the reaction was starting material.  In light of 
this the literature methodology was returned to. 
The following step in the reaction series is the benzyl protection of the 3-hydroxyl group on the 
pyridinone ring system and the parallel hydrolysis of the ester group to produce 3-(benzyloxy)-1-
(carboxymethyl)-2-(1H)-pyridinone (2.11).21  The reaction yields the desired product as a pure 
solid in yields around 60-70% (lit. 83%).  The literature procedure facilitates the use of BnCl as the 
protecting reagent, however it was found this produced lower yields than using benzyl bromide and 
so this reagent was used in its place.     
The reduction with borane-THF complex to produce 3-benzyloxy-1-(2-hydroxyethyl)-1H-pyridin-
2-one (2.12) has been previously described and the procedure was followed as published, with the 
exception of the requirement of up to 5 equivalents of borane-THF complex to drive the reaction to 
completion.84  Also, it was found that the product was not pure enough to be used without 
purification by column chromatography, however once this was performed the pure alcohol was 
isolated in yields typically around 30% (lit. 90%). 
Finally the substitution reaction to produce the desired 3-benzyloxy-1-(2-chloroethyl)-1H-pyridin-
2-one (2.13) was followed as described in the literature.  With typical yields of ~80% after 
purification via column chromatography, the reaction proceeds as expected.   To try and improve 
upon the yield of the reaction it was attempted with SOCl2 in dry DCM under reflux.  Although the 
product is realised from this reaction, with a yield before purification of 61%, it was found that the 
literature method was more effective.  The reaction time utilising tosyl chloride is 4 days (see 
experimental), it is thought initially the tosylate is formed and then this then reacts with the 
chloride anion to produce the desired chloride.84  The use of tosyl chloride over SOCl2 for 
chlorination is not extensive in the literature and so one could hypothesise that the authors intended 
55 
 
to make the tosylate analogue of the 3,2-HOPO but found the chloride under these conditions 
dominated as the product.   
 
2.3.3  Synthesis of 3-Benzyloxy-1-(2-chloropropyl)-1H-pyridin-2-one (2.17)  
 
In an attempt to create a more diverse library of chelators containing the HOPO functionality, the 
chain length of attachment, or the spacer group, between the core and the HOPO was lengthened. 
The aim being that the viability of the attachment of the groups to the core would be similar, but 
produce molecules which could be compared with only one variable.   
Therefore, the synthesis of 3-benzyloxy-1-(2-chloropropyl)-1H-pyridin-2-one (2.17) was of interest 
and was successfully achieved by initially following a procedure involving the CsF assisted 1,4-
Michael addition of ethyl acrylate to 2,3-dihydroxypyridine to produce 1-[(ethoxycarbonyl)ethyl]-
3-hydroxy-2(1H)-pyridinone (2.14), Scheme 2.4,  in yields typically 60-70% (lit. 74%) as the pure 
product.85  
 
Scheme 2.4 Synthetic route to 2.17.  Reagents and conditions: (i) ethyl acrylate, CsF, MeCN, 90°C, 
48 hours (ii) 90% MeOH, NaOHaq (4M), BnBr/BnCl, reflux 8 hours (iii) borane-THF, dry THF, rt 
(iv) TsCl, Et3N, dry DCM/DCM, SOCl2 
 
The sequential steps in the synthetic scheme are analogous to those required for 3-benzyloxy-1-(2-
chloroethyl)-1H-pyridin-2-one (2.13).  The benzyl protection and in parallel ester hydrolysis occurs 
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as previously described for 2.10 to yield the pure 3-(benzyloxy)-1-(carboxyethyl)-2-(1H)-
pyridinone (2.15) in yields typically 50-70%.  Compound 2.15 is thought to be novel in that it has 
not previously been isolated in any known literature procedure to date, though molecules 2.16 and 
2.17 have been previously accessed. The reduction with borane-THF yields the crude product and 
after purification the pure alcohol, compound 2.16 can be achieved in 30-40% yield.  The 
chlorination of the alcohol with TsCl proceeds as described previously for 3-benzyloxy-1-(2-
chloroethyl)-1H-pyridin-2-one (2.17) and yields the desired chloride in 52% yield after purification 
via column chromatography.  As in the previous synthesis the use of SOCl2 in the chlorination step 
has been explored for this molecule.  The results were found to vary between repeats.  In one 
experiment, the reaction has yielded the product as a crude solid in yield 36% after purification, but 
a further attempt produced near pure 2.17 in almost quantitative yield, requiring little to no 
purification.  The reason for this is unclear, however both methods employed produced the desired 
compound which can be isolated in excellent purity after column chromatography.   
 
2.3.4 Coupling of Prepared 3,2-HOPO Moieties with CTG 
 
Functionalization of CTG with the 3,2-HOPO was firstly attempted via substitution chloride of 
2.13  by CTG on the three sites (Scheme 2.5).  
 
Scheme 2.5 Addition of 2.13 to CTG.  Reagents and conditions: (i) NaH, DMF, (ii) K2CO3, acetone  
 
57 
 
Firstly, the synthesis was attempted using a modified literature method, involving functionalization 
CTG through an alkyl halide.28  The method employed the use of NaH in DMF.  These conditions 
were explored but unfortunately the isolated product from the reaction was thought to be the result 
of elimination of HCl from the alkyl halide chain at the N-position of the 3,2-HOPO moiety (2.19, 
Figure 2.6).  In light of this, the reaction conditions were altered to accommodate for the tendency 
of the N-alkyl group to degrade in the presence of strong nucleophiles.      
 
Figure 2.6 – Chemical structure of the product thought to be the result of using NaH as a base 
 
Alternative conditions attempted included the use of K2CO3 with acetone as a solvent.  
Unfortunately, this reaction did not proceed as expected and a complex mixture of products was 
recovered after separation by column chromatography.  It was noted that upon addition of K2CO3 
to CTG the solid changed to a deep green from an off-white.  This could have been due to the 
incorporation of the K+ ion into the ‘bowl’ like cavity of deprotected CTG and is one hypothesis as 
to the failure of the reaction.  This hypothesis could be tested via the addition of 18-crown-6 to the 
green solution to see if any colour change occurs, possibly the result of the competition for the K+ 
ion, however this needs to be attempted to give evidence towards the hypothesis.  Failing to 
produce the target molecule for the shorter chained 3,2-HOPO-chloride, analogous conditions were 
used to attempt the reaction with the longer chained 3,2-HOPO-chloride, Scheme 2.6. 
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Scheme 2.6 Addition of 2.17 to CTG. Reagents and conditions: (i) NaH, DMF, (ii) K2CO3, acetone 
(iii) K2CO3, acetone, NaI (iv) Cs2CO3, MeCN 
 
Conditions attempted to produce the target molecule 2.20  (Scheme 2.6) were K2CO3 with acetone 
as the solvent with the addition of NaI as a catalyst.  This reaction, as previously seen for the 
shorter chained 3,2-HOPO produced a complex mixture of products.      
In addition, Cs2CO3 as a base in MeCN was tried; however this too failed to produce the target 
molecule.  Here, Cs2CO3 was used to attempt to prevent the potential incorporation of the cation 
into the cavity of CTG, K+ seemed to preferentially bind to the core scaffold however, the Cs+ ion 
is larger and so it was hypothesised that incorporation of the cation would be somewhat decreased.  
Although the resulting product was not of compound 2.20 it was observed that the previously noted 
colour change did not occur when using Cs2CO3.   
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2.3.5 Preparation of Iminuim Salt (2.21) 
 
In light of the failing of 2.13 and 2.17 to react with CTG via the expected route, a different 
synthetic methodology was required.  Literature data provided an alternative bidentate unit which 
would allow the target compound to be accessed, the iminium salt (2.21), Scheme 6.39 
 
Scheme 2.7 Formation of iminium salt (2.21).  Reagents and conditions: (i) (MeSO2)2O, Et3N, dry 
DCM (ii) CHCl3 
 
2.21 was prepared in accordance with the literature procedure.   2.12 was stirred at room 
temperature in dry DCM under an inert atmosphere with Et3N and mesyl anhydride.  This produces 
the corresponding mesylated 3,2-HOPO which when stirred in chloroform, rearranges to produce 
2.21 in high purity and good yields (72-85%).  The 3,2-HOPO-hydroxyl intermediate was prepared 
as previously discussed.    The compound was stored under an inert N2(g) atmosphere at 4°C prevent 
degradation by atmospheric moisture.   
2.21 has been shown to be susceptible to ring opening reactions at two sites, Figure 2.7.85,86  Path A 
is the desired route to the addition of the moiety to the core scaffold.  Path B has been shown to be 
the product isolated in those reactions where the nucleophile (Nu-) is a primary amine.  The 
reaction of this group with more hindered amine nucleophiles and other functionality such as: 
phenols, thiols and hydroxyalkanes has been shown to favour the desired Path A, however; in the 
synthesis of the novel ligands utilising this group, though it would be unexpected, the possibility of 
the reaction occurring via Path B is always present.    
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Figure 2.7 Demonstrating the possible ring opening pathways of 2.21 with a nucleophile (Nu-) 
 
2.3.6  Preparation of the novel CTG-3,2-HOPO (2.22) ligand  
 
The reaction between CTG and 2.21 (Scheme 2.8) progressed well under conditions of Cs2CO3, dry 
MeCN, under reflux.  The crude product was accessed in high yield; subsequent purification of the 
crude product via column chromatography gave the desired (2.18) in excellent yield (93%).  As 
expected the reaction pathway for the ring opening of 2.21 by the CTG core scaffold progressed via 
the desired Path A and not Path B.   
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Scheme 2.8 Reaction of iminium salt (2.21) with CTG (2.2).  Reagents and conditions (i) Cs2CO3, 
dry MeCN, reflux (ii) 1:1 37%HClaq and glacial acetic 
 
The subsequent deprotection of molecule 20 was achieved through a standard debenzylation 
performed in 1:1 37%HClaq and glacial acetic acid over several days.  The free ligand could be 
achieved in high purity through precipitation with ether from MeOH, after being stored at 4°C for 2 
days.  The yields for this deprotection were variable, from 12-28%.  Undoubtedly, some of the 
compound did not precipitate out of solution when ether was applied and the reaction purification 
stage requires optimisation.       
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2.3.7 Preparation of novel 6-(chloromethyl)-1-(prop-2-en-1-yloxy)-1,2-dihydropyridin-2-
one (2.28) 
 
To achieve a variety of HOPO groups on the CTG scaffold a synthetically accessible derivative of 
the 1,2-HOPO was developed to allow for attachment to nucleophilic core scaffolds, such as CTG.   
The synthetic methodology for the preparation of 2.28 was developed in house and is yet to be 
published.1   
   
 
Scheme 2.9 Synthetic route for 1,2-HOPO molecules (2.24-2.28).  Reagents and conditions; (i) 
peracetic acid, acetic acid (ii) SOCl2, MeOH (iii) Allyl bromide, K2CO3 (iv) NaBH4, MeOH, THF 
(v) SOCl2, dry DCM 
 
The preparation of 2.28 began with the N-oxidation of 6-hydroxy-picolinic acid (2.23), as has been 
previously shown in the literature.87  However, it was found that the literature procedure 
requirement for TFA was unnecessary and the compound could be isolated in good purity and yield 
following through oxidation with peracetic acid in acetic acid.  The reaction proceeds as expected 
to yield the desired N–oxide (2.24) in good yields (73-76%) and high purity, the crude isolate 
requiring no purification.87  Step (ii) involves the methylation of the free acid (2.24) to ensure that 
                                                     
1 Synthetic methodology developed by David Workman, to be published.   
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over allylation does not occur in the following step.  The methylation occurs as is reported in the 
literature to give 2.25 in excellent yields (up to 96%) and high purity, again requiring no 
purification.88  Step (iii) yields the N-allyloxy protected HOPO (2.26) in yields of up to 98% 
without requiring purification.  The subsequent reduction of 2.26 to the hydroxymethyl-1,2-HOPO 
(2.27) derivative was developed following a literature procedure and yields novel 2.27 in yields up 
to 41%, often requiring purification by column chromatography.89  The chlorination of 2.27 occurs 
with good purity and yields of up to 81%, without the need for purification to give 2.28.   
2.3.8 Preparation of the novel CTG-1,2-HOPO (2.30) ligand 
The formation of the protected tris-ally-CTG-1,2-HOPO molecule 2.29, was successfully 
performed in dry MeCN with Cs2CO3 to yield the desired compound in yields up to 79% after 
purification.   
 
Scheme 2.10 Synthetic route for molecule (2.30).  Reagents and conditions; (i) Cs2CO3, dry MeCN 
(ii) Pd/C, 0.15M TFA, dioxane:H2O (4:1) 
64 
 
The subsequent deprotection of 2.29 to yield the free ligand was achieved utilising a literature 
method.90  The method employs using Pd/C catalyst with H2O:dioxane (1:4) as the solvent with 
0.15M TFA.  The reaction proceeds at reflux overnight to yield the desired 2.30 in yields up to 
87%, the pure ligand could be isolated by precipitation from MeOH with diethyl ether.     
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2.4 L:Fe
3+
 Stoichiometry Determination 
2.4.1 Modified Job’s Plot Analyses for 2.22 and 2.30 
 
L:Fe3+ stoichiometry was determined via a method described in the Experimental section, which is 
based on a literature procedure for L:M stoichiometry determination.91   
The modified Job’s plot analyses for 2.22 shows, in the first instance, after 2 days of equilibration a 
ligand: metal stoichiometry of 1:1.  This would suggest efficient binding of the metal by the ligand 
as the desired stoichiometry was reached after a short time.  To assess the stability of the complex 
in solution, and therefore the thermodynamic favourability, the measurements were repeated after 
14 days equilibration.  The results after 14 days showed the system was still displaying the same 
stoichiometry which would suggest that the binding of Fe3+ by this ligand was kinetically and 
thermodynamically favoured.  
 
 
Figure 2.8 Modified Job's plot analysis for 2.22 binding Fe3+ after 2 days.  Measurements taken at 
room temperature in DMSO/H2O.   
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Figure 2.9 Modified Job's plot analysis for 2.22 after 14 days.  Measurements taken at room 
temperature in DMSO/H2O.   
  
The modified Job’s plot analysis for 2.30 showed in the first instance that after 2 days to equilibrate 
the system had reached a ligand:metal stoichiometry of 1.7L:1M.  This ratio shows ineffective 
metal binding by the ligand, from the ideal 1:1 stoichiometric ratio.  This could be result of the 
methylene bridges being insufficient to allow for thermodynamically stable metal binding.  
Alternatively, this could be the result of a slow rate of metal chelation by the ligand; the 
measurements were therefore repeated after 14 days of equilibration.   
 
 
Figure 2.10 Modified Job's plot analysis for 2.30 after 2 days.  Measurements taken at room 
temperature in DMSO/H2O.   
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Figure 2.11 Modified Job's plot analysis for 2.30 after 14 days.  Measurements taken at room 
temperature in DMSO/H2O.   
 
The data shown in Figure 2.11 for 2.30 displays a L:Fe3+ ratio of 1L:2M.  The resulting re-
equilibration of the system to incorporate more of the metal bound would suggest that the initial 
binding was slow.  However, upon reaching an equilibrated state it appears the ideal 1:1 ratio has 
been exceeded.  This could suggest the ‘bowl’ like character of CTG could be accommodating 
some of the Fe3+ cation, as has been shown for this core for a number of small ionic guest 
molecules.   
 
2.5 Chapter Conclusions 
 
This chapter has presented the successful design and synthesis of two novel hexadentate chelators, 
based upon the core molecular scaffold CTG.  The chelators have design features which owe to the 
strong and selective binding of Fe3+ such as the inclusion of the HOPO moieties and the potential 
preorganisation the scaffold provides.   
The synthetic methodologies for the ligands presented utilises readily available starting materials 
which are converted into the final ligands in several steps.  The synthetic routes for the 3,2-HOPO 
moieties are from literature procedures and are all high yielding reactions, with little room for 
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improvement.  In the 1,2-HOPO case, most of the reactions to obtain the 1,2-HOPO-chloride are 
high yielding except the reduction step, there is room here for improvement to the yield of the 
reaction, however the high purity which can be obtained from these methods is favourable.  
The protected ligands are able to be accessed in good yields with high purity.  The conditions 
required for their synthesis are mild and would lend well towards scale up to multi-gram quantities.  
The deprotection steps to access the free ligand 2.22 containing the 3,2-HOPO units, although 
provides the ligand with good purity does so in relatively low yields.  This could be due to the 
purification via precipitation from methanol; some of the ligand may still be dissolved, lowering 
the accessible yield.  However, the deprotection of 2.29 to access ligand 2.30 gives the pure 
product in 87% yield, which would lend itself well to scale up reactions.  Although, alternative 
deprotection methods were not tested, one which does not require the use of a Pd/C catalyst would 
be more favourable in terms of ‘green-ness’ and more suited to scale up.   
The UV-Vis analysis of the stoichiometry regarding the binding of Fe3+ yielded some interesting 
results.  2.22 showed efficient 1:1 L:Fe3+ binding after the initial reading and, in later readings also.  
This would suggest that the ligand does in fact bind Fe3+ with some degree of affinity and the 
resulting complex formed is both thermodynamically and kinetically stable over the time period.  
The analyses for (2.30) show that at the 2 day measurements the L:Fe3+ stoichiometry is measured 
at 1.7L:1M, however we see this re-equilibrate to 1:2 L:Fe3+ stoichiometry after 14 days.  This 
result could be indicative of the incorporation of the Fe3+ into the molecular cavity of CTG as well 
as the binding of Fe3+ by the HOPO moieties.  This hypothesis would also go towards confirmation 
that the K+ cation, as previously discussed, may also be incorporated into the molecular cavity of 
CTG preventing the nucleophilic attack of the 3,2-HOPO-chlorides (2.13 and 2.17).  However, we 
do not see this behaviour for ligand (2.22).  One possibility is that the longer chained HOPO 
ligands are more sterically hindering and therefore restrict the access to the ‘bowl’ cavity of CTG, 
preventing the binding of a secondary ion.  This is yet to be established and is therefore only 
speculative at this point, further work is required to confirm.   
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2.6 Future Work 
 
For the CTG scaffold, work which could extend what has been presented herein could take the 
form of improving the aqueous solubility of the ligand, possibly by functionalising the core 
scaffold with polar groups such as sulfonate.   
In addition, though unsuccessful in this work, the achievement of the longer chained 3,2-HOPO on 
this scaffold would be a useful derivative for comparison and for determining how the chain length 
serves to effect the binding properties of ligands based on this core.   
The data shows the possibility of 2.30 binding greater than one equivalent of Fe3+ after a 14 day 
period.  This is an interesting property of this particular ligands and further study to confirm this or 
the achievement of a crystal structure of such a complex would be of particular interest.  The 
addition of a longer-chained 1,2-HOPO derivative would also be of particular interest here so as to 
see if the greater than 1:1 stoichiometry for the complex still exists for this derivative.  However, 
the bidentate longer chained 1,2-HOPO has not yet been accessed in a form which would allow for 
its attachment to the CTG scaffold.       
The elucidation of the thermodynamic properties of the ligands i.e. pFe3+ and logβ values would be 
necessary to allow a comparison between the structural features of the ligands and the effect this 
has on binding strength.  This data would also give an insight into differences noted between 
ligands when applied to a biological system.   
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Utilisation of the 1,3,5-tris(aminomethyl)-
2,4,6-triethylbenzene Core Scaffold in the 
Synthesis of Novel Fe3+ Chelators Bearing 
hydroxypyridinone Binding Groups 
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3 Chapter Aims 
 
The aims of this chapter are to introduce 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene (Figure 3.1) 
as a core molecule with potential to produce powerful Fe3+ chelators with the addition of HOPO 
binding groups.  The core introduction includes previous work in this area and how this research is 
a logical expansion of that. 
 
Figure 3.1 Structure of 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene (3.1)  
 
The synthetic methodology for the core scaffold will be provided, based upon literature data.  In 
addition the synthetic methods for the bidentate HOPO moieties which have not been previously 
discussed will also be provided herein.   
The synthesis will be provided for the coupling of the bidentate units to the core scaffold and the 
subsequent deprotection of the hexadentate protected ligands.  The 1,2-HOPO, 3,2-HOPO and 3,4-
HOPO have all been accessed for this core molecule providing a range compounds for comparison.  
In addition, the synthesis of the previously accessed EMECAM will be described, following 
procedures based on previous literature.     
Analysis of the compound’s L:Fe3+ stoichiometric ratio, determined using UV-Vis spectroscopy 
and a modified Job’s plot analysis is provided.   
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3.1 Introduction to 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene  
 
3.2 Previous technology 
 
Previously, the 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene core scaffold has been explored by 
Raymond et al. due to the ababab arrangement (groups arranged on alternating faces) of functional 
groups around the benzene core.  This core has also been explored for Fe3+ chelation with 
catecholate binding groups.  Molecules MECAM, MeMECAM and EMECAM were synthesised 
by Raymond et al.  and reported in 1997.67  
  
 
Figure 3.2 Structure of previous catecholate containing ligands MECAM, MeMECAM and 
EMECAM based upon the 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene core scaffold 
 
As previously discussed (Chapter 1, Introduction) the EMECAM ligand, which bears ethyl 
functionality on the core scaffold which facilitates in the predisposition of the binding moieties 
towards Fe3+ chelation, has a high affinity for Fe3+.  As a result, the affinity for the metal centre has 
been reported as logβ110 = 47.1 and pFe3+ = 32.667 which is approaching that of enterobactin logβ110 
= 49 and pFe3+ = 34.3. 
The literature also provides information on the amide functionality of attachment and the effect that 
methylation at the 2° amide anchor has on the binding affinity of MECAM derivatives (3.3).  This 
work reported in 1999 by Hider et al. was an investigation into the synthesis and properties of 
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ligands bearing 3,2-HOPO functionality.  This article showed that employing TBTU (N,N,N′,N′-
Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate) as a coupling reagent for acid-
functionalised HOPO groups to the MECAM triamine core scaffold could be a viable synthetic 
methodology to produce ligands based on this core.  The structures and binding affinities were 
provided for the ligands shown in Figure 3.3.   
 
 
Figure 3.3 Structures of ligands presented in Tetrahedron, 1999, 55, 1129-1142 conatining 3,2-
HOPO moiety as the binding mode 
 
The ligand bearing 2° amide functionality (R=H) displayed a logβ110 of 28.2±0.84 and pFe3+ of 
24.8.  Methylation of this position was shown to alter the affinity constants minimally as when R = 
Me, logβ110 = 28.7±0.64 and a pFe3+ of 25.1.92  The data showed that the disruption of the possible 
H-bonding network available to the 2° amide has little influence on the stability of complex 
formation. 
In addition to being utilised for Fe3+ binding, the core scaffold has also been used to build sensors 
for citrate and monosaccharides.  Examples of the structures of these molecules are displayed in 
Figure 3.4.93,94 
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Figure 3.4 Molecules based upon the core 1,3,5-functionalised-2,4,6-triethylbenzene scaffold used 
for monosaccharide molecular recognition (left) and a citrate receptor (right) 
 
Interestingly in 1998, Ward and Lutz published the synthesis of Fe2+ and Fe3+ chelators based upon 
the triethylbenzene core scaffold.95  They reported the synthesis of a ligand with the potential 
property to switch binding mode depending on the oxidation state of the metal centre. The 
dodecadentate ligands which could host either Fe3+/Fe2+ or a combination, Figure 3.5, were 
synthesised based upon the triethylbenzene and TREN core scaffolds.  The harder metal centres 
preferring the inner coordinative atoms i.e. oxygen donors closer to the core scaffold where the 
softer metal centres would preferentially bind the bipyridine moieties       
 
Figure 3.5 Example of a potential redox active Fe3+/Fe2+ dodecadentate chelator reported in 1998 by 
Ward and Lutz 
75 
 
The molecule incorporates both hard and soft donor sites and so can accommodate either iron 
oxidative state.  The ligands presented have the potential to sequester iron from the whole available 
pool which includes Fe(II) species, this could have attractive potential uses in the distortion of 
bacterial growth.   
 
3.3 Bacterial testing 
 
Molecules based upon the functionalised triethylbenzene scaffold have been shown to have effects 
on the growth of bacteria.  In 1983 Raymond et al. published the effects of several enterobactin 
analogues on the growth profiles of E. coli strains.96  It was discovered that both MECAM and 
MMECAM promoted the growth of several strains of E. coli, including those which were lacking 
the enterobactin receptor protein in the outer membrane.  The results indicate that there is potential 
for the core scaffold to be utilised by bacteria and therefore have a promoting effect on the 
clinically relevant strains, rather than the desired bacteriostasis.  Also, there is an increased risk of 
this occurring due to the analogues not appearing to be taken through specific membrane receptors, 
several uptake mechanisms seem to be operational.   
However, the novel ligands to be presented herein contain HOPO moieties as the binding mode 
and, although these are bioisosteric with the catecholate moiety, the binding groups around the 
metal centre have been shown to be important in receptor recognition and so may help to reduce 
the potential of the ligands to be utilised by bacterial nutrient sequestration systems.   
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3.4 Results and Discussion 
3.5 Ligand Synthesis 
3.5.1 Synthesis of 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene (3.11) 
 
The successful synthesis of the core scaffold has been previously reported via two synthetic routes.  
The first stage of the core synthesis is the same for both synthetic routes and involves the formation 
of the 1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene molecule.   
 
 
Scheme 3.1 Synthetic routes for the synthesis of core scaffold 1,3,5-tris(aminomethyl)-2,4,6-
triethylbenzene (3.11).  Reagents and conditions: (i) paraformaldehyde, 33% HBr in acetic acid, 
ZnBr2, 90°C (ii) DMSO, potassium phthalimide, N2(g) (iii) N2H2.H2O, EtOH/toluene, reflux (iv) 
NaN3, DMF (v) PPh3, THF, H2O 
 
The synthesis of 3.8 from 1,3,5-triethylbenzene proceeds as in the literature.94  Paraformaldehyde is 
dissolved in 33% HBr solution in acetic acid, to which 1,3,5-triethylbenzene (3.7) is added with 
ZnBr2 and the mixture heated to 90°C for 20 hours.  The resulting precipitate is collected and after 
washing with H2O and being dried in a desiccator yields the pure compound in yields 74-76% (lit. 
97%).   
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The next synthetic stage had the option to synthesise the triphthalimide derivative or the triazide.  
To limit the potentially dangerous use of NaN3, a potent toxin and also to avoid the synthesis of 
potentially dangerous relatively low molecular weight azide compounds the preparation of the 
triphthalimide (3.9) was attempted.94  3.8 was stirred with potassium phthalimide in DMSO and 
worked up as described in the literature.  Unfortunately, a mixture of products was obtained and the 
pure compound was never isolated as described.  The alternative synthetic route for this compound 
and the literature procedure for the synthesis of this compound described the use of a slurry of 
NaN3 being poured down the condensing unit to the compound at 80°C.
93  However, it was 
discovered that simply stirring in DMF at room temperature was sufficient to provide the desired 
compound.  The reaction was easily followed by TLC and after work up yielded the pure 
compound 3.10 in yields around 45% (lit.89%).93  Following this synthetic route the triazide was 
reduced to the desired core molecule 3.11 via the Staudinger reaction with PPh3, in THF and H2O 
in 77% yield (lit. 99%).93     
 
3.5.2 Preparation of 3-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid 
(3.14) 
 
The retro-3,2-HOPO bidentate unit has previously been prepared in the literature.  The 
methodology described the use of NH3(g) in the first stage of the HOPO formation.  Instead of this 
H4N
+-OAc was used as a source of NH3 to avoid handling the gas.
97   
 
Scheme 3.2 Synthetic route for retro-3,2-HOPO.  Reagents and conditions: (i) THF, AlCl3 (ii) MeI, 
DMF, K2CO3 (iii) 1:1 MeOH:4M NaOH then 37% HCl 
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The preparation of 3.14 which includes carboxylic acid functionality, to allow attachment to the 
core scaffold is the reaction between chloroacetone, H4N
+-OAc and sodium diethyloxy acetate in 
the presence of AlCl3 to produce the unprotected retro-3,2-HOPO-ester functionalised 3.12, 
Scheme 3.2 in yields 35-43%.  The next stage in the preparation is dimethylation/protection of the 
free hydroxyl and amine functional groups.  This is done with MeI in DMF with K2CO3.  The 
reaction proceeds to give the desired crude product 3.13 which is used in the next stage without 
purification.98  The hydrolysis of the 4-ethyl ester groups takes place in MeOH with an equivolume 
of 4M NaOH(aq).  The reaction is refluxed for 4 hours and, once the MeOH has been removed, 
acidification yields the crude product.  This is recrystallised in EtOAc to yield the pure acid 3.14 in 
yields around 50% as a tan solid.98   
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3.5.3 Preparation of 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid (3.15) 
 
The synthesis of 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid has been previously 
reported.87  This compound allows for the incorporation of the 1,2-HOPO binding group onto this 
core scaffold via an amide linkage.  The molecule was synthesised as per the literature procedure. 
 
Scheme 3.3 Reaction scheme for the synthesis of the 1,2-HOPO-acid functionalised.  Reagents and 
conditions: (i) K2CO3, BnBr, MeOH at reflux, 37% HCl(aq) 
 
The synthesis of 3.15 began with the previously synthesised 1,2-HOPO derivative (Chapter 2).  
2.24 is subjected to benzylation at the N-hydroxyl position by benzyl bromide in MeOH under 
reflux.  The acidification of the crude evaporated reaction mixture yields the pure product as a 
white solid in a good yield of 88%,.   
 
3.5.4 Preparation of 2-[3-(benzyloxy)-4-oxo-1,4-dihydropyridin-1-yl]acetic acid (3.18) 
 
The preparation of 3.18 was undertaken to allow for attachment of the 3,4-HOPO to the core 
scaffold, creating a series of ligands which incorporate a larger range of the possible HOPO 
isomers.  The synthesis (Scheme 3.4) begins with the benzylation of maltol (3.16).  This reaction is 
documented in the literature and occurs as is reported to give the desired benzyl protected maltol 
3.17 in yields of approximately 86%.99   
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Scheme 3.4 Synthesis of 2-[3-(benzyloxy)-4-oxo-1,4-dihydropyridin-1-yl]acetic acid (3.18).  
Reagents and conditions: (i) 8M NaOH(aq), MeOH, BnBr, reflux (ii) Sodium glycinate, H2O, reflux 
 
The latter stage of the synthesis to yield the protected 3,4-HOPO occurs by reaction of benzyl 
maltol (3.18) with sodium glycinate in H2O at reflux.
100  The reaction proceeds as in the literature 
procedure to yield the product in 65% yield, requiring no purification.   
 
3.5.5 Preparation of protected ligands based on the 1,3,5-triethylbenzene-2,4,6-
trisaminomethyl core scaffold (3.19-3.23) 
 
As previously discussed (3.1 Introduction to 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene) the use 
of TBTU was already reported in the literature as being appropriate for the successful coupling of 
trisaminomethyl-aryl core scaffolds to acid functionalised HOPO groups.53  The implementation of 
this method as described allowed for the preparation of the five ligands shown in Scheme 3.5.   
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Scheme 3.5 Synthetic route for molecules 3.19-3.23.  Reagents and conditions (i) TBTU, N-Me-
morpholine, dry DMF, 60°C 
 
The molecules 3.19 and 3.20 were accessed using the previously described molecules 2.11 and 
2.15. For all the molecules 3.19-3.23 the coupling reaction proceeds to completion after 24 hours at 
60°C.  The DMF is then mostly removed and, following purification by column chromatography 
produces the protected ligands in yields: 3.19 38-59% 3.20 41-50% 3.21 61-72% 3.22 82% 3.23 
59-64%.  This is an effective method to access 3.19-3.23, however the obtained yields for some of 
the molecules after purification were less than for the others.  When the same procedure is followed 
for each reaction it would be expected the yields to be approximately the same, especially between 
repeat reactions.  In this respect the method can be somewhat unreliable and perhaps other coupling 
methods could aid in the optimisation of the lower yielding reactions, though this is yet to be 
explored.   
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3.5.6 Preparation of final ligands based on 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene 
scaffold (44-47) 
 
The deprotection of the protected ligands 3.19-3.23 all occurred via the same method.  A standard 
O-benzyl deprotection of 1:1 HCl:AcOH was performed for all these ligands, Scheme 3.6.   
 
Scheme 3.6 Deprotection of ligands 3.19, 3.20, 3.22 and 3.23.  Reagents and conditions: (i) 
37%HCl:glacial acetic acid 1:1, 60°C 5-7 days 
 
The O-benzyl deprotection methods all produced the free ligands after several days at 60°C.  
Purification of the ligands was achieved through precipitation from MeOH with diethyl ether.  The 
ligands were collected via suction filtration and stored in a desiccator as they appeared to be 
hygroscopic.  Typical yields for the deprotection reactions were between 22-40% for the 3,2-
HOPO and 1,2-HOPO containing ligands.  The compounds were typically hygroscopic when 
isolated.     
The deprotection method for the O-Me protected ligand 3.21 (Scheme 3.7) was performed using 
BCl3 (1M in heptane) in dry DCM.  The reaction was stirred for 2 days under an inert N2(g) 
atmosphere and the pure product could be isolated after quenching with MeOH, evaporating to 
dryness and precipitation of the pure product 3.28 was achieved with MeOH.  The product could be 
isolated in typical yields of 55-60%.     
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Scheme 3.7 Deprotection of ligand 3.21.  Reagents and conditions: (i) BCl3 (1M in heptane), dry 
DCM, room temperature, N2(g), 2 days 
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3.5.7 Preparation of EMECAM (1.32) 
 
The hexadentate, triscatecholate ligand EMECAM has been previously accessed in the first 
instance by Raymond et al. via the following synthetic route, Scheme 3.8.   
 
Scheme 3.8 Previous synthetic route for EMECAM.  Reagents and conditions: (i) CHCl3, room 
temperature-60°C (ii) BBr3, DCM. 
 
The synthetic methodology requires the protection of 1,2-dihydroxybenzoic acid and the 
subsequent activation with 2-mercaptothiazoline of this compound before coupling the activated 
ester with the 1,3,5-trisaminomethyl-2,4,6-triethylbenzene core scaffold.  As has been previously 
noted the coupling reagent TBTU has successfully been utilised in the coupling of HOPO-acid 
derivatives with this core scaffold.  This method was therefore employed in the synthesis of 
EMECAM to the advantage that it would allow the synthetic route to be one step shorter, through 
negating the requirement of an activation step.   
The preparation of EMECAM began with the di-O-benzylation of the hydroxyl moieties on 2,3-
dihydroxybenzoic acid (3.31) the procedure for which was based upon literature precedent.101  This 
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reaction proceeded well with BnBr using K2CO3 as a base in a solvent of acetone.  The O-benzyl 
protective group was utilised here instead of the O-methyl because of the previous success 
achieved with the protection group on this core scaffold for the HOPO ligands.  The molecule 3.32 
was achieved and used without further purification in the subsequent step.   
 
Scheme 3.9 Preparation of EMECAM.  Reagents and conditions: (i) BnBr, K2CO3, acetone then 5M 
NaOH(aq), MeOH reflux (ii) 3.11, TBTU, N-Me-morpholine, DMF, 60°C(iii) dry DCM, BCl3 (1M 
in heptane), 18 hours, 0°C-room temperature 
 
The coupling of 3.32 and the core scaffold 3.11 was performed under the same conditions as those 
that successfully produced the protected ligands 3.19-3.23.  The coupling reaction proceeded as per 
previously discussed and gave the protected ligand in 52-54% yield after purification via column 
chromatography.   
The subsequent deprotection of 3.33 was attempted via the same method as per the other O-benzyl 
protected molecules.  Concentrated acids 37% HCl:glacial acetic acid (1:1) were employed as the 
deprotection method.  Unfortunately, the resulting product was not that of the expected deprotected 
molecule.  The crude residue lacked the purity of free ligand which had previously been achieved 
for the other ligands.   
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Alternative deprotection methods were therefore sought.  The deprotection via hydrogenation was 
attempted using Pd/C with a catalytic amount of H+ in EtOH and H2O.  However, this reaction after 
24 hours did not show complete removal of the benzyl protection by TLC.  This could have been 
the result of the inability of the catalyst to access all of the groups to be removed due to steric 
hindrance.  This method was therefore abandoned and as such a further method was sought.  The 
use of BCl3 in the removal of the O-benzyl groups proved to be an effective solution, Scheme 3.9. 
The deprotection of the O-benzyl groups via this method produced the free EMECAM ligand in 
85% yield as the pure compound after precipitation from MeOH with diethyl ether.  The compound 
was found to be hygroscopic and so stored in a vacuum desiccator over P2O5.    
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3.6 UV-Vis Spectroscopic Determination of L:Fe
3+
 Stoichiometry 
 
L:Fe3+ stoichiometry was determined via a method described in the Experimental section, which is 
based on a literature procedure for L:M stoichiometry determination.91   
 
3.6.1 Modified Job’s Plot Analyses for Ligands 3.24-3.28 
 
The modified Job’s plot analyses for the ligands 3.24-3.28 are presented.  In these analyses an 
intercept of 0.5 at the x axis would indicate a ratio of 0.5:0.5 L:Fe3+ would be indicative of a 1:1 
stoichiometric ratio.  Some of the solutions were subject to precipitation; therefore some of the 
Job’s plot analyses have been modified to omit spurious results for clarity.   
 
Figure 3.6 Modified Job's plot analysis for TEB-SC-3,2-HOPO 3.24 after 2 days.  Measurements 
taken at room temperature in DMSO/H2O.   
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Figure 3.7 Modified Job's plot analysis for TEB-SC-3,2-HOPO 3.24 after 14 days.  Measurements 
taken at room temperature in DMSO/H2O.   
 
The modified Job’s plot analysis for ligand (44) showed that after a 2 day period of equilibration 
time the calculable L:Fe3+ stoichiometric ratio was 1:1.  This indicates that the ligand binds the 
metal as expected and over a relatively short time period, owing to the kinetic viability of this 
ligand.    The L:Fe3+ stoichiometry after 14 days for ligand 3.24 was shown to be 0.45:0.55, which 
is still close to the 1:1 L:Fe3+ which was described for the 2 day reading.  This would suggest that 
the ligand complex is stable over this time period and so both thermodynamically and kinetically 
preferentially forms the 1:1 L:Fe3+ complex.   
-0.04
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0 0.2 0.4 0.6 0.8 1 1.2
A
-A
l-
A
m
 
[Ligand]/[Ligand]+[Metal] 
89 
 
 
Figure 3.8 Modified Job's plot analysis for TEB-LC-3,2-HOPO 3.25 after 2 days.  Measurements 
taken at room temperature in DMSO/H2O.   
 
 
Figure 3.9 Modified Job's plot analysis for TEB-LC-3,2-HOPO 3.25 after 14 days.  Measurements 
taken at room temperature in DMSO/H2O.   
 
For 3.25 the modified Job’s analysis shows, in the first instance that after 2 days the L:Fe3+ 
stoichiometry is 1:1.  This denotes efficient binding of the metal centre by the ligand, as designed.  
The measurements were repeated and after 14 days the L:Fe3+ stoichiometry was found to be the 
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same 1:1 as previously found.  This would be indicative of thermodynamic stability of the complex 
as the formed ferric complex is stable over a long time period.   
 
Figure 3.10 Modified Job's plot analysis for TEB-3,4-HOPO 3.26 after 2 days.  Measurements taken 
at room temperature in DMSO/H2O.   
 
Figure 3.11 Modified Job's plot analysis for TEB-3,4-HOPO 3.26 after 14 days.  Measurements 
taken at room temperature in DMSO/H2O.   
 
For 3.26 the modified Job’s plot analysis showed in the first instance, after 2 days the L:Fe3+ 
stoichiometry to be 1:1.  However, this ligand at the second reading, after 14 days, displayed a 
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L:Fe3+ ratio of 0.4:0.6, a result which indicates equilibration away from the ideal 1:1 ratio.  This 
could be rationalised by the initial kinetically driven binding being thermodynamically 
unfavourable.  If this is so it could be attributed to the meta-para attachment of the binding units 
with respect to the anchoring N-atom.  It has been noted in the literature that an ortho-meta 
attachment is important for strong and favoured chelation and so where initially a 1:1 ratio is 
kinetically favoured it is not the most thermodynamically stable arrangement.   
 
 
Figure 3.12 Modified Job's plot analysis for TEB-1,2-HOPO 3.27 after 2 days.  Measurements taken 
at room temperature in DMSO/H2O.   
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Figure 3.13 Modified Job's plot analysis for TEB-1,2-HOPO 3.27 after 14 days.  Measurements 
taken at room temperature in DMSO/H2O.   
 
The modified Job’s plot analysis for the initial reading taken after 2 days equilibration for 3.27 
showed the molecule to have a L:Fe3+ stoichiometry of approximately 0.7L:0.3M.  After 14 days 
this can be seen to re-equilibrate to a 1:1 ratio.  This initial result could be due to the lower pKa of 
the 1,2-HOPO compared with the other HOPO moieties, in the first instance the binding of the 
metal centre maybe more favoured by the binding of more ligands per metal centre if the complex 
formation was under kinetic control.  Then, as the equilibration time increases a re-equilibration to 
a 1:1 ratio is more thermodynamically favoured. 
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Figure 3.14 Modified Job's plot analysis for TEB-retro-3,2-HOPO 3.28 after 2 days.  Measurements 
taken at room temperature in DMSO/H2O.   
 
 
Figure 3.15 Modified Job's plot analysis for TEB-retro-3,2-HOPO 3.28 after 14 days.  
Measurements taken at room temperature in DMSO/H2O.   
 
The modified Job’s plot analyses for the TEB-retro-3,2-HOPO ligand 3.28 reveal that at the initial 
reading taken after 2 days the stoichiometry is determined to be 0.44L:0.56M.  This ratio is close to 
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L:Fe3+ stoichiometry had changed only by a slight amount to 0.46:0.54.  This ratio is closer still to 
the desired ratio and may indicate a re-equilibration to the more thermodynamically stable state 
over the time period.  However the alteration is so small that further measurements are required to 
fully test this hypothesis.  The non-ideal ratio we see in the first instance may be the result of the 
methylated N-atom which could serve to provide steric hindrance and hence slow the rate of 
formation of the metal complex.  The results of all of the modified jobs plot analyses are displayed 
in Table 3.1.   
 
Table 3.1Table summary of the calculated L:Fe3+ ratios taken for the ligands 3.24-3.28 
Ligand 
Initial Reading 
After 2 days /L:Fe
3+
 
Reading After 
14 days/ L:Fe
3+
 
TEB-SC-3,2-HOPO 3.24 0.5:0.5 0.45:0.55 
TEB-LC-3,2-HOPO 3.25 0.53:0.47 0.53:0.47 
TEB-3,4-HOPO 3.26 0.51:0.49 0.40:0.59 
TEB-1,2-HOPO 3.27 0.68:0.31 0.48:0.51 
TEB-R-3,2-HOPO 3.28 0.44:0.56 0.46:0.54 
 
3.7 Chapter Conclusions 
 
In summary, five novel ligands based upon the 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene 
scaffold have been synthesised bearing a range of HOPO moieties.  The ligands are based upon 
previously accessed molecules, however the coupling of these together on the triethylbenzene 
scaffold to produce powerful Fe3+ chelators remains novel.  The ligands design include all of the 
necessary features to promote powerful Fe3+ binding and although the stability constants for the 
Fe3+ complexes have yet to be measured, the UV-Vis profiles and modified Job’s plot analyses 
have shown the ligands to bind Fe3+ successfully.  
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The synthesis of the core molecule 3.11 occurs via a three step procedure, two of which are 
relatively high yielding.  However, the second synthetic step to access the triazide derivative 
proved to yield the product in only 45% yield.  It is possible that the loss of yield is due to the work 
up as it involves the addition of DCM to the reaction and then washing the excess NaN3 and DMF 
out with H2O.  It is likely some of the compound is removed in these aqueous washings, as TLC 
indicated 100% conversion from the tribromide, and so an alternative work-up may prove to yield 
better.  In addition, the alternative method from the literature which did not give the desired 
triphthalimide derivative may prove higher yielding if the reaction conditions were able to be 
optimised so as to produce the fully derivatised product.     
The synthetic route for the retro-3,2-HOPO molecule 3.14 occurs via a 4 step reaction sequence.  
The first step is relatively low yielding at 35-43%.  However, the starting materials for this reaction 
are relatively low cost, which would lend this reaction well to a scale up synthesis.  Also, the 
product requires no extensive purification and so this would also be a desired attribute were the 
synthesis to be scaled.  The subsequent step is the dimethylation of the ester-HOPO derivative, the 
reaction proceeds as expected and the product, after removal of the DMF and excess MeI was used 
without purification as the following step provided the necessary purification and the final acid-
derivitised-retro-3,2-HOPO is isolated in around 50% yield.  This yield could be indicative that the 
final compound is somewhat soluble when cool in EtOAc, the recrystallization solvent.  Improved 
yields could be accessed by an alternative solvent.   
The synthesis of 3.15 the 1,2-HOPO-acid derivative occurs via a modified literature procedure in 
good yield of 88%.  The synthesis could be employed in scale up synthesis due to the compound 
being readily accessible in high yield and purity.  In addition, the synthesis 3.18 via a two-step 
route, starting from maltol, also lends itself well to scale up reactions.  The starting materials are 
accessible commercially for low cost and so the production of the compound is very economical.   
The protected ligands were all able to be synthesised via the prescribed literature method published 
by Hider et al.  The utilisation of the TBTU coupling reagent proved effective in that all of the 
coupling reactions were successful.  However, the yields for these reactions were somewhat 
unreliable which could cause issues if the ligands were going to be applied to commercial 
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applications.  However, the reactions were all able to be completed in a short time and only 
required purification by column chromatography to access the pure ligands.   
The four O-benzyl protected ligands were all able to be easily deprotected in the presence of 
concentrated acids, precipitation of the free ligand afforded the pure product in all cases.  The O-
Me protected retro-3,2-HOPO derivative however required the use of BCl3 (1M in heptane).  This 
reaction does not lend well to potential scale up synthesis, due to the toxic nature of this reagent.  
Alternative methods were not attempted due to the small scale reaction being successful, however 
ideally a less toxic reagent should be sourced.        
The UV-Vis spectroscopic determination of L:Fe3+ stoichiometry yielded some interesting results.  
In general, the ligands displayed L:Fe3+ of 1:1 or very close to this expected ratio.  However ligand 
3.26 appeared to equilibrate away from this 1:1 ratio.  In the literature it has been shown that 
attachment point on the binding moiety to the ligand scaffold is important for the focus of the 
binding atoms towards the metal centre.  The meta-para attachment this ligand has with respect to 
the N-atom in the ring system could create a disparate, unfocussed arrangement of the binding 
groups which overall could give a thermodynamically unstable complex and so could serve to drive 
the binding away from a 1:1 stoichiometry.  3.28 displayed slightly askew L:Fe3+ ratios from the 
desired 1:1 even after 14 days.  This could be result of the steric hindrance the N-Me groups would 
contribute.  However, if the metal were unable to sufficiently access the binding centre of the 
ligand the ratio would display a higher ligand contribution, in this case we see a more pronounced 
Fe3+ contribution.    Further investigation is therefore required to elucidate the cause of this 
however, the 14 day reading indicated that the ratio was closer to a 1:1 complex and so the issue 
could simply be the rate of complex formation.   
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Design and Synthesis of Novel 
tris(piperazin-1-yl)-1,3,5-triazine based Fe3+ 
Selective Ligands Bearing 
hydroxypyridinone Binding Moieties 
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4 Chapter Aims 
 
This chapter aims to explore the tris(piperazin-1-yl)-1,3,5-triazine core scaffold as a viable base on 
which to build strong and selective Fe3+ chelators.  The chapter will provide the synthetic 
methodology to synthesise the molecules displayed in Figure 4.1.    
 
 
Figure 4.1 Structures of the tris(piperazin-1-yl)-1,3,5-triazine based chelators provided 
 
The synthetic methodology will be provided for the core molecule as based on literature 
procedures.   The synthetic methodology for the HOPO units synthesised for attachment to the core 
has been previously reported (Chapter 2).  The 3,2-HOPO and 1,2-HOPO bidentate moieties have 
been the focussed upon due to their accessible derivatives which allow for attachment to the core 
scaffold.   
The preparation of the protected hexadentate chelators and the subsequent deprotection methods 
are provided.    
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4.1 Introduction to tris(piperazin-1-yl)-1,3,5-triazine 
 
The tris(piperazin-1-yl)-1,3,5-triazine core scaffold provides a favourable skeleton to allow for the 
incorporation of three HOPO binding units; due to the tri-piperazine scaffold which would be 
available to attach to appropriate electrophilic HOPO groups.   
This core molecule has previously been synthesised to be the base of dendritic scaffolds which 
were made to function as drug-delivery vehicles, Figure 4.2 (4.1).     
 
 
Figure 4.2 Structure of dendrimer containing tris(piperazin-1-yl)-1,3,5-triazine scaffold 
 
The work was published by Simanek et al. in 2004.102  The dendrimers were substituted with 
various surface groups such as phosphate, sulfonate and carboxylic acids.  The research found that 
those groups containing cationic functionality were far more cytotoxic than those bearing anionic 
or neutral PEG groups, when tested on cell lines.   
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In addition in 2007 Simenak et al. synthesised more dendrimers based around this core scaffold.  
The aim of which was to allow for the protected amine scaffolds to provide molecular handles on 
which to create functionalise dendrimers, Figure 4.3.      
 
 
Figure 4.3 Structure of the dendrimer scaffold, based upon the tris(piperazin-1-y)-1,3,5-triazine 
molecule.  Reagents and conditions: (i) K2CO3, CHCl3, THF, rt, overnight 
 
The synthetic routes to the molecules 4.1 and 4.4 displayed in Figure 4.2 and Figure 4.3 show that, 
not only is the tris(piperazin-1-y)-1,3,5-triazine core synthetically accessible from commercially 
available starting materials but the core scaffold is also able to be functionalised with electrophilic 
substrates, owed to the nucleophilic 2° amine systems.   
As far as can be ascertained from literature searches, the core scaffold has never been utilised for 
the production of Fe3+ chelator technology.  Due to these contributing factors, the core scaffold 
would seem an ideal choice from which to build Fe3+ ligands.       
It is not immediately obvious for this core scaffold whether the hydroxypyridinone groups will 
have sufficiently long chains to allow successful binding of Fe3+.  The scaffold itself appears quite 
large.  Due to the potential interconversion available to the piperazine ring systems between the 
chair conformers (Figure 4.4) it is unclear as to what conformation will be adopted by the ligands.     
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Figure 4.4 Figure displaying possible interconversion which may occur for the piperazine groups on 
the tris(piperazin-1-y)-1,3,5-triazine ligand.  Showing two chair conformations (left and right) and 
the intermediary twist boat conformation (middle) 
 
It is possible that once the HOPO groups bind Fe3+ this will create thermodynamic stability to 
prevent of this interconversion and affix the ligand so as to be organised towards the Fe3+ centre, it 
could be argued that the twist boat conformation, although perhaps not the most stable conformer 
before Fe3+ binding, may prove to be the conformation adopted because it angles the binding 
groups towards each other, Figure 4.5.  However, the overall binding of Fe3+ will be dependent in 
the first instance on the chain length of the HOPO moiety.   
 
Figure 4.5 Possible conformation of the three piperazine units optimised for Fe3+ binding in the boat 
conformation 
 
The interplay between the core scaffold conformations and the HOPO chain length may serve to 
create powerful Fe3+ binding if the correct parameters are found.  It is therefore important to access 
a variety of chain length linkers for HOPO moieties for this core scaffold.  
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4.2 Results and Discussion 
4.2.1 Preparation of tris(piperazin-1-yl)-1,3,5-triazine (4.2) 
 
From literature precedents the synthetic route for the preparation of tris(piperazin-1-yl)-1,3,5-
triazine 4.2 can be achieved by the route shown in Scheme 4.1.   
 
 
Scheme 4.1 Synthetic route for 4.2.  Reagents and conditions; (i) (boc)2O, dry DCM, K2CO3 (ii) 
K2CO3, THF, 80°C, trichlorotriazine (iii) TFA:DCM (1:1) 
 
The first step in the synthesis of 4.2 is the asymmetric mono-boc protection of piperazine.  This 
reaction was performed in dry DCM with K2CO3 as a base.  4.6 was achieved in yield of 61% (lit. 
88%) as the pure compound.103  Step (ii) yields 4.7 as a result of a triple nucleophilic aromatic 
substitution at the three chloride sites situated around the trichlorotriazine ring system.  The 
reaction was performed in THF at 80°C overnight, with K2CO3 as a base.  The resulting product 
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achieved in 58% yield (lit. 86%) as the pure compound.104  The deprotection of the protected core 
4.7 was performed as a standard DCM:TFA (1:1) room temperature overnight reaction to yield the 
product 4.2 in 35% (lit. 95%) yield after workup.  
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4.2.2 Preparation of triazine-1,2-HOPO 4.9 
 
As previously discussed (Chapter 2), the synthesis of 6-(chloromethyl)-1-(prop-2-en-1-yloxy)-1,2-
dihydropyridin-2-one (2.28) was developed in house and has allowed for the attachment of the 1,2-
HOPO moiety via nucleophilic substitution at the chloromethyl position.  Therefore the triazine 
core molecule (4.2) was reacted with the 1,2-HOPO-chloride (2.28) to produce the allyl protected 
molecule (4.8), Scheme 4.2. 
 
Scheme 4.2 Synthetic route to trazine-1,2-HOPO (4.9).  Reagents and conditions: (i) dry MeCN, 
Et3N, N2(g), reflux, 48 hours. (ii) Pd/C, dioxane:H2O (4:1), TFA (0.15M), reflux 
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4.2 and 2.28 are reacted in dry MeCN in the presence of Et3N for 48 hours at reflux to produce the 
desired protected ligand 4.8.  The crude ligand required purification via column chromatography, 
elution in DCM:MeOH 3-12% gave the desired product in 17% yield after purification.  This 
method was devised from following a literature source for the addition of an electrophile to a 
piperazine core.39 
The deprotection of the protected ligand 4.8 was achieved via the afore mentioned method for the 
allyl-deprotection of molecule (2.29).90  This method employing the use of 0.15M TFA and Pd/C 
catalyst has been useful for allowing access to the free ligands containing the 1,2-HOPO moiety.  
The deprotection of 4.8 occurs to give the desired 4.9 in 79% yield, requiring no purification except 
the precipitation of the pure ligand from MeOH with diethyl ether.   
The first step of the synthesis of 4.9 i.e. the synthesis of the triamine core occurs with a 27% loss of 
yield when compared to the literature value provided.  This is possibly due to the amine being 
partially soluble in the aqueous phase during the work up, some may be left behind if sufficient 
repeated extractions with ether are not performed.  Step (i) is the nucleophilic substitution reaction 
which occurs via the displacement of the three chloride ions by the mono-boc piperazine.  This 
reaction again occurs with some loss of yield from literature precedent which may be due to 
insufficient reaction time, although the synthetic method was followed as was described.  The final 
stage in the core molecule synthesis is the deprotection of the three boc groups to yield the free 
amine.  There is here significant loss of yield with respect to the literature.  This is most likely due 
to the deprotected core molecule being soluble in the highly basic aqueous solution which the crude 
residue is dissolved in.  The extractions of this solution with DCM were therefore insufficient to 
allow effective transfer of the product to the organic phase.  In future, the synthesis of this 
molecule could be improved upon by using a solvent which allows more favourable transfer of the 
product into the organic phase.  Alternatively, if one cannot be found which surpasses DCM in this 
way simply more extractions of the aqueous phase are necessary.  Despite this the synthesis of the 
core can be scaled up to produce multi-gram quantities of the desired amine.  The starting materials 
are cheap and the reactions occur with little need to purify.     
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The substitution reaction (i) which occurs via nucleophilic attack of the electrophilic chloromethyl 
position of the bidentate HOPO unit produced the compound in only 17% yield.  However, the 
purification method was suitably tailored to provide the desired compound in excellent purity.  
Future synthetic attempts to produce this compound would require optimisation of the reaction 
parameters if scale up is to be desired.  The deprotection produced the desired ligand in 22% yield.  
Again, if scale up of this molecule is required then these conditions would require optimising.   
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4.2.3 Preparation of triazine-3,2-HOPO (4.11) 
 
As previously discussed (Chapter 2), the synthesis of the literature compound iminium salt 2.21 
allowed for the attachment of the 3,2-HOPO moiety to CTG via a two carbon chain.  2.21 has 
previously been shown to react with hindered nucleophiles, such as secondary amines to allow for 
the attachment of the moiety to a scaffold.  The triazine core molecule 4.2 was reacted with the 
iminium salt to produce the protected molecule 4.10, Scheme 4.3.   
 
Scheme 4.3 Synthetic route to the  triazine-3,2-HOPO ligand (4.11)  Reagents and conditions: (i) 
dry MeCN, Et3N, N2(g), 3 days room temperature then 24 hours reflux: (ii) 37% HCl:glacial acetic 
acid (1:1), room temperature to 60°C, 5 days 
 
 
108 
 
The synthesis of 4.10 was performed in dry MeCN with Et3N as a base.  The reaction was in the 
first instance stirred at room temperature; however TLC showed that after 3 days the reaction was 
incomplete.  After a further 24 hours at reflux, TLC showed the consumption of the starting 
materials had taken place.  After workup, the product was purified with column chromatography 
and yielded the desired protected ligand in 26-29% yields after purification.   
The subsequent deprotection of 4.10 was performed as a standard O-benzyl deprotection using 
concentrated acids 37%HCl:glacial acetic acid (1:1).  The deprotection conditions afford the 
desired molecule 4.11 after precipitation from MeOH with diethyl ether in yields around 22%. 
The synthesis of the triazine-3,2-HOPO protected ligand begins with the nucleophilic addition of 
the triamine-triazine core scaffold to the iminium salt.  The addition reaction occurs in yields up to 
29%.  This is a relatively low yield and does not reflect the yield achievable when the CTG core is 
subjected to the same bidentate unit.  This could be due to the use of Et3N as a base in the reaction.  
2.21 has been shown to produce alternative products to the desired ring opening through multiple 
competing pathways of addition, when small molecule nucleophiles are present, such as primary 
amines.  However, because a tertiary amine was used, this degradation should not have occurred.   
The loss of yield would suggest that multiple pathways were present producing side products which 
were not isolated.  The desired protected ligand is however achieved in good purity after 
chromatographic purification.  If this reaction were to be scaled up, the reaction conditions should 
be optimised so as to improve upon the yield, possibly through discounting the use of triethylamine 
as a base.  The deprotection to produce the free ligand occurs in yield around 22%.  This low yield 
is undoubtedly due to some of the ligand being soluble in the MeOH-ether solution and not fully 
precipitating out.  This method did provide the product in sufficient quantity to take through to the 
bacterial testing phase. 
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4.3 UV-Vis Determination of L:Fe
3+
 Stoichiometry 
 
L:Fe3+ stoichiometry was determined via a method described in the Experimental section, which is 
based on a literature procedure for L:M stoichiometry determination.91   
The modified Job’s plot analyses for the triazine-1,2-HOPO chelator 4.2 is displayed in Figure 4.6.  
The data shows that in the first instance, the L:Fe3+ stoichiometry is calculated as being 8.4L:1.6M.  
This would suggest that the binding of Fe3+ by this ligand is inefficient.  
 
 
Figure 4.6 Modified Job's plot analysis for triazine-1,2-HOPO ligand 4.2 after 2 days.  
Measurements taken at room temperature in DMSO/H2O.    
 
The poor binding of Fe3+ by this chelator could be due to the core molecule providing ineffective 
preorganisation of the binding moieties towards the metal centre.  If this is the case a more rigid 
group than the piperazine functionality could produce a better ligand for this particular binding 
group on this core.  Alternatively, the core scaffold could be too large for the methylene bridges to 
effectively bind the metal centre.  This would provide a large entropic barrier to chelation as the 
HOPO moieties would have to move a great deal to bind the metal centre and, if they are able to 
chelate the metal, the affinity would be somewhat reduced.   
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The modified Job’s plot for the same ligand after 14 days of equilibration shows the ratio L:Fe3+ to 
have changed to 1.5L:1M.  This stoichiometric ratio is somewhat more favourable to the initial 
readings as it is closer to the ideal 1:1 L:Fe3+.   
 
Figure 4.7 Modified Job's plot analysis for triazine-1,2-HOPO ligand 4.2 after 14 days.  
Measurements taken at room temperature in DMSO/H2O.   
 
The re-equilibration to this ratio could suggest that kinetically the binding of Fe3+ is slow, but 
overall is not as thermodynamically unflavoured as the original data suggests.  It is possible that 
this ratio could be interpreted as 3L:2M which could give rise to the arrangement displayed in 
Figure 4.8.  In this way, one chelating group is dissociated from a metal centre for each ligand.  
This sort of arrangement could be due to the protonation of one binding group per ligand, the cause 
of which could possibly be the lower pKa of the 1,2-HOPO ligand.  The proton concentration in 
solution would be higher for this ligand due to the low pKa of the proton at the  N-OH of the 1,2-
HOPO; protonation therefore of one binding group per ligand would cause its dissociation and give 
arrangements such as have been noted for tetradentate chelators.26   
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Figure 4.8 Representative diagram to display the possible 3L:2M stoichiometric arrangement of 
species in solution for ligand 4.2 at 14 days 
 
Alternatively, the 3L:2M stoichiometry could be simply due to the chain linkage attaching the 
HOPO moieties to the core scaffold being too short, preventing a 1:1 L:Fe3+ stoichiometry due to 
the three binding units being unfavourably arranged to facilitate the saturation of the coordination 
sphere of Fe3+ by one ligand.   
The modified Job’s analyses for ligand 4.11 show that at the first point of measurement the L:Fe3+ 
stoichiometry could be calculated as 4L:1M, Figure 4.9.  When compared to 4.2 this ratio is 
somewhat the same and undoubtedly the reasons for the inefficient binding of the metal centre are 
similar.  The rate of chelation of the metal centre could be reduced if the core fails to properly 
organise the ligands toward the binding of Fe3+.   
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Figure 4.9 Modified Job's plot analysis for triazine-3,2-HOPO ligand (58) after 2 days 
 
However, if we consider the measurements taken at a later time we can see that the L:Fe3+ 
stoichiometry has changed to now be 0.52L:0.48M, Figure 4.10.  This result shows that the binding 
of Fe3+ is now almost in the desired 1:1 ratio.  The realisation that this ligand, now containing a two 
carbon chain linker to the core scaffold can equilibrate, given time, to a 1:1 stoichiometry would 
suggest that the core scaffold is able to organise the binding moieties towards chelation and the 
chain length of 4.2 was not sufficient to facilitate chelation.   
 
 
Figure 4.10 Modified Job's plot analysis for triazine-3,2-HOPO ligand (58) after 8 days.  
Measurements taken at room temperature in DMSO/H2O.   
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4.4 Chapter Conclusions 
 
This chapter has presented the successful design and synthesis of two novel hexadentate chelators, 
based upon the core molecular scaffold tris(piperazin-1-yl)-1,3,5-triazine.  The chelators have 
design features which owe to the strong and selective binding of Fe3+ such as the inclusion of the 
HOPO moieties as the binding mode and the potential preorganisation the scaffold provides.   
The analysis of the UV-Vis spectral data revealed some interesting results.  The 1,2-HOPO unit 
attached via a methylene linker appears to either show signs that the linker is too short to allow 
efficient binding of the metal centre.  The data collected for the 3,2-HOPO analogue, which is 
supported by a two carbon linker, showed more favourable stoichiometric ratios were achievable 
after several days.  This would suggest at least a two carbon linker chain is possibly required to 
allow binding of an Fe3+ centre on the core scaffold.   Unfortunately the 1,2-HOPO analogue with a 
two carbon linker is not currently accessible in a derivative to allow attachment to the core 
scaffold.   
4.5   Future work 
The synthesis of the long chained 1,2-HOPO derivative is currently underway but has yet to be 
derivative in such a way as to allow attachment to the triazine core scaffold.  This work would 
allow a better comparative between the 1,2-HOPO and 3,2-HOPO binding units on the same core 
and how this effects their respective biological activities and Fe3+ binding properties.    
Attempted synthesis of the longer 3,2-HOPO derivative for this core scaffold was not pursued due 
to the previous failures on the CTG scaffold.  Once this chemistry has been improved and a viable 
coupling method/optimised reaction conditions have been discovered for this LC-3,2-HOPO 
coupling, the synthesis of the triazine derivative would be particularly sought after as it would 
provide a more flexible attachment of the HOPO to the core.  This would allow a comparison, as 
per the chapter introduction, of the chain length properties with respect to the binding mode and 
strength, once the thermodynamic properties of the ligands have been determined i.e. pFe3+, logβ.   
 
114 
 
 
 
 
 
The Use of Cholic Acid as a Core Scaffold 
in the Design and Synthesis of Novel Strong 
and Selective Fe3+ Chelators Bearing HOPO 
Binding groups. 
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5 Chapter Aims 
 
This chapter aims to introduce cholic acid as a feasible choice of core molecular scaffold on which 
to attempt to build powerful Fe3+ ligands.  Within is presented the methodology behind the 
attempted functionalization of cholic acid to facilitate Fe3+ binding.    
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5.1 Introduction to Cholic acid 
 
Bile acids have previously been noted as being versatile building blocks for several supramolecular 
arrays. They are considered important precursors for pharmaceutical industries due to their rigid, 
curved defined structures, Figure 5.1.  In cholic acid, Figure 5.1 the three hydroxyl functionalities 
have chemically different properties and the molecule is available commercially at low cost.  All of 
these features make them an attractive core scaffold.105  
 
 
Figure 5.1 Representative chemical structures for cholic acid 2D (left) and 3D (right) 
 
The 3D stucture of cholic acid lends itself well to being a viable molecular scaffold on which to 
build strong and selective Fe3+ chelators. The hydroxyl functionalities, as can be seen in Figure 5.1, 
are all presented on the same face of the molecule. It is this feature which could contribute to the 
preorganisation of pendant binding moieties and allow for the production of strong Fe3+ ligands. In 
addition, the three hydroxyl groups which, if three bidentate units could be attached would allow 
for the full saturation of the Fe3+ coordination sphere.  
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5.2 Results and Discussion 
5.2.1 Preparation of methyl cholate (5.2) 
 
The carboxylate group has been shown to bind Fe3+ and so in order to functionalise cholic acid with 
HOPO moieties and ensure the binding mode of the ligand will be through the HOPO units the 
methylation of the acid moiety was necessary.   
The methylation of cholic acid was performed in MeOH with H2SO4 at reflux, Scheme 5.1.  The 
reaction proceeds as described in the literature, the product achievable in good purity after 
recrystallization in toluene as a white solid in yields 66-88%.   
 
 
Scheme 5.1 Synthesis of methyl cholate (5.2).  Reagents and conditions: (i) MeOH, H2SO4, reflux 
 
5.2.2 Functionalising methyl cholate with the HOPO moiety 
 
The 3,2-HOPO-chloride (2.13), the synthesis of which was previously discussed (Chapter 2) 
provided a possible way to allow the attachment of the HOPO units to the core scaffold.  The 
nucleophilic attack of the alkyl halide chain would allow for the functionalization of the core 
scaffold.  The reaction conditions which were employed in the attempted synthesis of the target 
molecule are displayed in Scheme 5.2.   
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Scheme 5.2 Synthetic conditions attempted for methyl cholate with 3,2-SC-HOPO-chloride.  
Reagents and conditions: (i) K2CO3, acetone (ii) NaH, dry DCM 
 
Unfortunately none of the conditions used here for this reaction were able to successfully generate 
the desired product.  The 1H NMR of the products showed that there had been no functionalization 
of the core scaffold.  In light of the failings to functionalise the scaffold with this moiety the longer 
chained 3,2-HOPO moiety (14) was used in the attempted formation of the protected ligand, 
Scheme 5.3.   
Several different reaction conditions were used here.  Conditions (i) of K2CO3 in acetone were 
those previously utilised in the synthesis of the shorter chained analogue.  These again, did not 
produce the desired product.   
 
Scheme 5.3 Synthetic conditions attempted for methyl cholate with 3,2-LC-HOPO.  Reagents and 
conditions: (i) K2CO3, acetone (ii) NaI, K2CO3, acetone (iii) DIPEA, dry DCM (iv) Cs2CO3, DMF 
 
Failing this, NaI was added to try and catalyse the reaction; however this was unsuccessful in 
producing the desired product.  DIPEA and Cs2CO3 were also tried in dry DCM and DMF however 
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these conditions were, as previous, unsuccessful.  Attempts to functionalise the core scaffold via 
these methods were therefore abandoned due to the lack of success. 
The continued attempted functionisation of methyl cholate was done so by trying to couple 3,2-SC-
HOPO-acid 2.11 to the core scaffold via two methods, Scheme 5.4.  
 
 
Scheme 5.4 Synthetic conditions attempted for methyl cholate with 2.11.  Reagents and conditions: 
(i) DCC, DMAP, dry DCM (ii) Ph3P, DIAD, dry DCM 
 
The coupling reagent combination of DCCI and DMAP was utilised in the attempted coupling of 
the acid 2.11 to the scaffold.  However, this reaction did not proceed as expected and the starting 
materials were recovered unreacted.  As an alternative, a Mitsunobu coupling was attempted using 
Ph3P and DIAD.  However, this again failed to produce the desired compound and the starting 
materials were recovered unreacted.   
Failing to functionalise methyl cholate via any of the methods discussed, the functionalization of 
this was attempted with 2.21 of which there had been previous success (Chapter 2).  2.21 has 
previously been shown to react with hindered alcohols, to produce products with the HOPO moiety 
attached.86  In light of this it was thought this could be a viable route to the desired compound, 
Scheme 5.5 
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Scheme 5.5 Synthetic conditions attempted for methyl cholate and iminium salt.  Reagents and 
conditions: (i) Toluene, CaH2, reflux, 48 hours (ii) Pd/C, H2(g)    
 
There is literature precedent describing the use of CaH2 and toluene as the reaction conditions in 
the formation of functionalised methyl cholate molecules.  These conditions were employed here.  
The core scaffold was dissolved in toluene, to which CaH2 was added along with the iminium salt  
under an inert N2(g) atmosphere.  The reaction was held for 2 days at reflux after which time the  
residue was subject to purification via flash column chromatography to give the desire methyl 
cholate-3,2-HOPO-Bn protected ligand.   
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Figure 5.2 (+)-ESI low resolution mass spectrum of the purified methyl cholate-3,2-HOPO (5.3) for 
the reaction depicted in Scheme 5.5. 
 
The mass spectrum of the purified product from Scheme 5.5 showed peaks at m/z values which 
could be attributed to the di- and mono-functionalised core species by mass spec; m/z = 899.23 
[M++Na] for the di-functionalised molecule and the peak at m/z = 672.22 [M++Na] for the mono-
functionalised.  High resolution mass spectrometry has determined the possibility that the peak at 
m/z = 1143.87 could be attributed to the [M+Na+H2O] adduct.   
The product was hydrogenated using a H-Cube® Continuous-flow Hydrogenation Reactor 
(ThalesNano) in methanol, using a Pd/C cartridge (full H2(g) mode) to attempt removal of the O-
benzyl protection.  The low resolution (+)-ESI mass spectrum of the product isolated from the 
hydrogenation via this method displays in the region 872-878 m/z a peak corresponding to 873.86 
m/z.  Previously, the high resolution mass spectrum from the compound 5.3 displayed the 
[M+Na+H2O] adduct for this compound and in the same way it is believed the compound 5.4 is 
displaying the same adduct as indicated in Figure 5.3.    
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Figure 5.3 (+)-ESI low resolution mass spectrum of the hydrogenated product 5.4 
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The Synthesis of Novel and Previously 
Described TREN-based Fe3+ Selective 
Ligands Bearing hydroxypyridinone 
Binding Moieties 
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6 Chapter Aims 
 
This chapter aims to report the synthesis of two novel TREN-based ligands and two TREN based 
ligands which were synthesised based upon literature procedures for comparison; the molecules 
CP130 and TRENCAM. 
 
Figure 6.1 Structure of ligands to be reported herein: Novel ligands: TREN-R-3,2-HOPO (top left) 
and LC-CP130 (bottom left) and literature examples CP130 (top right) TRENCAM (bottom right) 
 
The synthetic methodology will be provided for the bidentate HOPO units which have not been 
previously discussed.  The methods of coupling to the core scaffold will be provided and the 
subsequent deprotection methods. 
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6.1 Introduction  
 
The TREN scaffold has been widely used in the design of chelators for various applications as a 
core tripodal molecule; the core itself has been shown to provide some preorganisation of binding 
groups towards Fe3+ chelation.  A network of intramolecular hydrogen bonds stemming from the 
secondary amide linkages has been shown to increase the stability of ligands based on this core in 
certain cases, Figure 6.2.25   
 
Figure 6.2 Figure displaying the intramolecular H-bonding which occurs within the TREN core 
scaffold within TAGE.  Replicated from Inorganic Chemistry, 2004, 43, 26, 8538 
 
This H-bond network has been shown by X-ray crystallography to help to organise the core 
scaffold towards binding a metal centre.106  The Fe3+ affinities for the compounds displayed in 
Figure 6.3 are displayed in Table 6.1. 
    
Figure 6.3 Structures of CP130 (1.6) TREN-Me-3,2-HOPO (6.3) and TRPN-Me-3,2-HOPO (6.4) 
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Table 6.1 Table displaying pFe3+ values for CP130, TREN-Me-3,2-HOPO and TRPN-Me-3,2-
HOPO 
Compound pFe
3+
 
TRENCAM 27.8 
CP130 27.6 
TREN-Me-3,2-HOPO 26.8 
TRPN-Me-3,2-HOPO 23.8 
 
When looking at the H-bonding in the molecules in Figure 6.3 it can be noted that from the crystal 
data CP130 does not have the arrangement to produce H-bonds, as this arrangement would form a 
thermodynamically disfavoured 7 membered ring.  This can be seen in Figure 6.4 which is 
reproduced from Xu et al.106 
 
Figure 6.4 Representative diagrams to show H-bonding in CP130, TREN-Me,3,2-HOPO and 
TRPN-Me-3,2-HOPO. 
 
The pFe3+ for CP130 is higher than that of the other two ligands, which would indicate a H-
bonding network is not necessary for the strong and selective binding of Fe3+ by TREN based 
ligands.  However, when we compare molecules TREN-Me-3,2-HOPO and the closely related 
TRPN-Me-3,2-HOPO molecule we can see a decrease in the pFe3+ when the core scaffold chain 
length is increased.  The extra methylene link introduces some strain to the complex and lowers the 
thermodynamic stability.   
The corresponding catecholate molecule TRENCAM which closely resembles the structure of 
TREN-Me-3,2-HOPO has been shown under different pH conditions to switch the organisation of 
its binding groups, Figure 6.5.107  Under more acidic conditions the two phenolic protons are 
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present and this facilitates the groups to point outwards and conversely point inwards when one of 
the catechol groups is deprotonated.    
 
Figure 6.5 Hydrogen bonding scheme for TRENCAM under different protonation conditions. 
 
TRENCAM has a pFe3+ value which is higher than any of the other analogues discussed (Table 
6.1).  This could be due to the extra stability gained from the secondary amide proton being linked 
with three basic positions on the right of the equilibrium, Figure 6.5, which has the effect of 
preorganising the ligand towards metal chelation.     
The molecules TRENCAM and CP130 will serve as useful comparisons for novel chelators which 
are based upon more sophisticated scaffolds (Chapters 2-5).  In addition to these two new TREN 
based ligands will be synthesised to see if modification will have an effect on their ability to induce 
growth inhibition.   
The longer chained CP130 (LC-CP130) is a novel compound and will be synthesised to allow 
access to a derivative where the core scaffold size (TREN) remains the same but the linking chain 
differs by an increase of one methylene per arm.   CP130 is a strong Fe3+ ligand however; some 
residual strain in the molecule must still exist as other TREN derivatives have shown higher pFe3+ 
values, such as TRENCAM.  The increase in the length of the linkage arm to the binding unit may 
serve to alleviate some strain and allow for a stronger chelator.   
In addition, the TREN-Me-3,2-HOPO derivative TREN-R-3,2-HOPO will be synthesised to try and 
increase the binding affinity of the original ligand with the inductive effect of the Me- group in the 
para-position relative to the hydroxyl functionality.  In this position the Me group should induct 
electron density towards the hydroxyl functionality, potentially increasing the electron donating 
character of the site and as a result increasing the basicity creating a stronger ligand.  The methyl 
group may also serve to make the ligand less likely to be recognised or to induce kinetic stability.   
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6.2 Results and Discussion 
6.3 Ligand Synthesis 
6.3.1 Preparation of CP130  
 
The preparation of the literature molecule CP130 was performed as per the literature precedent, 
Scheme 6.1.  2.11was firstly subjected to activation by NHS in DMF using DCCI to form the 
succinate ester.  The reaction proceeds to give the pure product after recrytallisation from ethyl 
acetate in 43% yield (lit. 82%).21    
 
Scheme 6.1 Synthetic route to compound (6.6).  Reagents and conditions: (i) NHS, DCCI, DMF, 
room temperature, 4 days. 
 
Following the successful formation of the activated ester 6.6, the reaction of the TREN core with 
this product allows for the formation of the protected CP130 ligand 6.7, Scheme 6.2.  The reaction 
proceeds via the addition of the triamine scaffold in DMF to a solution containing the activated 
compound.  After 24 hours the reaction provides the pure benzyl-protected ligand in 49% yield 
after work up and recrystallisation from EtOH and H2O.  The literature procedure does not include 
the isolation of this compound.  However, the 1H NMR clearly displays the expected peaks for 
amide protons in the correct integral ratio for the triamide to have been produced.     
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Scheme 6.2 Synthetic route to CP130 (1.6).  Reagents and conditions: (i) DMF, room temperature, 
24 hours. (ii) H2, Pd/C in EtOH:H2O (10:1), 24 hours room temperature. 
 
The deprotection of 6.7 proceeds as per the literature, Scheme 6.2, catalytic hydrogenation of 6.7 
affords the pure CP130 as a purple solid after recrystallisation from EtOH in 25% yield (lit. 72%).    
 
6.3.2 Preparation of LC-CP130 (6.9) 
 
The preparation of LC-CP130 (6.9) follows the methodology described for the molecules based 
upon the 1,3,5-trisaminomethyl-2,4,6-triethylbezene scaffold (Chapter 3).  Interestingly, after a 
thorough review of the literature it can be noted that the LC-HOPO-acid (2.15) has not previously 
been incorporated into a scaffold via an amide linkage, except reported herein (6.8).   
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The synthesis of this molecule was firstly attempted via the same methodology to produce the 
shorter chained CP130.  The activation of the free acid (2.15) was successful forming the succinate 
activated molecule in with N-hydroxysuccinimide and DCCI, however the pure product could not 
be accessed in high yield and amounts were insufficient to allow the coupling reaction to follow to 
produce sufficient ligand for testing.  To try and combat this yield issue, the N-hydroxyphthalimide 
activating group was tried however this failed to produce the desired activated ester.   
Following the failures to synthesise the ligand via the activated ester, the synthetic methodology 
used for other amide formations reported previously (Chapter 3) was used.  Utilising the same 
experimental procedure, 2.15 is coupled with the TREN core via use of the TBTU coupling 
reagent, Scheme 6.3.  This provided the novel protected LC-CP130 (6.8) in 23% yield after 
workup.  The lack of an activation step here provides a shorter route for the successful synthesis of 
the amide linked ligands; though the yields are not fully optimised the shorter synthetic preparation 
is favoured.         
The deprotection of the benzyl-protected LC-CP130 was attempted with concentrated acids as had 
been previously successful (Chapter 3) however; this failed to yield the desired product.  In light of 
this, the deprotection was performed as for CP130 and the catalytic hydrogenation afforded the free 
ligand 6.9 in 68% yield, requiring no purification. 
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Scheme 6.3 Synthetic route for molecule 6.9.  Reagents and conditions (i) TBTU, N-Me-
morpholine, dry DMF, 60°C (ii) H2, Pd/C in EtOH:H2O (10:1), 8 hours at room temperature. 
 
The novel LC-CP130 ligand may serve to be a valued intermediary molecule between the TRPN-
based ligand which contains a larger core scaffold and CP130 which carries some inherent strain.  
The LC-CP130 molecule has the same capping ligand size as the CP130 ligand, which has been 
determined to be almost perfect for binding Fe3+, but would allow an increased flexibility in the 
chain connecting to the HOPO group, which may serve to alleviate any strain and increase the 
binding affinity for Fe3+.   
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6.3.3 Preparation of TREN-R-3,2-HOPO (64) 
 
The preparation of the novel TREN-R-3,2-HOPO ligand which has a further methyl group attached 
in the 6-position of the HOPO ring system begins with the preparation of  compound 6.10 from the 
previously reported compound (35) (Chapter 3).  The activation of this molecule to the succinate 
ester is performed in dry DCM with EDCI as the coupling reagent, yielding the pure compound 
6.10 as yellow-orange solid in 88% yield (lit. 98%).     
 
Scheme 6.4 Synthetic route for molecule (6.10).  Reagents and conditions: (i) NHS, EDCI, dry 
DCM, room temperature for 3 days. 
 
The subsequent triamide formation to yield novel intermediate 6.11 occurs simply with addition of 
the TREN core scaffold to the activated ester in dry DCM.  The amide formed can be accessed as 
the pure compound after evaporation of the solvent and solidifies on standing.  The compound is 
accessed as an orange solid in 92% yield.   
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Scheme 6.5 Synthetic route for molecule 6.12.  Reagents and conditions: (i) dry DCM, room 
temperature, 2 days. (ii) dry DCM, BCl3 (1M in heptane), N2(g) atmosphere, room temperature 2 
days. 
 
The deprotection of 6.11 occurs via demethylation with BCl3 (1M in heptane) over two days.  The 
pure deprotected ligand 6.12 can be accessed in 23% yield via precipitation from MeOH.   
The previous molecules containing the retro-3,2-HOPO moiety as the binding group did not have 
in place the secondary methylated position as has been produced here 6.12.  This extra methyl, in 
the para-position with repect to the hydroxyl functionality may serve to induct electron density to 
this position and increase the binding affinity of the ligand with respect to TREN-Me-3,2-HOPO 
(pFe3+ = 23.8).   
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6.3.4 Preparation of TRENCAM 
 
Literature preparation of TRENCAM occurs via the following synthetic methodology.  Firstly, the 
2,3-dimethoxybenzoic acid is activated to produce the acyl chloride with SOCl2.  The activated 
compound allows the formation of the triamide when reacted with the TREN core scaffold, Scheme 
6.6 and Scheme 6.7.   
 
Scheme 6.6 Literature synthetic methodology for 2,3-dimethoxybenzoyl chloride.  Reagents and 
conditions: (i) SOCl2, benzene, reflux. 
 
Scheme 6.7 Literature synthetic methodology for TRENCAM.  Reagents and conditions: (i) DCM, 
NaOH (0.5M), simultaneous drop-wise addition. (ii) (i) BBr3, DCM, overnight, N2(g) atmosphere 
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The deprotection of the methoxy groups occurs via reaction of the protected compound with BBr3 
to produce the TRENCAM ligand. 
In an attempt to exploit the chemistry previously explored herein (Chapter 2) and shorten the 
synthetic route to TRENCAM an alternative synthetic methodology was sought.  The free acid 3.32 
whose synthesis was previously reported (Chapter 3) is subject to direct coupling with the TREN 
core, activated in situ with the TBTU reagent as has been previously discussed, Scheme 6.8.  This 
methodology provides a shortened sequence to the previous synthetic route, avoiding the need for 
isolation of the protected acyl chloride intermediate.  The coupling takes place with a yield of 41% 
after purification.   
 
 
Scheme 6.8 Synthetic route for molecule 6.16.  Reagents and conditions (i) TBTU, N-Me-
morpholine, dry DMF, 60°C (ii) 37%HCl:glacial acetic acid 1:1, 60°C 5-7 days 
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The final deprotection step to produce the free TRENCAM ligand 6.16, Scheme 6.9 occurs via 
reaction with concentrated acids.  The free ligand can be isolated by precipitation from MeOH with 
diethyl ether in yield of 77%, requiring no purification.    
6.4 Conclusions 
 
This chapter has reported the synthesis of two novel TREN-based ligands which display 
modification to the electronic structure (TREN-R-3,2-HOPO) and the chain length (LC-3,2-HOPO) 
of two previously accessed HOPO ligands TREN-Me-3,2-HOPO and CP130.   
The synthesis of the literature ligands CP130 and TRENCAM are reported with modification to the 
synthetic methodology for TRENCAM with respect to the literature procedure.    The synthesis of 
TRENCAM has been shortened compared to the literature which reports requiring activation of the 
protected 2,3-dihydroxybenzoic acid moiety, which the reported procedure here avoids.   
All of the ligands presented herein can be obtained in high purity following minimal purification.   
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7 Chapter Aims 
 
This chapter aims to present the microbes used in this study and highlight their significance as 
being of clinical relevance.  In addition, the results of MIC assays conducted for the ligands which 
have been previously presented in Chapters 2-6 will be reported.  An analysis of the MIC values 
will describe any important features which contribute towards inhibition of the organisms used. 
 
The study of the growth profiles of the organisms presented herein will be included in the form of 
kinetic studies, with respect to the optical density change over time.  This will help to provide an 
insight into the action of inhibition and to the distortion of the growth of microbes with and without 
the novel iron chelators and the previously accessed ligands from the literature.     
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7.1 Introduction  
7.1.1 Microorganisms 
 
In order to effectively assess the efficacy of the novel ligands presented herein to induce a 
distortion to the normal growth patterns of microorganisms; a panel of organisms which display 
differences in their cell structure and iron acquisition and regulatory systems were chosen.  In 
addition, these organisms displayed in Table 7.1 are all implicated in infections that are associated 
with hospital environments i.e. nosocomial, and so will provide an insight into the likelihood of 
these compounds being competent at reducing the ability of these pathogens to proliferate and 
spread disease.     
Table 7.1 Characteristics of the panel of microbes used in this study, some information on their cell 
structure and additional information regarding their clinical relevance.108-114 
Microorganism Panel Information Additional Info 
Escherichia coli     
18039 
Gram-negative, rod 
shaped. 
Found in lower intestine of warm mammalian hosts.  Causative 
agent in food poisoning though most strains harmless. 
Klebsiella pneumoniae  
30104 
Gram-negative, 
encapsulated, rod 
shaped, 
Able to infect tissues when the skin or mucosal barriers have 
been breached.  Klebsiellae have become important pathogens 
in nosocomial infections for impaired respiratory host 
defenses.  Klebsiella pneumonia is a form of bacterial 
pneumonia. 
Pseudomonas 
aeroginosa     19880 
Gram-negative, 
aerobic. 
Opportunistic human pathogen.  Colonises most man-made and 
natural environments.  An opportunistic, nosocomial pathogen 
of immunocompromised individuals, P. aeruginosa typically 
infects the pulmonary tract, urinary tract, burns, wounds, and 
also causes other blood infections.  Low antibiotic 
susceptibility. 
Acinetobacter 
Baumannii   30007 
Gram-negative, 
almost round rod 
shape. 
Opportunistic human pathogen to immunocompromised. 
Common association as a nosocomial infection causative 
agent. 
Staphylococcus aureus 
1104 
Gram-positive Able to infect tissues when the skin or mucosal barriers have 
been breached, prevalent in atopic dermatitis patients. 
Bacillus  subtilis  
23778 
Gram-positive, 
spore former 
Causes disease in severely immunocompromised patients.  
Otherwise non-infectious. 
Candida albicans     
1386 
Diploid fungus that 
grows both as yeast 
and filamentous 
cells 
Causal agent of opportunistic oral and genital infections 
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As discussed in Chapter 1, there are known structural biological differences between Gram-positive 
and Gram-negative bacterial cells which impact upon their iron uptake mechanisms.57  The Gram-
positive organisms have cytoplasmic membrane-anchored high affinity receptors which allow 
transport of ferri-siderophore complexes via an ATP binding cassette.  Conversely, the Gram-
negative cells possess an outer membrane and it is here that the high affinity ferri-siderophore 
receptors are located.  On binding, ferrisiderophore complexes are translocated to the periplasm 
where they then interact with lower affinity and more generic siderophore binding proteins that 
interact with an ATP binding cassette to initiate transport of the complex to the cytoplasm.  These 
differences are such that it is thought that the novel compounds presented in Chapters 2-6 will 
interact differently depending on the membrane structure.  In addition, the siderophores produced 
by different bacteria will be of particular importance when looking at the binding of extracellular 
iron.   
As previously discussed E. coli produces enterobactin, the most powerful natural siderophore yet 
discovered, therefore to see how this organism interacts with these novel compounds will be of 
particular interest.  E. coli is a diverse species that is a normal inhabitant of the healthy human gut.  
However, various strains have been implicated as the primary causative agent in outbreaks of food 
poisoning.  Other strains are diarrhoeagenic causing many thousands of deaths per year 
worldwide.113  In terms of nosocomial infections, E. coli is responsible for uncomplicated urinary 
tract infections in patients which cause severe discomfort and are often the result of interaction of 
the body with medical implements, such as catheters.115     
B. subtilis produces the siderophore bacillibactin which itself is a very powerful sideophore (Logβ 
= 48), and is thought of as the Gram-positive analogue of enterobactin due to their structural 
similarities.  Coupled with data from E. coli these two organisms will provide a good insight as to 
how the novel chelators perform in relation to powerful natural siderophores, assuming any 
inhibition mode is due to iron restriction and not due to the differences in the membrane 
architecture.  B. subtilis is generally considered to be non-pathogenic and infections are very rare, 
however there have been cases where infections have taken hold in severely immunocompromised 
patients such as those with leukaemia.111  
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K. pneumoniae, a Gram-negative rod-shaped organism is an important pathogen when considering 
nosocomial infection; K. pneumonia infections are  the primary cause of many deaths every year 
especially to the immunocomprised.110  In terms of the siderophores associated with this organism, 
it has been shown that under iron limitation K. pneumoniae is able to produce enterobactin.116  This 
was determined by the comparison of Rf values associated with the known phenolate compounds 
produced by enterobactin in 1979.  Chromatographic identification of enterobactin, linear-
enterobactin, (2,3-dihydroxybenzyoylserine)2, 2,3-dihydroxybenzyoylserine and 2,3-
dihydroxybenzoic acid was confirmed.  These products are the resulting fragments from the 
hydrolysis of enterobactin and thus confirm its presence.   The quantities of each isolate produced 
by K. pneumoniae were approximately equivalent to that of E. coli K12 under similar conditions, 
which could indicate the siderophore enterobactin is utilised in the same manner for both of these 
organisms.   
As shown in Table 7.1 P. aeruginosa is a Gram-negative opportunistic human pathogen,117 for 
which the primary siderophores associated with this organism are those of the pyoverdines (pFe3+ = 
~27) and pyochelin (pFe3+ = 16).117-119  Of the pyoverdines (PVDs) there are three group types 
shown in Figure 7.1 which were found from several different strains of the bacteria in a large 
study.118   
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Figure 7.1 Structures of the three group types for PVDs; siderophores secreted by P. aeruginosa.  
Structures reproduced from; Microbiology, 1997, 143, 35-43 
 
The specificity for Fe3+ by PVDs would suggest that this is the primary siderophore used for iron 
sequestration.  Conversely, the pyochelin molecule, Figure 7.2 , has a pFe3+ = 16 which is a 
significantly lower affinity for Fe3+.  However, other pseudomonad species, such as P. cepacia 
have been shown to produce pyochelin, which acts alongside cepabactin (a 1,2-HOPO based 
siderophore, Chapter 1) to form a ternary complex to bind Fe3+.66   
 
Figure 7.2 Structure of pyochelin; a siderophore secreted by P. aeruginosa.  
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It has been suggested that within the crystal structure of FptA (the ferri-pyochelin receptor) that the 
ternary complex is involved in iron release to the cell.  However, it is yet unreported as to whether 
P. aeruginosa is capable of producing cepabactin and hence utilising the complex in its iron uptake 
and regulatory systems.   
S. aureus infections have become a major concern.  In 2008 the volume of infections associated 
with the bacterium in hospitals led to this organism being the most isolated human bacterial 
pathogen that year.120  The organism itself is a Gram-positive bacterium whose iron regulatory 
systems are quite well established. 115  S. aureus has an added disadvantage with respect to human 
infections; certain pathogenic strains are showing antibiotic resistance to the point of being of 
global concern.  MRSA (methicillin resistant Staphylococcus aureus) is resistant to all β-lactam 
based antibiotics.120  The spread pattern for an MRSA infection has been linked with, in some 
opinions, the same pattern which is noted from methicillin-susceptible S. aureus (MSSA).112  The 
organism is able to survive on nearly all surfaces and has been found currently populating: the air, 
tools of medicine, bed frames and linen, stationery, furniture, food, flooring, clothing and toilets.112  
The strain used in this study is not antibiotic resistant organism, however it should be able to 
provide a good level of insight as to how all S. aureus would react to the ligands.  Staphylococci 
have been primarily shown to utilise trihydroxamate based siderophores.  There are two 
siderophores associated with staphylococci in particular which are staphyloferrin A and 
staphyloferrin B, Figure 7.3.   
 
Figure 7.3 Structures of staphyloferrin A (left) and staphyloferrin B (right); siderophores secreted 
by S. aureus 
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A. baumannii is a Gram-negative bacterium which is an opportunistic human pathogen and is 
commonly associated with infections following traumatic war wounds.108  This bacterium has the 
added danger of being capable of quickly adapting antibiotic resistance, creating MDR (multi-drug 
resistant) and PDR (pan-drug resistant) mutants.108,121    In 2012 Zurawski et al. showed that the 
addition of a chelating agent (2,2-bipyridyl, Figure 7.4), which is non-specific to iron but is capable 
of binding iron, can significantly reduce the surface mobility of the organism with comparison to a 
growth media lacking the ligand.   
 
Figure 7.4 Structure of 2,2-bipyridyl 
 
Certain strains of A. baumannii have been shown to secrete the siderophore acinetobactin (Figure 
7.5), this siderophore is associated with those species that secrete histamine as this is a precursor to 
acinetobactin.   
 
Figure 7.5 Structure of acinetobactin; a siderophore produced by A. baumannii 
 
Also, those strains showing histamine secretion were in general found to express a FatA like 
protein receptor within their membrane architecture.122  Those strains lacking the FatA-like protein 
have been proposed to utilise a catecholate iron acquisition system as they also do not secrete the 
histamine precursor and so most likely do not utilise acinetobactin in iron acquisition.122  The strain 
A. baumannii 30007 used in this study does produce acinetobactin as a siderophore as per the 
providers information and so may be able to utilise ligands with a catecholate binding mode.     
Candida species are known to be common opportunistic pathogens in humans and are the agents 
responsible for most fungal infections per year globally.109  C. albicans of all of the species is the 
dominant causative agent in human infections; however other species such as C. glabrata, C. 
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tropicalis and C. parapsilosis are also involved in the causation of infection.109  Iron is necessary 
for C. albicans to proliferate as a pathogen and the ability of this organism to acquire iron from the 
host is linked to virulence, as has been seen for bacterial species.6,61,123  C. albicans has three main 
high-affinity pathways to acquire iron from a host; (i) a reductive system allowing host transferrin 
and ferritin to be utilised (ii) a siderophore uptake system (iii) a haem-iron uptake system.123  
Though C. albicans has been shown to secrete siderophore compounds in biological assays, the 
siderophore systems within C. albicans are thought to be typically xenosiderophoric in nature as no 
genes have been found which  encode for the biosynthesis of siderophores from C. albicans.123  
The Sit1/Arn1 receptor is present as a transport receptor and has been shown to allow for a range of 
ferri-siderophore complexes to be taken up which were derived from a range of other organisms.123    
In addition, the uptake system for the iron-ferrichrome complex has been discovered for C. 
albicans,124 this siderophore group has been shown to be an important growth factor for many 
organisms, including bacterial species.125     
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7.1.2 MIC assessment methods 
For the purpose of this study a broth serial dilution technique was employed to determine the MIC 
levels for the ligands tested on all microorganisms.  In this way, the liquid media may give a better 
insight into the sorts of levels which would be required to be employed when in a cleaning solution.  
The general layout of the 96-well plates used in this study is given, Figure 7.6.   
 1 2 3 4 5 6 7 8 9 10 11 12 
A           - + 
B           - + 
C           - + 
D           - + 
E           - + 
F           - + 
G           - + 
H           - + 
 
Figure 7.6 Figure denoting the general layout of the 96-well plates used in MIC assays. + indicates 
positive control well, - indicates negative control.  Arrow denotes serial dilution to next column for 
all rows which had compound in A-H.  No cross plating of bacteria occurred to minimise 
contamination.    
However, there are variations on this method which have been previously used to determine the 
MIC level for other compounds, including ligands assumed to work via iron restriction.   For 
example, recently in 2011 Hider et al. employed an agar dilution technique.  This method involves 
preloading the agar media with the agent and then using this to create agar plates on which the 
inoculated culture of the organism desired is added.46  The technique is standardised with respect to 
a text on the subject of antimicrobial susceptibility.126  However, this agar dilution method is 
dependent on the ability of the ligands to solubilise and diffuse through the media and since the 
solubility and diffusion properties of the compounds presented herein in an agar media are 
unknown, in order to maximise the likelihood of obtaining results at sort of levels which are needed 
for testing the broth dilution technique was deemed to be more suitable.    
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7.2 Materials and Methods 
7.2.1 Preparation of bacteriostatic agents  
The solutions of these compounds were prepared by dissolving the chelators in deionized water.  
Volumetric flasks were rinsed with an EDTA solution (10mM in deionised water) before each use 
and then several times with deionised water.  The solutions of the chelators were obtained after the 
addition of NaOH (3 mol eq) to produce the expected trisodium salt which in all cases was then 
soluble after heating in deionised water.  The solvated ligands were then filtered through 0.2µm 
sterile filters to remove any contaminant bacteria or particulate matter and stored at 4°C in sterile 
plastic universal vials.  TREN-1,2-HOPO* results were provided by David Workman, with 
consent, the compound was prepared by dissolving in deionised water and required no sonication 
or heating.        
7.2.2 Bacterial strains  
All microbes were purchased from DSMZ and cultured in the media and conditions recommended 
by the provider.  Subcultures of all bacteria were produced on BHI agar purchased from Sigma-
Aldrich except C. albicans 1386 was grown on a yeast selective media.  For MIC assays, all 
microbes were inoculated in sterilised glass universal tubes containing 10mL BHI broth media.  C. 
albicans 1386 was incubated for 48 hours at 28°C, A. baumannii 30007 and B. subtilis 23778 were 
incubated at 30°C for 48 hours.  The remaining bacteria: E. coli 18039, K. pneumoniae 30104, S. 
aureus 1104 and P. aeruginosa 19880 were incubated at 37°C for 24 hours prior to performing the 
MIC assay.   
7.2.3 MIC Assay 
All compounds were tested in duplicate in MIC assays at several appropriate concentrations so as 
to determine their efficacy.  All assays were cultured at 37°C for 24 hours before being assessed by 
eye and were conducted in 96 well U-bottomed sterile microtitre plates.   For C. albicans, A. 
baumannii and B. subtilis an additional 24 hours was given after the initial assessment to determine 
any change.  OD kinetic studies were repeated with F-bottomed microtitre plates (E. coli, K. 
pneumoniae) or U-bottomed microtitre plates (P .aeruginosa, A .baumannii, B .subtilis, S .aureus 
and C .albicans), runs were carried out at 37°C for 24 hours with agitation for 30s before each 
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reading.  The incubation media was BHI broth and the experiment performed once for the 
compounds which showed inhibition in MIC assays.  All wells contained 100µL of inoculum and 
100µL of compound to be assessed following 2x serial dilutions for the MIC assays and the volume 
of each was halved for the OD studies.  Positive and negative control wells were included for each 
plate and in all cases were cleared.   
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7.2.4 Recap of ligand structures used in this study 
 
Figure 7.7 Structures of the bacteriostatic agents for which the MIC values were determined in this 
study.  SC denotes short-chained and LC denotes long-chained, CTG = cyclotriguaiacylene, TEB = 
triethylbenzene, triazine = tris(piperazin-1-yl)-1,3,5-triazine, and TREN = tris(2-aminoethyl)amine.  
CP130 is designated as per literature precedent.  TREN-1,2-HOPO was provided by an external 
source (see 7.2.1 Preparation of bacteriostatic agents)
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7.3 Results and Discussion 
7.4 MIC Assay Results 
The MIC assays for the compounds presented previously (Chapters 2-6, Figure 7.7) yielded some 
interesting results with regard to the structural features of the compounds and their relative effects 
on the panel of microbes, the results of which are displayed in Table 7.2. 
The data shows that there are three principal candidates that display an inhibitory effect across the 
panel of microbes.  The CTG-1,2-HOPO molecule, the TEB-1,2-HOPO molecule, TEB-R-3,2-
HOPO and TREN-1,2-HOPO molecule all inhibit growth at relatively low concentrations i.e. 
<500µM, with the exception of TEB-R-3,2-HOPO on K. pneumoniae which showed an MIC of 
964µM.  These compounds inhibited growth with no differential between Gram-positive/Gram-
negative/fungus, .  Conversely, the TEB-SC-3,2-HOPO molecule displayed no inhibitory effect 
across the whole panel of microbes.  This was unexpected because in the previous UV-Vis studies 
(Chapter 3) this molecule was shown to bind Fe3+ in a 1:1 stoichiometry.  This may suggest the 
molecule is being utilised by the microbes’ own siderophore uptake systems and is therefore 
‘feeding’ the organisms.  However, further work is required to confirm this hypothesis.  The same 
observations for TEB-LC-3,2-HOPO, CP130 and LC-CP130, with the exception of TEB-LC-3,2-
HOPO molecule on C. albicans which showed inhibition only at high concentration 3855µM.  
Though the UV-Vis binding study for CP130 and the LC-CP130 were not performed in this work 
CP130 has been shown to bind Fe3+ in a 1:1 stoichiometry;127 the extra carbon for the LC-CP130 is 
not expected to alter the binding stoichiometry drastically and so both should bind Fe3+ in a 1:1 
stoichiometry, but are seen to be non-inhibitory.  In addition, as in the TEB-SC-3,2-HOPO the 
TEB-LC-3,2-HOPO molecule showed a 1:1 stoichiometry binding Fe3+ in UV-Vis studies but 
shows no inhibitory effect again lending to the hypothesis of growth promotion.              
TRENCAM and EMECAM show relatively mediocre inhibition across the panel, both having no 
inhibition against C. albicans.  With the exception of TRENCAM on K. pneumoniae (MIC = 
535µM) and both molecules on S. aureus (MIC = 482µM) for which the inhibition is fairly 
promising.    
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Table 7.2 MIC for the hexadentate ligands tested on the clinically relevant panel of microbes.  Assays were performed in BHI broth over 24 hours.  (-) denotes no inhibition 
was noted.  (*) Results obtained from external source (see 7.2.1 Preparation of Antimicrobial Agents)    
 E. coli K. pneumoniae P. aeruginosa A. baumannii S. aureus B. subtilis C. albicans 
Compound MIC/µM ppm MIC/µM ppm MIC/µM ppm MIC/µM ppm MIC/µM ppm MIC/µM ppm MIC/µM ppm 
CTG-3,2-HOPO - - 3855 3162 3855 3162 3855 3162 241 198 1928 1581 482 395 
CTG-1,2-HOPO 241 188 482 375 482 375 241 188 241 187 482 375 120 94 
triazine-3.2-HOPO 3855 2873 - - - - 2855 2873 964 718 3855 2873 482 359 
triazine-1,2-HOPO 482 339 964 678 482 339 - - - - - - 120 85 
TEB-SC-3,2-HOPO - - - - - - - - - - - - - - 
TEB-LC-3,2-HOPO - - - - - - - - - - - - 3855 2873 
TEB-1,2-HOPO 241 159 482 319 482 319 241 159 241 159 241 159 241 159 
TEB-R-3,2-HOPO 241 180 964 718 482 359 60 45 241 180 241 180 241 180 
TEB-3,4-HOPO - - - - - - - - - - - - 964 718 
CP130 - - - - - - - - - - - - - - 
LC-CP130 - - - - - - - - - - - - - - 
TREN-R-3,2-HOPO 2944 1889 - - 2944 1889 368 236 368 236 1472 944 1472 944 
TREN-1,2-HOPO* 625 371 313 186 313 186 313 186 5 3 313 186 313 186 
TRENCAM 1928 1069 964 535 1928 1069 1928 1069 482 267 1928 1069 - - 
EMECAM 3855 2537 1928 1268 1928 1268 1928 1268 482 317 1928 1268 - - 
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CTG-3,2-HOPO appears to be ineffective at inhibiting the growth of E. coli up to the highest 
concentration of the ligand which corresponds to 7710µM (6324ppm).  This could indicate that the 
bacteria in this case have the capability to utilise any Fe3+ complexed by this molecule or, 
alternatively that the Fe3+ is not successfully bound by the ligand.  Though this would contrast with 
the UV-Vis binding studies previously discussed (Chapter 2) where the ligand was shown to bind 
iron in a 1:1 stoichiometry.  Alternatively, the result could indicate a kinetic issue of the speed at 
which the ligand binds Fe3+.  If the ligand binding is a slow process there may not be any inhibition 
to be seen within the timeframe.  In contrast, this molecule appears to be reasonably inhibitory 
against Gram-positive S. aureus, reaching levels of 241µM (197ppm).   The difference between 
these results could be due to the structural differences in the membrane architecture between Gram-
negative and Gram-positive or even the ferri-siderophore shuttling mechanisms. Alternatively, it 
could be the differences in competing siderophores produced by the two bacteria and how they 
interact with the ligand i.e. E. coli can produce the very powerful enterobactin.   
The CTG-1,2-HOPO ligand bearing CTG scaffold was as effective at inhibiting the growth of E. 
coli as S. aureus.  This could indicate that this molecule is not interacting with the uptake of Fe3+ in 
terms of the receptor proteins involved but more likely is just binding extracellular Fe3+.  It may be 
expected to see a difference in the levels of inhibition obtained if the inhibition was due to an 
interaction with the siderophore receptors, as these are different for the different organisms.  In 
addition, as can be seen for the CTG-1,2-HOPO analogue, if the inhibition were a case of 
competing siderophore interaction we might expect to see a difference between Gram-positive and 
Gram-negative such as for CTG-3,2-HOPO.  It may be, as per the UV-study, that we have seen this 
molecule able to hold possibly 2 equivalents of Fe3+ per ligand that this has shown its effectiveness 
in both cases.  The Fe3+ cation maybe held too strong/close into the ligand; cavity facilitated by the 
shorter linkage, to allow competing siderophores to sequester the Fe3+ away from the complex, in 
this way inducing growth inhibition.  Alternatively, another mechanism of inhibition may be in 
effect for the 1,2-HOPO bearing ligand.   
The triazine-1,2-HOPO molecule was shown to inhibit effectively at relatively low concentration 
(<500µM) for the organisms E. coli, P. aeruginosa and C. albicans.  The ligands also showed 
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inhibition for K. pneumoniae at slightly higher levels (678µM).  However, the molecule displayed 
no inhibitory effect against the Gram-positive organisms or A. baumannii.  These results could 
indicate certain selectivity for the inhibition of Gram-negative organisms; however a larger panel 
of microbes must be explored to test this selectivity as A. baumannii was uninhibited.  Conversely, 
the triazine-3,2-HOPO molecule showed inhibition against the Gram-positive organisms however, 
not to below 500µM.  Both of the triazine-based ligands showed good inhibition towards C. 
albicans, this may be in part due to the limited siderophore transport systems the organism has 
available.  UV-Vis analysis showed that the triazine-1,2-HOPO molecule does not quickly bind 
Fe3+ in a 1:1 stoichiometry but the 3,2-HOPO analogue does after 14 days, under the experimental 
conditions described.  The activity of the triazine-1,2-HOPO could be due to kinetically favourable 
binding of Fe3+, which, once bound is unable to be used by the microbes.  Alternatively, the 
exchange reaction rates between the ferrated ligand complex and the siderophore molecules may be 
too slow to allow the organisms own systems to successfully overcome the nutrient deficiency.  
The triazine-3,2-HOPO molecule can form a 1:1 complex with Fe3+ which is undoubtedly 
thermodynamically favoured however this is achieved at a slow rate.  It could be the case that the 
siderophore systems form the ferric complexes at a faster rate and although the triazine-3,2-HOPO 
ligand may form a stable complex thermodynamically, under the experimental conditions, the rate 
of Fe3+ binding is too slow to be effective.             
The results for the molecules which are built upon the triethylbenzene (TEB) scaffold raise some 
interesting observations.  The TEB-1,2-HOPO and TEB-R-3,2-HOPO molecules show inhibition at 
low concentrations (<500µM) across the panel, with the exception of the TEB-R-3,2-HOPO on K. 
pneumoniae which was inhibitory at 718µM.  Whereas, the other compounds built upon this core: 
TEB-SC-3,2-HOPO, TEB-LC-3,2-HOPO and TEB-3,4-HOPO showed no or poor inhibition across 
the panel.  The TEB-LC-3,2-HOPO on C. albicans which inhibited at high concentration <1000µM 
and the TEB-3,4-HOPO on C. albicans which inhibited at 964µM.  This may suggest that these 
molecules are being utilised by the microbes’ own siderophore transport systems and are therefore 
‘feeding’ the organisms.  However, further work which involves a colony number determination 
portion is required to confirm this hypothesis.   
154 
 
The selectivity for inhibition which is seen for the 1,2- and R-3,2 HOPO moieties could be 
attributed to a number of contributing factors.  Firstly, it may be that the selection of either the 1,2-
HOPO or the R-3,2-HOPO moiety to induce non-species dependent inhibition is important for this 
core scaffold, as these are the only full panel inhibitors.  The presence of a carbon chain spacer 
between the HOPO moiety and core scaffold appears to be detrimental to the ability of the ligand to 
inhibit growth.  For example the TEB-SC-3,2-HOPO and the TEB-LC-3,2-HOPO molecules show 
no inhibition, whereas the 1,2- and R-3,2-HOPO analogues display strong inhibition across the 
panel.  Possibly, the closer the binding moieties are to the core scaffold the more effective the 
microbial growth inhibition.  A carbon chain spacer between HOPO and core may facilitate 
recognition by the microbial systems or it could lower the binding affinity of the ligand for the 
metal centre and allow competing siderophore molecules to sequester the metal from the ferrated 
ligand complex.  The poor inhibition in the 3,4-HOPO containing ligand could be due to the 
orientation of the binding atoms with respect to the attachment which has been show previously to 
be important.  Although in UV-Vis studies the molecule was shown to bind Fe3+ in a 1:1 
stoichiometry.    The binding affinities for the compounds would need to be determined in order to 
explore this reasoning.   
The results for the TEB core mirror those displayed for the CTG core scaffold in that the 1,2-
HOPO which includes a shorter chain attachment of HOPO to the core than the 3,2-HOPO 
analogue is a more effective inhibitor of growth across the panel of organisms, with the exception 
of S. aureus which showed an MIC of 241µM for both molecules.  The triazine results show that 
although the 3,2-HOPO containing analogue inhibited more organisms than the 1,2-HOPO the 
concentration levels were lower in the cases for the 1,2-HOPO for the same organism.  These 
results could indicate that chain length is important for inhibition and that the inclusion of the 1,2-
HOPO is significant.  However, without further work to dissect these two contributing factors the 
significance of either with respect to the other cannot be distinguished.           
The TREN-based ligand results show that CP130 and the novel LC-CP130 were ineffective at 
inhibiting across the panel.  Conversely, the TREN-R-3,2-HOPO molecule showed inhibition at 
low concentration against A. baumannii and S. aureus (>500µM) and inhibition at medium 
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concentrations (>1000µM) for B. subtilis and C. albicans.  These results might indicate that the 
3,2-HOPO moiety is again possibly being recognised on this core scaffold in both the short and 
long chained analogues, as was possibly seen for the TEB based ligands.  Whereas, the R-3,2-
HOPO is again proving more effective than those ligands where the HOPO moiety is attached via 
the N-atom of the ring system and which contain a carbon chain spacer between the attachment at 
the ligand core and HOPO group.  In addition, results obtained for the TREN-1,2-HOPO* indicate 
inhibition across the panel <500µM with all microbes except E. coli which showed inhibition at 
625µM.  Again, these results corroborate the hypothesis that the 1,2-HOPO and R-3,2-HOPO are 
important moieties for inhibition of the microbes in this panel as they once again stand out on the 
same core as being effective with respect to the 3,2-HOPO both long and short chained derivatives.  
Whether this is due to the lack of a carbon spacer these ligands possess or that they are unable to be 
recognised and therefore prevent iron uptake requires more in depth study.    
C. albicans was shown to be more susceptible to growth inhibition by more of the ligands than the 
other species; this could in part be due to the organism having been found to so far to have no 
known genes for the biosynthesis of its own siderophores.  This may mean it has no high affinity 
iron sequestants with which to compete for the extracellular iron.  Though C. albicans has been 
noted to utilise siderophores from other organisms, the ligands presented here may be too alien for 
the organism to utilise for its own means of iron acquisition, with the exception of those which 
showed no inhibition.   
S. aureus was shown to be susceptible to inhibition by the compounds to concentrations below 
500µM in all cases except for the triazine-3,2-HOPO where inhibition was noted at 964µM.  The 
other organisms showed some resistance to one or more ligands to above 1000µM.  This could 
signify that S. aureus is more susceptible to inhibition through the induction of an Fe3+ nutrient 
deficiency than the other organisms, or that once inhibited S. aureus is not able to recover or 
compete for the Fe3+ effectively via its own siderophore uptake mechanisms.    
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7.5 Determination of the Inhibitory Effect of Novel Chelators on the Growth of 
Clinically Relevant Microbes 
 
The ligands presented herein were assessed on their ability to inhibit the growth of the panel of 
microbes through measurement of the optical density (OD) of a solution containing: growth media, 
ligand and microbe with respect to the same solution containing no ligand, over an appropriate time 
period at 630nm.  The kinetic assays were performed for those compounds which showed an 
inhibitory effect in MIC assays as previously discussed.  These assays were performed at 
concentrations to two dilutions below the MIC value for comparison, graphs have been normalised 
for clarity.   The results of the assays are to be discussed in terms of an apparent ‘lag time’ which 
for these purposes refers to the time required to observe bacterial growth via the development of 
turbidity.  In addition the differences in final cellular yield of each culture (indicated by a simple 
ratio OD630 (treated):OD630 (untreated)) will also be discussed. All kinetic assay graphical analyses are 
available in the Appendix.  The assays performed on S. aureus for TEB-R-3,2-HOPO, TREN-R-
3,2-HOPO, TRENCAM and EMECAM were unsuitable to extract any data from and so have been 
omitted from discussion, however these are available in the Appendix .   
In general, most of the MIC values were found to be valid in this system also.  In a number of cases 
however, some growth was noted at the MIC concentrations.  In most cases it is clear that an 
appropriate MIC for this assay system (with periodic agitation and presumed media reoxygenation) 
is the concentration represented by the next highest concentration in the series.   
 
7.5.1 Assessment of the effect of the CTG-3,2-HOPO ligand (2.22) on the growth of 
microbes: K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus, B. subtilis and C. 
albicans  
 
The results of the kinetic assays performed on the K. pneumoniae bacterium for the CTG-3,2-
HOPO molecule show that at the MIC level (3855µM) there is no discernible growth of bacteria 
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over the 24 hour period, Figure 7.8.  However, at those concentrations below that of that MIC 
(1928 and 964µM) the growth of bacteria is normal,, although at approximately the 12 hour time 
point the data shows slightly erratic OD readings, the growth of bacteria is still visible.   The 
bacterial growth at lower concentration occurs with no significant ‘lag-time’ with respect to the 
control but the final OD630 values are lower than those of the control indicating lower bacterial 
concentration over the same time period.   
 
 
Figure 7.8 OD630 development over 24 hours for CTG-3,2-HOPO (2.22) on K. pneumoniae (MIC = 
3855µM).  Values displayed in legend are given as micromolar (µM) concentrations.     
 
This assay confirms that at the MIC level the CTG-3,2-HOPO molecule is bacteriostatic in this 
adjusted format.  At this stage assessment of the bacteriocidal activity has not been carried out.  
Growth is apparent early in all sub-MIC cultures but the growth rate is reduced with respect to 
increasing inhibitor concentration.  This could be a due to the thermodynamic stability of the Fe3+-
CTG-3,2-HOPO complex being too high for competing natural siderphores to sequester the metal 
away or, that the complex to ‘too alien’ for the organisms regulatory systems to utilise the complex.   
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
00:00:00 06:00:00 12:00:00 18:00:00 24:00:00
O
D
6
3
0
 
Time/HH:MM:SS 
Control
MIC Level - 3855
1928
964
158 
 
 
Figure 7.9 OD630 development over 24 hours for CTG-3,2-HOPO (2.22) on P. aeruginosa (MIC = 
3855µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
The CTG-3,2-HOPO molecule shows similar results for the assays performed on P. aeruginosa and 
A. baumannii, Figure 7.9 and Figure 7.10, though some differences are apparent.  Both P. 
aeruginosa and A. baumannii show no discernible growth at the predetermined ligand MIC 
(3855µM) and, both organisms show an apparently extended lag period for those concentrations 
below the MIC value, summarised in Table 7.3.  A. baumannii in particular displays a reduced 
growth rate with increasing chelator concentration, Figure 7.10.     
 
 
Figure 7.10 OD630 development over 24 hours for CTG-3,2-HOPO (2.22) on A. baumannii (MIC = 
3855µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
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The organism S. aureus shows no growth at the MIC level (241µM).  However, significant growth 
is illustrated at those concentrations below the MIC after a lag period, results displayed in Table 
7.3.  
 
Figure 7.11 OD630 development over 24 hours for CTG-3,2-HOPO (2.22) on S. aureus (MIC = 
3855µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
However, these curves are complex and poorly reproducible; the characteristic incomplete cell 
division of this organism may be important here.  S. aureus daughter cells infrequently dissociate 
from the parent cell on division and consequently these form multicellular clumps which could 
influence their rate of settling and the overall growth kinetics in the culture plates.  Nevertheless, 
marked extension of the apparent lag period with increasing sub-MIC concentrations is evident.   
In contrast, the organism B. subtilis displays no significant difference in the lag time and final 
OD630 at the concentrations 1928, 964 and 482µM, of which 1928µM is the determined MIC value.  
The rate of growth of the MIC value with respect to the lower concentrations appears to be 
reduced, however, overall the same levels are reached, Figure 7.12.  The resulting growth at the 
MIC value could be a result of the stimulation to growth that may occur when organisms are 
subject to agitation, as per the conditions of the assay.  In addition, it may be the case that the 
organism has reached a different growth phase with respect to other organisms and requires an 
acclimatisation period which may produce the synchronised lag time periods for the three 
concentrations.     
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Figure 7.12 OD630 development over 24 hours for CTG-3,2-HOPO (2.22) on B. subtilis (MIC = 
1928µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
Figure 7.13 OD630 development over 18 hours for CTG-3,2-HOPO (2.22) on C. albicans (MIC = 
482µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
C. albicans displays no discernible growth as determined by turbidity detection at the MIC value 
previously determined or at those concentrations below the MIC value, displayed in Figure 7.13.   
Table 7.3 summarises the data for those organisms which displayed growth, the lag time for these 
organisms at the various concentration and the difference in OD630 between the control and ligand 
containing samples is given.  The ODL/ODC value is a measure of how successful an organism is at 
growing to the same OD as the control sample; in this representation a value close to 1 denotes 
strong growth relative to the control.     
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Table 7.3 Summary of the lag time at concentrations of ligand which showed growth and the 
observed difference in OD630 for those organisms that displayed growth for the CTG-3,2-HOPO 
(2.22) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 of the 
control sample.  
Organism 
Concentration 
/µM 
 
MIC/µM 
Extended Lag time/ 
approximate hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/OD
C 
K. 
pneumoniae 
1928 
3855 
0 
0.54 
0.47 0.87 
964 0 0.49 0.90 
P. 
aeruginosa 
1928 
3855 
5 
0.86 
0.62 0.72 
964 3 1.08 1.26 
A. 
baumannii 
1928 
3855 
6 
0.55 
0.06 0.11 
964 6 0.14 0.25 
S. aureus 
120 
241 
6 
0.25 
1.35 5.40 
60 0 1.27 5.08 
B. subtilis 
1928 
1928 
4 
0.53 
0.13 0.25 
964 4 0.12 0.25 
482 4 0.12 0.25 
 
The data (Table 7.3) indicates that in terms of lag time, K. pneumoniae does not show any 
measureable difference in the starting points of organism growth with or without chelator.  Also, at 
those values below the MIC, the growth of the samples containing CTG-3,2-HOPO (2.22) is fairly 
uninhibited, reaching a similar OD630 as the control.   In contrast P. aeruginosa displays lag times 
of 3 and 5 hours at concentrations 1928 and 964µM respectively.  The OD630 measurements here 
show that at 1928µM the OD630 with the ligand reaches levels around 72% of that of the control.  
However, the ODL/ODC value for 964µM shows over 100% OD630 is reached which could indicate 
some growth promotion properties at this concentration.  A. baumannii showed favourable lag 
periods at both concentrations of approximately 6 hours and in both case the levels of growth 
reached were significantly reduced with respect to the control measurement.  S. aureus displayed 
what may be considered significant organism growth with respect the control the ODL/ODC for the 
values 120 and 60µM being 5.40 and 5.08 respectively.  This could signify utilisation of the ligand 
complex by the organism, producing a growth promotion effect.  However, these values should not 
be over interpreted due to the relatively poor data from which they were derived.  B. subtilis 
showed a similar lag period of 4 hours for all three measured concentrations and the ODL/ODC 
value indicates that all of the samples reached the same final OD630 with respect to the control.  The 
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growth at the MIC level could be attributed to some stimulation to growth cause by the agitation as 
per the conditions of the kinetic assays which was not the case for the MIC assays.   
 
7.5.2 Assessment of the effect of the CTG-1,2-HOPO (2.30) ligand on the growth of 
microbes: E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus, B. subtilis 
and C. albicans  
 
The kinetic OD630 assays performed for the CTG-1,2-HOPO (2.30) showed that for E. coli and K. 
pneumoniae no significant lag period could be detected in their growth profiles in the assay time 
period.  In addition, for both organisms, the MIC showed no growth with respect to the control.  
However, at the concentrations tested below the MIC value growth could be seen but reaching 
OD630 values below that of the control, summary in Table 7.4. 
P. aeruginosa displayed no growth at the MIC level (482µM) but displayed growth at two dilutions 
below this level (120µM) to a lower OD630 than the control and with a lag period as displayed in 
Figure 7.14.  The data for 3855µM showed significant precipitation and has been removed for 
clarity, full data available in the Appendix.  Both of the organisms A. baumannii and B. subtilis 
displayed no growth at the MIC level or at the dilution below this; growth was only seen at two 
dilutions below and to significantly reduced level of OD630 with respect to the control.  In both 
cases a lag time of approximately18 hours was noted.  The organisms S. aureus and C. albicans 
showed no growth over the assay time period with the lowest concentration of inhibitor applied, 
suggesting that both are more sensitive to this type of inhibition. 
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Figure 7.14 OD630 development over 24 hours for CTG-1,2-HOPO (2.30) on P. aeruginosa (MIC = 
482µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
  
Table 7.4 Summary of the lag time at concentrations of ligand which showed growth and the 
observed difference in OD630 for those organisms that displayed growth for the CTG-1,2-HOPO 
(2.30) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 of the 
control sample.   
Organism 
Concentrati
on 
/µM 
 
MIC/µM 
Extended 
Lag time/ 
approxima
te hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/ODC 
E. coli 
120 
241 
0 
0.41 
0.12 0.29 
60 0 0.21 0.51 
K. 
pneumonia
e 
241 
482 
0 
0.54 
0.20 0.37 
120 0 0.29 0.54 
P. 
aeruginosa 
120 482 4 0.86 0.22 0.26 
A. 
baumannii 
60 241 12 0.55 0.02 0.04 
B. subtilis 120 482 15 0.53 0.12 0.23 
 
 
The data displayed in Table 7.4 shows that in most cases the levels to which the organisms grow to 
as determined by the ODL/ODC ratio are reduced in the CTG-1,2-HOPO (2.30) ligand with respect 
to the CTG-3,2-HOPO (2.22).  This can be interpreted as the 1,2-HOPO containing ligand being 
more effective at creating an inhibitory effect.   
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7.5.3 Assessment of the effect of the triazine-1,2-HOPO (4.9) ligand on the growth of 
microbes: E. coli, K. pneumoniae, P. aeruginosa,  and C. albicans 
 
The results from the assays containing the triazine-1,2-HOPO ligand (4.9) show that on the 
organism E. coli there is no growth seen at the MIC level.  However, at both dilutions below this 
concentration growth is noted.  There is no appreciable lag time between the growth control and the 
growth at 241 and 120µM however there is a definite difference in the OD630 reached,  Table 7.5.  
It can be noted that the cellular yields appear to decrease with increasing chelator concentration.   
 
Figure 7.15 OD630 development over 24 hours for triazine-1,2-HOPO (4.9) on E. coli (MIC = 
482µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
Treatment of K. pneumoniae generated similar results in the assay, in that no growth over the 24 
hour period was noted at the MIC concentration (964µM) however, at the two dilutions below this 
some growth was noted, summarised in Table 7.5. 
For P. aeruginosa the same trend was displayed, however the growth at the second dilution 
(120µM) below the MIC (482µM) occurred at a rapid rate and to reach an OD630 at 94% that of the 
control. This contrasts with the other organisms where this level of growth was not reached.  
However, the rate of growth for this organism was markedly diminished with respect to the control.  
This may be due to the growth speed difference between the organisms or that at this concentration, 
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once the initial inhibition is overcome P. aeruginosa may be able to utilise the ligand for its own 
nutrient sequestration systems.  Alternatively, the profiles may be explained by a low inoculum 
concentration eventually generating a high concentration of siderophore which then supports the 
rapid growth of the culture.    
 
Figure 7.16 OD630 development over 24 hours for triazine-1,2-HOPO (4.9) on P. aeruginosa (MIC 
= 482µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
C. albicans showed no growth in the periodically agitated assay format at any concentration at or 
below the predetermined MIC (120µM).  This organism can adopt yeast and filamentous growth 
modes.  It is possible that the agitation necessary for this technique may have induced a different 
growth mode than the static MIC determinations, reducing the MIC in this assay format.     
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Table 7.5 Summary of the lag time at concentrations of ligand which showed growth and the 
observed difference in OD630 for those organisms that displayed growth for the triazine-1,2-HOPO 
(4.9) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 of the 
control sample.   
Organism 
Concentration 
/µM 
 
MIC/µM 
Extended Lag 
time/ 
approximate 
hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/ODC 
E. coli 241 
482 
0 
0.41 
0.24 0.59 
 120 0 0.29 0.70 
K. 
pneumoniae 
482 
964 
2 
0.54 
0.27 0.50 
241 0 0.34 0.63 
P. 
aeruginosa 
241 
482 
7 
0.86 
0.32 0.37 
120 5 0.81 0.94 
       
7.5.4 Assessment of the effect of the triazine-3,2-HOPO (4.11) ligand on the growth of 
microbes: E. coli, A. baumannii, S. aureus, B. subtilis and C. albicans 
 
The kinetic assays for this particular ligand were compromised by the precipitation of the 
compound and as a result some of the higher concentrations gave unusable data, all data shown in 
Appendix.  However, some assays did show useful data sets such as the E. coli  bacterium at two 
levels below the MIC (964µM) which showed no appreciable lag time in the growth and reached 
an OD630 close to that of the control.   
A. baumannii, S. aureus and B. subtilis showed no growth at any of concentrations tested which in 
both cases were 3855, 1928 and 964µM where 3855µM was the predetermined MIC for this ligand 
on those bacteria.   
C. albicans was found to show no growth at the MIC level (482µM), Figure 7.17.  However, 
several dilutions below this level showed no growth.  Growth was recorded at 30µM ligand 
concentration but no extension to the lag period was observed and culture turbidity almost reached 
the same levels as the control assay.    
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Figure 7.17 OD630 development over 18 hours for triazine-3,2-HOPO (4.11) on C. albicans (MIC = 
482µM).  Values displayed in legend are given as micromolar (µM) concentrations 
. 
7.5.5 Assessment of the effect of the TEB-LC-3,2-HOPO (3.25) ligand on the growth of C. 
albicans 
 
The TEB-LC-3,2-HOPO (3.25) only displayed inhibition on the growth of the organism C. 
albicans.  There was no growth noted at the MIC level (3855µM) however, at the second dilution 
below this level (964µM) growth was noted.  An extension to the lag time of approximately 3 
hours could be noted and an ODL/ODL of 0.50 (Figure 7.18).   
 
Figure 7.18 OD630 development over 18 hours for TEB-LC-3,2-HOPO (3.25) on C. albicans (MIC 
= 3855µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
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7.5.6 Assessment of the effect of the TEB-1,2-HOPO (3.27) ligand on the growth of 
microbes: E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, B. subtilis and C. 
albicans 
 
In the kinetic assay for the TEB-1,2-HOPO (3.27) E. coli displayed no growth at the MIC level, but 
as previously seen for other samples showed growth at the two dilutions below this.  There was no 
extension to the apparent lag time noted in the growth with respect to the control; however, the 
OD630 was diminished with respect to the control, Table 7.6.   
The organism K. pneumoniae showed similar trends to that of E. coli, the two levels below the MIC 
value showed growth with respect to the control.  In contrast P. aeruginosa only displayed growth 
at the second dilution (120µM) below the MIC, only reaching an OD630 around 30% of that of the 
control samples.  Both K. pneumoniae and P. aeruginosa showed no masureable lag time with 
respect to the growth control, Table 7.6.   
 
Figure 7.19 OD630 development over 24 hours for TEB-1,2-HOPO (3.27) on A. baumannii (MIC = 
241µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
The organism A. baumannii displayed both growth inhibition and a lag time period with respect to 
the control at the two dilutions below the MIC, no growth was shown at the MIC level (241µM).  
At a fairly low concentration of 120µM a lag time of approximately 6 hours is noted on A. 
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baumannii; similar or longer lag periods have been noted previously for the CTG based ligands 
2.22 and 2.30.  Neither S. aureus nor C. albicans showed no growth with respect to the control over 
the assay time periods at or below the MIC value. 
Table 7.6 Summary of the lag time at concentrations of ligand which showed growth and the 
observed difference in OD630 for those organisms that displayed growth for the TEB-1,2-HOPO 
(3.27) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 of the 
control sample.   
Organism 
Concentration 
/µM 
MIC/µM 
Extended Lag 
time/ 
approximate 
hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/ODC 
E. coli 
120 
241 
0 
0.41 
0.21 0.51 
60 0 0.37 0.90 
K. 
pneumoniae 
241 
482 
0 
0.54 
0.10 0.19 
120 0 0.32 0.59 
P. 
aeruginosa 
120 
482 
0 
0.86 
0.27 0.31 
A. 
baumannii 
120 
241 
6 
0.55 
0.19 0.35 
60 2 0.40 0.73 
B. subtilis 60 241 4 0.53 0.14 0.26 
 
7.5.7 Assessment of the effect of the TEB-R-3,2-HOPO (3.28) ligand on the growth of 
microbes: E. coli, K. pneumoniae, P. aeruginosa, A. baumannii,  B. subtilis and C. 
albicans 
 
Kinetic assays for the compound TEB-R-3,2-HOPO (3.28) showed that for E. coli there was no lag 
time in the growth of the organism at those concentrations which displayed growth which were the 
MIC level (241µM)  and the two dilutions below this level (120 and 60µM), Figure 7.20.  That 
there was growth detected at the MIC level could be due to stimulation of growth by the agitation 
set in the conditions of the assays.  It is worthy to note that the MIC level did not reach the same 
OD630 and therefore, it may be the case that this is not detectable by eye as per the MIC assays.  
The dilution two below the MIC level did show recovery to the same level as the control sample 
which could be indicative of the organism overcoming the bacteriostasis through production of its 
own siderophores in response to application of the ligand.   
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Figure 7.20 OD630 development over 24 hours for TEB-R-3,2-HOPO (3.28) on E. coli (MIC = 
241µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
The organisms K. pneumoniae, P. aeruginosa and A. baumannii displayed similar trends in that the 
MIC level for each displayed no growth but as has been previously shown, the two dilutions below 
this displayed measurable growth to an OD630 below the control value, Table 7.7.  P. aeruginosa at 
184µM showed a lag time in the growth of the organism of 2 hours and A. baumannii displayed a 
lag time of 5 hours for the concentration 23µM.   
The organism B. subtilis displayed no growth at the MIC level (241µM), however as previously 
noted the two levels below this displayed growth.  The concentration 120µM showed a lag time of 
approximately 3 hours with respect to the control, however, the result at 60µM showed almost 
uninhibited growth reaching the same level as the control sample, Table 7.7.  C. albicans showed 
no growth with respect to the control at any concentration tested on TEB-R-3,2-HOPO (3.28).   
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Table 7.7 Summary of the lag time at concentrations of ligand which showed growth and the 
observed difference in OD630 for those organisms that displayed growth for the TEB-R-3,2-HOPO 
(3.28) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 of the 
control sample.   
Organism 
Concentration 
/µM 
MIC/µM 
Extended Lag 
time/ 
approximate 
hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/ODC 
E. coli 
241 
241 
0 
0.41 
0.26 0.63 
120 0 0.33 0.80 
60 0 0.41 1.0 
K. 
pneumoniae 
482 
964 
0 
0.54 
0.21 0.39 
241 0 0.37 0.69 
P. 
aeruginosa 
241 
482 
2 
0.86 
0.29 0.34 
120 0 0.30 0.35 
A. 
baumannii 
30 
60 
5 
0.55 
0.26 0.47 
15 0 0.49 0.89 
B. subtilis 
120 
241 
3 
0.53 
0.36 0.70 
60 0 0.53 1.0 
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7.5.8 Assessment of the effect of the TREN-R-3,2-HOPO  (6.12) ligand on the growth of 
microbes: E. coli, P. aeruginosa, A. baumannii, B. subtilis and C. albicans 
 
The results from the assay containing the TREN-R-3,2-HOPO (6.12) performed on E. coli after 15 
hours were difficult to analyse as they displayed large and unusual fluctuations in optical density 
below the MIC value, however both of these concentrations of ligand did display growth until this 
time point and the results are summarised in Table 7.8.  After 15 hours the MIC concentration 
(2944µM) displayed growth reaching a level somewhat diminished with respect to the control 
(ODL/ODC = 0.34) the compound therefore at the MIC level seems to create a profound 
bacteriostatic effect, which only after 15 hours is overcome by the organism, Figure 7.21.     
For the organisms P. aeruginosa and A. baumannii a similar trend can be noted; both show growth 
at the MIC level and to two dilutions below the MIC level, however the A. baumannii is seen to 
grow to a higher ODL/ODC compared to P. aeruginosa indicating the organism is able to recover 
more effectively from the bacteriostasis, Table 7.8.   
 
 
Figure 7.21 OD630 development over 18 hours for TREN-R-3,2-HOPO (6.12) on E. coli (MIC = 
2944µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
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B. subtilis displayed issues similar to that of E. coli and after around 15 hours the data was no 
longer viable to extract useful information (see Appendix).  However, some information regarding 
the lag time and OD630 levels reached for the dilutions below the MIC value (1472µM) can be 
obtained and is therefore displayed in Table 7.8.  C. albicans showed no growth at the MIC or at 
dilutions below this level over the assay time period.   
 
Table 7.8 Summary of the lag time at concentrations of ligand which showed growth and the 
observed difference in OD630 for those organisms that displayed growth for the TREN-R-3,2-
HOPO (6.12) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 
of the control sample.   
Organism 
Concentration 
/µM 
MIC/µM 
Extended Lag 
time/ 
approximate 
hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/ODC 
E. coli 
2944 
2944 
12 
0.41 
0.14 0.34 
1472 1 0.30 0.73 
736 0 0.39 0.95 
P. 
aeruginosa 
 
2944 
2944 
7 
0.86 
0.19 0.22 
1472 3 0.38 0.44 
736 0  0.57 0.66 
A. 
baumannii 
368 
368 
6 
0.55 
0.28 0.51 
184 2 0.39 0.71 
92 2  0.47 0.85 
B. subtilis 
736 
1472 
6 
0.53 
0.12 0.23 
368 0 0.26 0.49 
 
 
7.5.9 Assessment of the effect of the TRENCAM (6.16) Ligand on the growth of microbes: 
E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and B. subtilis  
 
The TRENCAM ligand when applied to E. coli in the kinetic assay showed a different result for the 
MIC concentrations with respect to the MIC assays performed previously.  At the predetermined 
MIC level (964µM) we can see in Figure 7.22 that growth is apparent at the MIC level, and at the 
two concentrations below this.  At these lower concentrations the OD630 exceeds that of the control, 
indicating a possible growth promoting mode of action of the compound.  This for E. coli is not 
surprising as the organism has the capability to interact and utilise catecholate based ligands i.e. 
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enterobactin and this may be the cause of the lack of inhibition.  The concentrations above the 
determined MIC show some inhibition for this organism with a lag time of ~9 hours for the highest 
concentration of ligand before growth is noted.  The lack of inhibition and the observed difference 
in the MIC value could be a result of the stimulation to growth which occurs when the solutions are 
agitated however, further work is required to confirm this wherever this phenomenon has been 
noted.    
 
Figure 7.22 OD630 development over 24 hours for TRENCAM (6.16) on E. coli (MIC = 964µM).  
Values displayed in legend are given as micromolar (µM) concentrations. 
 
The organism K. pneumoniae displayed similar results as those for E. coli in that growth was noted 
at the MIC level to the same OD630 as the control sample, though the same observed levels of the 
control OD630 were noted only in the case of the lowest concentration (241µM).     
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Figure 7.23 OD630 development over 24 hours for TRENCAM (6.16) on K. pneumoniae (MIC = 
964µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
 
P. aeruginosa displayed growth to a concentration one dilution above the predetermined MIC level 
(1928µM) however; the growth was diminished with respect to the control OD630 reached, Table 
7.9.  B. subtilis displayed growth at the MIC level but remained totally inhibited above this 
concentration; the levels of growth in this case did not exceed that of the control as have been 
discussed previously for E. coli and K. pneumoniae with TRENCAM.  This may indicate the 
inability of B. subtilis to utilise the synthetic chelator as a siderophore.  A lag time of around 7 
hours could be noted at the MIC level for A. baumannii, Table 7.9.      
At an assay time point above ~18 hours the results of the B. subtilis OD630 reading were deemed 
unsuitable to extract viable data from.  However, up until this time point it can be noted that B. 
subtilis showed growth at the MIC level with a lag time of around 7 hours with respect to the 
growth of the control.  The other concentrations below this level also showed lag times, but not to 
this extent and in addition the final level of OD630 reached in all cases where growth was noted was 
nearing that of the control.  This indicates that any inhibition is being overcome by the organism 
within the timeframe of the experiment, Table 7.9.   
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Table 7.9 Summary of the apparent lag time at concentrations of ligand which showed growth and 
the observed difference in OD630 for those organisms that displayed growth for the TRENCAM 
(6.16) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 of the 
control sample.   
Organism 
Concentration 
/µM 
MIC/µM 
Extended Lag 
time/ 
approximate 
hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/ODC 
E. coli 
3855 
1928 
7 
0.41 
0.16 0.39 
1928 2 0.35 0.85 
964 0 0.46 1.12 
482 0 0.48 1.17 
241 0 0.48 1.17 
K. 
pneumoniae 
964 
964 
2 
0.54 
0.55 1.01 
482 0 0.55 1.01 
241 0 0.62 1.15 
P. 
aeruginosa 
 
1928 
1928 
0 
0.86 
0.34 0.40 
964 0 0.62 0.72 
482 0 0.48 0.56 
241 0 0.58 0.67 
A. 
baumannii 
1928 
1928 
7 
0.55 
0.23 0.42 
964 0 0.36 0.65 
482 0 0.43 0.78 
B. subtilis 
1928 
1928 
7 
0.31 
0.30 0.97 
964 3 0.31 1.0 
482 3 0.31 1.0 
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7.5.10 Assessment of the effect of the EMECAM (1.32) Ligand on the Growth of Microbes: 
E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and B. subtilis  
 
At the MIC concentration (3855µM) for the organism E. coli the ligand EMECAM appeared 
inhibitory with a growth lag time of approximately 7 hours.  At this level the final ODL/ODC was 
0.46 indicating the culture reached only around half of the OD630 as the growth control.  At the 
concentrations below the MIC (1928 and 964µM) the growth of the culture reach the same levels 
as the control, however did display some lag in the initial growth start time.  Data shown in Figure 
7.24 
 
Figure 7.24 OD630 development over 24 hours for EMECAM (1.32) on E. coli (MIC = 3855µM).  
Values displayed in legend are given as micromolar (µM) concentrations. 
 
The E. coli organism has been shown to utilise catecholate based siderophores within its natural 
iron regulatory systems i.e. enterobactin and so it is not surprising that the EMECAM compound 
may not produce a profound inhibitory effect on this organism at low concentration.  At the MIC it 
may be that the compound is toxic and below this level it is able to be utilised or is not a strong 
enough ligand to disturb the growth cycle significantly of E. coli.   
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As displayed in Table 7.10, the organism K. pneumoniae displayed full inhibition by the 
EMECAM ligand at the MIC concentration (1928µM) however below this level the organism 
displayed virtually no distortion with respect to the growth control.  No lag time was observed and 
the OD630 was shown to equal that of the control, with possible evidence of growth of a promoted 
effect at 964µM.  P. aeruginosa showed a similar trend to K. pneumoniae however; at even at the 
MIC level an ODL/ODC value of 0.66 was calculated for this organism.  Both P. aeruginosa and K. 
pneumoniae have been shown to able to utilise catecholate siderophores (see 7.1.1) which may be 
the cause of their lack of lag time and ability to show measureable growth at the MIC concentration 
in the case of P. aeruginosa and to show virtually no inhibition below the MIC for K. pneumoniae.   
The organism A. baumannii displays a relatively prolonged lag time in its growth at the MIC level 
with respect to the control of 15 hours for EMECAM (1928µM) and only reaches an OD630 of 
around 13% of that of the control.  However, below this level no lag time is noted and the growth 
of the organism is relatively uninhibited with respect to the control, Figure 7.25.   
 
 
Figure 7.25 OD630 development over 24 hours for EMECAM (1.32) on A. baumannii (MIC = 
1928µM).  Values displayed in legend are given as micromolar (µM) concentrations. 
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below the MIC the growth of the organism was more pronounced (ODL/ODC = 0.62) the control 
OD630 was never reached, Table 7.10.  Though some growth was detected at the concentration 
above the MIC (3855µM) the level of OD630 reached was significantly reduced with respect to the 
control and so may have been undetectable by eye.  Measurements for B. subtilis were taken after 
14 hours as above this the data was deemed unusable, full data set is available in the Appendix.     
 
Table 7.10 Summary of the apparent lag time at concentrations of ligand which showed growth and 
the observed difference in OD630 for those organisms that displayed growth for the EMECAM 
(1.32) ligand.  aODL/ODC = OD630 with the ligand at the corresponding concentration/OD630 of the 
control sample.     
Organism 
Concentration 
/µM 
MIC/µM 
Extended Lag 
time/ 
approximate 
hours 
Final 
Control 
OD630 
Final 
Ligand 
OD630 
Ratio 
a
ODL/ODC 
E. coli 
3855 
3855 
7 
0.41 
0.19 0.46 
1928 3 0.40 0.98 
964 1 0.41 1.0 
K. 
pneumoniae 
964 
964 
0 
0.54 
0.58 1.07 
482 0 0.5 0.93 
P. 
aeruginosa 
964 
1928 
0 
0.86 
0.57 0.66 
482 0 0.57 0.66 
241 0 0.57 0.66 
A. 
baumannii 
1928 
1928 
15 
0.55 
0.07 0.13 
964 0 0.44 0.8 
482 0 0.49 0.83 
B. subtilis 
3855 
1928 
7 
0.53 
0.08 0.15 
1928 4 0.24 0.45 
964 2 0.33 0.62 
482 2 0.33 0.62 
 
7.6 Chapter Conclusions 
 
The work presented herein has demonstrated the ability of a series of novel compounds to inhibit 
the growth of microorganisms.  The compounds were designed to be strong Fe3+ ligands and this is 
the proposed mode of action for the inhibition, though further study is required to fully assess the 
mode of inhibition.   
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The ligands CTG-1,2-HOPO, TEB-1,2-HOPO and TEB-R-3,2-HOPO consistently inhibit across a 
diverse panel of microbes tested.  This broad spectrum inhibition defines these three compounds as 
the most promising candidates for application in the reduction of nosocomial infections.  Further 
study of their efficacy in authentic surface colonisation assays is required.  Likewise,  bactericidal 
rate determination is required to confirm their mode of action.    
A. baumannii appears to be particularly susceptible to the inhibition of growth with respect to the 
induction of an extended lag time from the normal growth.  This is particularly pronounced at the 
MIC level but does in some cases extend to below this level (CTG-3,2-HOPO and TREN-R-3,2-
HOPO).   
Some ligands show signs of growth promotion in the kinetic assays such as the CTG-3,2-HOPO 
ligand on the organisms P. aeruginosa and S. aureus at concentrations 964µM and <120µM 
respectively.  Further work is required to assess whether this is the case and to what extent the 
growth promotion effect can be induced to determine an iron transport route.       
 
7.7 Future Work 
 
Future work in this area would be to confirm the mode of action of the compound which showed 
inhibition.  This could be achieved through radiolabelled uptake studies determining what portion 
of the available iron remained bound to the ligands in the extracellular matrix.  This technique 
would also be useful in confirming the possible growth promotion which has been noted in some 
assays.   
In addition, any ligands showing promotion and recovery of the culture OD630 to that of the control 
could be used in purified receptor-ligand assays to determine by what system they are being 
utilised if this is the mode of action.  Alternatively, utilising a panel of modified microbes with 
various siderophore receptor systems modified may aid in the elucidation of any inhibition and 
promotion modes of action.   
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7.8 Project Summary 
 
The project was carried out to discover whether core molecular scaffolds, that have both previously 
been associated and new scaffolds that have not been associated with Fe3+ binding, could be 
synthesised to have incorporated hydroxypyridinone binding groups onto them.  The purpose of 
this being to produce powerful Fe3+ ligands.  There are many applications for ligands of this type 
which include; potential antimalarial drugs, anti-Alzheimer’s drugs and MRI contrast agents.  
However, for the purposes of this study the bacteriostatic properties of the ligands has been 
assessed.  The ligands when applied to a microbial system should restrict the available nutrient Fe3+ 
available to the organisms and induce a distortion to growth.  This distortion should be in the form 
of bacteriostasis, where the organisms, unable to feed are therefore unable to multiply to levels 
which may cause potential harm in the environment. 
To test this hypothesis, ligands have been designed based upon cyclotriguiaicylene (CTG), 
tris(piperazin-1-yl)-1,3,5-triazine, 1,3,5-tris(aminomethyl)-2,4,6-triethyl benzene (TEB) and the 
tris(2-aminoethyl)amine (TREN) core molecular scaffolds, with attempted functionalization of the 
methyl cholate molecule.  These core scaffolds were chosen for their unique properties (i) 
potentially preorganise the HOPO binding moieties towards Fe3+ chelation (ii) to be potentially 
‘alien’ enough to avoid recognition in microorganism Fe3+ uptake (iii) be able to support three 
HOPO groups to allow for hexadentate ligands to be accessed.   
HOPO groups have previously never been associated with the CTG or triazine cores.  
Functionalization of these cores has been achieved utilising a previously accessed 3,2-HOPO 
derivative and a novel 1,2-HOPO-chloride which has been developed in house.  This 
functionalization has produced ligands which have variation in: chain length, HOPO group, core 
size and attachment mode (ether and tertiary amine).   
These property variations have impacted upon the outcomes of the ligands abilities to bind Fe3+, as 
determined via UV-Vis spectroscopy.  The triazine-based ligands have shown that where in the 
first instance if allowed to equilibrate for only two days, the stoichiometry for the 1,2-HOPO and 
the 3,2-HOPO based ligands was approximately the same.  However, after fourteen days the 
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triazine-3,2-HOPO ligand showed that it was able to accommodate a 1:1 L:M stoichiometry, which 
was the preferred outcome.  However, this was not the case for the triazine-1,2-HOPO ligand and 
this was attributed primarily to the shorter connecting chain between core scaffold and binding 
group.  Whereas for the CTG based ligands it was discovered through the same technique that in 
the first instance the 3,2-HOPO containing ligand showed a clear 1:1 L:M stoichiometry after two 
days which was retained for the fourteen day test period.  Conversely, the CTG-1,2-HOPO ligand 
in the first instance showed signs, such as was shown for the triazine-1,2-HOPO, the stoichiometry 
favoured more ligands per metal centre, which could be indicative that the shorter chain linker was 
effecting the ability of the ligand to bind Fe3+ in the preferred 1:1 ratio.  However, after the test 
period it was discovered that the CTG-1,2-HOPO ligand appeared to be able to accommodate more 
than one metal into the most stable complex formula, as determined via modified Job’s plot 
analysis.  This phenomenon has been attributed to the previous literature surrounding the ability of 
the CTG scaffold to accommodate small cationic guests into the molecular cavity. 
The library of TEB-based ligands, of which five have been produced all displayed similar 
characteristics in terms of Fe3+ binding as determined by UV-Vis spectroscopy.  With the exception 
of the 3,4-HOPO bearing ligand whose stoichiometry after the test period was 0.6:0.4 L:M, which 
may be attributed to previous literature precedent surrounding the position of attachment of the 
scaffold to the binding moiety, all the ligand showed their preference for a 1:1 L:M stoichiometry.  
Previously, only one example of a HOPO has been shown for a TEB core scaffold, which includes 
the retro-3,2-HOPO binding moiety.  In light of this, this work has extended the range of ligands 
for Fe3+ binding available for this core significantly.  The novel ligands include variations in chain 
length and HOPO isomer.   
Furthermore, the ligands produced herein have added to the range of TREN-based technology 
currently available.  Previous to this study, the CP130 ligand had been shown to bind Fe3+ in a 1:1 
ratio, however, the pFe3+ indicates that this binding is not perfect and so the LC-CP130 produced 
herein may help to alleviate some of the strain and increase the potential to bind Fe3+ with greater 
affinity.  The previous TREN-Me-3,2-HOPO containing ligand has also been modified to include 
an extra methyl group on the binding moiety in the para-position to the binding hydroxyl 
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functionality.  It is hoped that this may increase the binding affinity through induction of electron 
density through the hydroxyl functionality.   
The novel ligands and some literature examples were assessed for their bacteriostatic activities in 
two ways; firstly, MIC values have been deduced from dilution assays to gather an overview of the 
chelators’ performance with respect to each other and the literature examples.   Secondly, kinetic 
assays have been performed to attempt to further asses the properties of these ligands and to 
discover any preliminary evidence for their use as bacteriostatic agents. 
Of the fourteen synthesised ligands only three showed no measurable activity on any of the 
microbes tested.  The other all showed some activity on at least one organism.  The inhibition to 
growth doesn’t seem to be biased towards a particular core scaffold, which may mean the ligands 
are working as designed, by binding extracellular Fe3+.   Those of particular significance are the 
CTG-1,2-HOPO, TEB-1,2-HOPO and TEB-R-3,2-HOPO which inhibited growth at relatively low 
concentrations across the panel of microbes.  In addition the TREN-1,2-HOPO* literature ligand 
has shown strong activity.128  Implicating that there may be an activity-HOPO relationship in which 
the R-3,2-HOPO and the 1,2-HOPO are important functionalities for ligands for strong growth 
inhibition.   
Since the conditions provided to the microorganisms in the assays here were suited for growth i.e. 
nutrient rich media, the concentrations required here to inhibit the growth of organisms do not 
reflect those which may be necessary for inhibition on a surface.  Surfaces do not have a rich 
nutrient supply and so it may be the case that far less of the compounds are needed to inhibit 
growth in a ‘real life’ situation.  That being so, the ligands’ which showed inhibition >500µM and 
were not flagged as being particularly good in MIC assays may still prove to be successful at 
inhibiting growth on a surface.  The CTG-3,2-HOPO and TREN-R-3,2-HOPO showed appreciable 
inhibition of many of the panel members and so, they could provide  targets along with the three 
previously highlighted to take through to a real testing situation.   
Kinetic assays have provided a positive insight into the ligands ability to perturb the growth of 
organisms with respect to their normal growth profile.  Many of the ligands could be seen to 
elongate the time period before detectable growth could be measured by OD.  This property of the 
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molecules is of particular interest due to the implications for prolonging a disinfection timeframe.  
This apparent elongation of the growth lag time could be indicative of the mode of action of these 
ligands being bacteriostatic in nature.     
The next stage in the development of these molecules is to confirm their mode of action of growth 
inhibition as bacteriostasis.  This could be achieved through viable colony count analysis; this 
information, coupled with the acquired kinetic data should provide a good insight into the 
inhibition mechanism of these compounds.  In addition, the realistic testing of the ligands to give 
similar results in terms of the inhibition of growth on surfaces should be analysed.  This can be 
achieved through applying the ligands onto surfaces and to see how they are able to affect the 
growth of organisms in a situation more akin to that which you would find in a hospital 
environment.    
The Fe3+ binding affinities for these compounds are still yet to be assessed in as far as the 
determination of their logβ or pFe3+ values is concerned.  This information would help to provide 
an insight into whether the inhibitory efficacy of the compounds is linked to their respective 
binding affinities or whether it is purely a matter of ligand architecture which is the cause of the 
inhibitory effect i.e. are the 1,2-HOPO and R-3,2-HOPO binding moieties required for strong 
inhibition for these ligands?  Despite this evidence, the library of chelators produced here have 
provided lead ligand candidates to take through to further testing whose action of growth inhibition 
on the microorganisms discussed herein is believed to be bacteriostasis induced by Fe3+ nutrient 
restriction.   
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8 Experimental  
8.1 Materials and Methods 
 
All solvents and reagents were purchased from Sigma-Aldrich, Acros Organics or Alfa-Aeser and 
used without further purification, unless otherwise specified.  Reactions were followed by TLC 
using silica gel with UV254 fluorescent indicator.  Column chromatography was conducted using 
0.060 - 0.20 mm silica gel (70 - 230 mesh), automated flash column chromatography was 
conducted using a Biotage Isolera One ISO-1SV. 
8.2 General physical measurements 
 
NMR spectra were recorded using a Jeol JNM Ex270 instrument at 270 MHz and 68 MHz or a Jeol 
JNM-ECS400 instrument at 400 MHz and 100 MHz, as specified, for 1H- and 13C- NMR 
respectively.  1H NMR data are reported as follows: chemical shift (δ, ppm), multiplicity (s = 
singlet, d = doublet, t =triplet, q = quartet, m = multiplet, br = broad), integration, coupling 
constants reported in Hz.  Data for 13C NMR are reported in terms of chemical shift (δ, ppm).  
UV/Visible spectra were run on a Varian Cary 50 UV-Visible spectrophotometer (range 600-
200nm), using a 10mm quartz cell at room temperature (20°C).  Infrared spectra were obtained 
using a Durascope diamond ATR system on a Perkin Elmer RX1 FTIR spectrometer.  Positive and 
negative electrospray ionisation mass spectrometry (ESI-MS) was conducted using a Thermo LCQ 
Advantage spectrometer by direct injection and high resolution mass spectrometry (HRMS) was 
performed by the EPSRC National Mass Spectrometry Service (Swansea, Wales).  Melting points 
were taken on a SRS DigiMelt MPA161 digital melting point apparatus (200 to 250 VAC 1/2AMP 
50-60Hz).  Samples were read in SAMCO soda glass capillary tubes 100mm and are reported 
uncorrected.  Optical density measurements were performed on a SynergyTMHT Multi-Detection 
Automated Microplate Reader from Bio-TEK® using greiner bio-one CELLSTAR® 96 well sterile 
culture plates.  Compound names were generated via the Reaxys programme online as the preferred 
IUPAC name unless simplified as designated in the text.            
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8.3 Determination of L:M Stoichiometry 
 
The UV-Vis spectra were measured for the L:M ratios displayed in Table (Table 8.1) over the 
range 600-200nm.  The overall volume of solutions was kept constant as was the total molar 
concentration of species in solution.   
Table 8.1 Table displaying ratios of ligand and metal recorded in UV-Vis experiments.  Solutions 
made in distilled H2O using the minimum volume DMSO to solvate ligand.  FeCl3.6H2O used as 
iron source.  Spectra were recorded over the range 200-600nm at room temperature. 
Solution [Ligand]/µM [Metal]/µM [Ligand]/[Ligand]+[Metal] 
1 200 0 1 
2 180 20 0.9 
3 160 40 0.8 
4 140 60 0.7 
5 120 80 0.6 
6 100 100 0.5 
7 80 120 0.4 
8 60 140 0.3 
9 40 160 0.2 
10 20 180 0.1 
11 0 200 0 
 
The obtained UV-Vis spectra were then subject to analysis following literature procedure.  The 
absorbance of the resulting complex obtained at the λmax in the visible region (~430nm) was 
corrected by taking the observed absorbance and removing the percentage contributions for the free 
ligand and free metal in solution to leave the absorbance of the complex (A-AM-AL).  This was 
plotted against [Ligand]/[Ligand]+[Metal] to give a modified Job’s plot of which the highest point 
of absorbance is then taken to be the stoichiometric ratio for the species. 
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8.3.1 Experimental CTG Molecules 
 
 
[3-methoxy-4-(prop-2-en-1-yloxy)phenyl]methanol 
(2.7): Vanillyl alcohol (5.00g, 32.4mmol) and K2CO3 (4.50g, 32.5mmol) were stirred in acetone 
(30mL).  Allyl bromide (4.50g, 37.19mmol) was added dropwise to the stirring suspension, after 
addition the reaction was allowed to reflux at 70°C for 18 hours.  The solution was cooled to room 
temperature and the solvent and excess allyl bromide removed under high vacuum.  Distilled H2O 
(100mL) was added and the aqueous solution extracted with DCM (5 x 50mL).  The organic 
extracts were combined and dried (MgSO4), evaporated to dryness and left to dry in air.  Upon 
cooling a yellow-green solid crystallised from the yellow oil.  This yielded the pure product in 93% 
yield (5.83g).  1H NMR (CDCl3) δ (ppm) = 6.91 (s, 1H) 6.83 (s,2H) 6.12-5.99 (m, 1H) 5.38 (dd, 3J1 
= 17.4Hz 3J2 = 1.4Hz) 5.28 (dd, 
3J1 = 10.5Hz 
3J2 = 1.4Hz) 4.60 (s, 2H) 4.59 (s, 2H) 3.86 (s, 3H) 
1.70 (t, 3J = 6Hz, 1H); 13C NMR (CDCl3) δ (ppm) = 149.59, 147.53, 134.04, 133.35, 119.34, 
118.10, 69.99, 65.31, 55.95. 
 
Tris-allyl-CTG 
(2.8):  (2.7) (5.95g, 0.03mol) was dissolved in MeOH (38mL) and stirred at 0°C.  70% HClO4 
solution (18.5mL) was added dropwise to the stirring solution which was allowed to stir at room 
temperature for 48 hours.  (After 3 hours a white solid precipitated out of the pink solution).  DCM 
(100mL) was added and the product extracted into DCM (2 x 100mL).  The organic extracts were 
washed with distilled H2O (~ 1L) to ensure no residual was HClO4 present.  The DCM extract was 
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dried (MgSO4) and evaporated to dryness.  Ether (50mL) was added and the product allowed to 
precipitate fully overnight.  The precipitate was collected by suction filtration to yield a light pink 
solid in 38% yield (2.05g). 1H NMR (CDCl3) δ (ppm) = 6.84 (s, 3H) 6.78 (s, 3H)   6.04 (m, 3H) 
5.36 (dd, 3J1 = 17.4Hz, 
3J2 = 1.4Hz, 3H) 5.23 (dd, 
3J1 = 10.5Hz, 
3J2 = 1.4Hz, 3H) 4.72 (d, 
3J = 
13.7Hz, 3H) 4.58 (m, 6H) 3.82 (s, 9H) 3.52 (d, 3J = 13.7Hz, 3H); 13C NMR (CDCl3) δ (ppm) = 
148.23, 146.78, 133.79, 132.37, 131.78117.62, 115.54, 70.24, 56.16, 36.61 
 
CTG 
Cyclotriguaiacylene (2.2): (2.7) (1.00g, 1.89mmol) was dissolved in dry dioxane (8mL) at 50°C under 
a nitrogen atmosphere.  EtOH (18mL), Pd/C (0.20g) and 70% HClO4 (0.20mL) were added under a 
nitrogen atmosphere and the reaction stirred at 57-60°C for 24 hours.  The reaction was allowed to 
cool to room temperature and the catalyst removed by filtration and washed with DCM (40mL).  
The organic solution was washed with distilled H2O (5 x 100mL), dried (MgSO4) and evaporated 
to dryness yielding a white solid in 37% yield (0.29g).  Mp = >260°C 1H NMR (DMSO-d6) δ 
(ppm) = 6.80 (s, 3H) 6.78 (s, 3H) 4.54 (d, 3J = 13.2Hz, 3H) 3.67 (s, 9H) 3.31 (d, 3J = 13.7Hz, 3H); 
13C NMR (DMSO-d6) δ (ppm) = 146.5, 145.4, 133.1, 131.0, 117.3, 114.4, 56.5, 36.6  
 
ethyl 2-(3-hydroxy-2-oxo-1,2-dihydropyridin-1-yl)acetate  
(2.10) 2,3-dihydroxy pyridine ( 20.35g, 0.1832mol) and ethyl bromoacetate (101.6mL, 0.9159mol) 
were refluxed at 155-160°C for 48 hours.  The solution was left to cool in a water-ice bath, until a 
grey-brown solid precipitated.  The solid was collected by suction filtration, the filtrate evaporated 
and cooled again and any further precipitate collected.  The solid was washed with ice-cold acetone 
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(50mL) and ice-cold distilled water (50mL).  Recrystallisation from hot ethanol:H2O 95:5 yielded 
product in 50% yield (18.29g).  Mp = 151-153°C. 1H NMR (DMSO-d6) δ (ppm) = 6.84 (dd, 3J1 = 
7.17Hz, 3J2 = 1.73Hz, 1H) 6.77 (dd, 
3J1 = 6.93Hz, 
3J2 = 1.73Hz, 1H) 6.20 (t, 
3J = 7.17Hz, 1H) 4.26 
(q, 3J = 7.17Hz, 2H) 1.30 (t, 3J = 7.17Hz, 3H)  13C NMR (DMSO-d6) δ (ppm) = 168.20, 158.06, 
146.84, 129.03, 115.51, 105.37, 61.12, 50.48, 14.22 
 
2-[3-(benzyloxy)-2-oxo-1,2-dihydropyridin-1-yl]acetic acid 
(2.11):  (2.10) (3.88g, 0.01967mol) was dissolved in MeOHaq (120mL, 90%) at 50°C with stirring.  
The solution was adjusted to ~ pH 12 with NaOHaq (4M).  Benzyl bromide (10mL, 0.08407mol) 
was added drop wise to the stirring solution and the solution refluxed for 8 hours at 90-100°C.  The 
solution was allowed to cool to room temperature, and MeOH was removed by rotary evaporation.  
The aqueous solution was washed with DCM (3 x 50mL) and the aqueous phase diluted with 
distilled H2O (30mL).  The solution was acidified to pH 1 with HClaq (37% w/v) whereupon a solid 
precipitated.  The solid was collected via suction filtration and recrystallised from hot EtOH:H2O 
95:5 to yield fluffy white crytals, 4.02g (78%).  Mp = 182-187°C. 1H NMR (DMSO-d6) δ (ppm) = 
7.38 (m, 5H) 7.24 (dd, , 3J1 = 6.9 Hz, 
3J2 = 1.2 Hz, 1H) 6.92 (dd, , 
3J1 = 7.6 Hz, 
3J2 = 1.5 Hz, 1H) 
5.00 (s, 2H) 4.6 (s, 2H); 13C NMR (DMSO-d6) δ (ppm) = 169.94, 157.60, 148.41, 137.01, 131.25, 
128.95, 128.53, 128.48, 116.22, 104.35, 70.27, 50.74 
 
 
3-(benzyloxy)-1-(2-hydroxyethyl)-1,2-dihydropyridin-2-one 
(2.12): (2.11) (1.96g, 7.56mmol) was suspended in dry THF (25mL) under N2(g) and cooled in an 
ice-water bath for 30mins.  BH3(THF) (1M in THF, 30mL) was added to the cooled suspension under 
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N2(g) over 10 minutes and the solution allowed to stir at room temperature for 24 hours.  After 24 
hours a further addition of BH3(THF) (1M in THF, 12mL) was made and stirring continued for 4 
days.  The reaction was cooled to 0°C and quenched with ice.  The aqueous solution was extracted 
with DCM(3 x 100mL), dried (MgSO4) filtered and the DCM removed by rotary evaporation to 
yield pure product in 78% yield (1.46g).  1H NMR (CDCl3) δ (ppm) = 7.33 (m, 5H) 6.93 (dd, , 3J1 = 
6.8 Hz, 3J2 = 1.3 Hz, 1H) 6.64 (dd, , 
3J1 = 7.3 Hz, 
3J2 = 1.4 Hz, 1H) 5.03 (s, 2H) 4.00 (t, 
3J = 5.0 Hz, 
2H) 3.69 (m, 2H). 13C NMR (CDCl3) δ (ppm) = 158.9, 148.7, 136.1, 130.2, 128.7, 127.4, 115.9, 
105.0, 70.8, 61.3, 53.2  
 
3-(benzyloxy)-1-(2-chloroethyl)-1,2-dihydropyridin-2-one  
(2.13): (2.12) (0.77g, 3.13mmol) was dissolved in dry DCM(50mL), to this solution tosyl chloride 
(0.77g, 4.02mmol) and triethyl amine (1.20mL 9.16mmol) were added, the solution was allowed to 
stir at room temperature for 36 hours.  DCM (100mL) was added and the resulting solution was 
washed with saturated sodium carbonate solution (3 x 50mL) and brine (50mL), dried (MgSO4) 
and evaporated to dryness to yield a yellow oil 0.92g which solidified on standing.  The crude oil 
was purified by column chromatography over silica gel, eluting with ethyl acetate:DCM 1:1 
increasing polarity to 5% MeOH after elution of first impurity.  The purified product was isolated 
after column fractions were dried (MgSO4) and evaporated to dryness to yield a yellow oil of mass 
0.67g (81%) which solidified on standing.  Rf = 0.54. 
1H NMR (CDCl3) δ (ppm) 7.38 (m, 5H) 6.94 
(dd, , 3J1 = 6.8 Hz, 
3J2 = 1.8 Hz, 1H) 6.67 (dd, , 
3J1 = 7.3 Hz, 
3J2 = 1.8 Hz, 1H) 6.02 (t, 
3J = 6.8 Hz, 
1H) 5.1 (s, 2H) 4.23 (t, 3J = 5.5 Hz, 2H) 3.89 (t, 3J = 5.9 Hz, 2H). 13C NMR (CDCl3) δ (ppm) = 
158.1, 148.7, 136.2, 130.3, 128.7, 128.1, 127.4, 115.8, 104.5, 71.2, 53.5, 52.4, 46.4, 42.0  
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ethyl 3-(3-hydroxy-2-oxo-1,2-dihydropyridin-1-yl)propanoate  
(2.14):  2,3-dihydroxy pyridine (5.00g, 0.045mol) was added along with CsF (10mol %) to 
acetonitrile (40mL).  Ethyl acrylate (4.51g, 0.045mol) was added and the mixture allowed to reflux 
for 48 hours at 90°C.  The solution was cooled to room temperature and acidified to pH 1 with 
HClaq (37% w/v) and distilled H2O (200mL) added.  The product was extracted into DCM 
(200mL), the DCM extracts washed with distilled H2O (4 x 100mL), brine (1 x 20mL), dried 
(MgSO4) and evaporated to dryness.  The product was isolated pure as a brown solid, 6.44g (72%). 
Mp = 92-98°C. 1H NMR (CDCl3) δ (ppm) = 6.9 (dd, , 3J1 = 6.9 Hz, 3J2 = 1.7 Hz, 1H) 6.74 (dd, , 3J1 
= 7.1 Hz, 3J2 = 1.7 Hz, 1H) 6.06 (t, 
3J = 6.8 Hz, 1H) 4.18 (t, 3J = 6.4 Hz, 2H) 4.06 (q, 3J = 7.1 Hz, 
2H) 2.78 (t, 3J = 6.4 Hz, 2H) 1.16 (t, 3J = 7.0 Hz, 3H); 13C NMR (CDCl3) δ (ppm) = 169.94, 157.60, 
148.41, 137.01, 131.25, 128.95, 128.53, 128.48, 116.22, 104.35, 70.27, 50.76   
 
3-[3-(benzyloxy)-2-oxo-1,2-dihydropyridin-1-yl]propanoic acid  
(2.15): (2.14) (5.00g, 0.0236mol) was dissolved in MeOHaq (90%, 130mL) and adjusted to pH 12 
with NaOHaq (4M). Benzyl bromide (12.41g, 0.071mol) was added dropwise and the solution 
allowed to reflux for 48 hours at 75-80°C, the pH being kept above pH 10 with NaOHaq (4M).  The 
solution was cooled to room temperature and the methanol and excess benzyl bromide removed by 
rotary evaporation.  The aqueous solution was extracted with DCM (4 x 100mL) and diluted with 
distilled H2O (30mL).  Acidification with HClaq (37% w/v) yielded a yellow precipitate which was 
collected by suction filtration to yield the product in 75% yield (6.14g).  Mp = 182-187°C. 1H 
NMR (DMSO-d6) δ (ppm) = 7.39 (m, 5H) 7.26 (dd, 3J1 = 6.9 Hz, 3J2 = 1.5 Hz, 1H) 6.89 (dd,  3J1 = 
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7.4 Hz, 3J2 = 1.5 Hz, 1H) 6.10 Hz (t, 
3J = 6.9 Hz, 1H) 4.99 (s, 2H) 4.06 (t, 3J = 6.9 Hz, 2H) 2.64 (t, 
3J = 6.9 Hz, 2H);  13C NMR (DMSO-d6) δ (ppm) = 172.94, 157.32, 148.54, 137.17, 130.99, 128.97, 
128.51, 120.74, 111.56, 104.50, 70.32, 45.90, 33.47 
 
3-(benzyloxy)-1-(3-hydroxypropyl)-1,2-dihydropyridin-2-one  
(2.16): (2.15) (4.97g, 0.0181mol) was suspended in dry THF (100mL) under an atmosphere of 
nitrogen, stirred and cooled to 0°C.  To this, BH3(THF) (1M in THF, 90mL) was added under 
nitrogen and the solution was allowed to stir at room temperature for 48 hours. The solution was 
cooled to 0°C and quenched with ice.  The product was extracted into DCM (5 x 100mL), the 
extracts washed with distilled H2O (4 x 250mL), brine (250mL), dried (MgSO4), filtered and 
evaporated to dryness to yield a viscous purple liquid of mass 3.07g.  Crude product purified by 
column chromatography over silica gel eluent DCM:ethyl acetate 1:1 increasing polarity to 10% 
MeOH after Rf >0.2 eluted.  Yielding pure product in 31% yield (1.49g) Rf = 0.10.  
1H NMR 
(CDCl3) δ (ppm) = 7.30 (m, 5H) 6.84 (dd, 3J1 = 6.9 Hz, 3J2 = 1.7 Hz, 1H) 6.62 (dd,  3J1 = 7.6 Hz, 3J2 
= 1.5 Hz, 1H) 6.00 (t, 3J = 6.9 Hz, 1H) 5.04 (s, 2H) 4.08 (t, 3J = 5.9 Hz, 1H) 3.42 (q, 3J = 5.7Hz, 
2H) 1.83 (p, 3J = 5.7 Hz, 2H); 13C NMR (CDCl3) δ (ppm) = 158.99, 148.64, 136.12, 128.96, 
128.67, 128.15, 127.44, 116.07, 106.02, 70.87, 57.69, 45.93, 32.38 
 
 
3-(benzyloxy)-1-(3-chloropropyl)-1,2-dihydropyridin-2-one  
(i) (2.17): (2.16) (1.49g, 5.768mmol) was dissolved in dry DCM (50mL) to this triethyl 
amine (2.41mL, 0.0173mol) and tosyl chloride (1.43g, 7.498mmol) were added and the 
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solution allowed stirring at room temperature for 4 days.  Solution was diluted with 
DCM (50mL) washed with saturated sodium carbonate solution (2 x 100mL) and brine 
(50mL).  Organic extracts were dried (MgSO4) and evaporated to give a red-brown oil.  
Crude product purified by column chromatography eluted with DCM:ethyl acetate 1:1 
over silica gel to yield pure product as a red-brown solid 0.84g (52%), Rf = 0.634. mp 
= 72-74°C 
 
(ii) (2.17): (2.16) (0.2717g, 1.01mmol) was dissolved in dry DCM (15mL) and the 
solution stirred at 0°C.  SOCl2 (0.74g, 6.88mmol) was added and the solution allowed 
to reflux at 50°C overnight.  The reaction was quenched with ice water, extracted into 
DCM (150mL), washed with saturated sodium carbonate solution (100mL), dried 
(MgSO4) and evaporated to dryness to yield the product in near quantitative yield. 
 1H 
NMR (CDCl3) δ (ppm) = 7.30 (m, 5H) 6.89 (dd, 3J1 = 6.9 Hz, 3J2 = 1.7 Hz, 1H) 6.59 
(dd, 3J1 = 7.4 Hz, 
3J2 = 1.7 Hz, 1H) 5.97 (t, 
3J = 6.9 Hz, 1H) 5.03 (s, 2H) 4.06 (t, 3J = 
6.4 Hz, 2H) 3.47 (t, 3J = 5.9 Hz, 2H) 2.20 (p, (t, 3J = 6.4 Hz, 2H). 13C NMR (CDCl3) δ 
(ppm) = 158.22, 149.01, 136.29, 129.48, 128.64, 128.07, 127.39, 115.62, 104.66, 
70.84, 47.67, 41.99, 30.91 
 
 
Iminium salt 
(2.21): (2.12) (1.38g, 5.62 x 10-3mol) was dissolved in dry DCM (30mL) and added under N2(g) to a 
flame dried 3n-round bottomed flask under N2(g).  Et3N (1.14g,11.25mmol) was added and the 
solution brought to 0°C in an ice-water bath and stirred for 10 mins.  Mesyl anhydride 
(1.47g,835mmol) was added as a solution in dry DCM (10mL) dropwise to the stirring solution.  
Stirring was maintained at 0°C for 1 hour and then at room temperature for 1.5 hours.  The DCM 
was removed by rotary evaporation, CHCl3 (50mL) was added and the reaction stirred for 17 hours 
at room temperature.  The chloroform was evaporated and the residue was triturated with EtOAc (6 
x 80mL) which was decanted from the solid formed.  The product was obtained as a yellow powder 
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mass = 1.54g (85%).  1H NMR (CDCl3) δ (ppm) = 8.50 (d, 3J = 6.41Hz, 1H), 7.67 (d, 3J = 8.24Hz, 
1H), 7.35 (m, 6H) 5.40 (t, 3J = 9.16, 2H) 5.25 (s, 2H) 5.22 (t, 3J = 9.16Hz, 2H) 2.67 (s, 3H).  13C 
NMR (CDCl3) δ (ppm) = 153.88, 142.93, 133.92, 130.18, 129.20, 129.10, 127.92, 127.77, 119.77, 
77.32, 72.62, 72.11, 39.54. 
 
 
1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxylic acid 
(2.24): 6-hydroxypyridine-2-carboxylic acid (20.0g, 0.1437mol) was suspended in glacial acetic 
acid (240mL).  36-40% wt% peracetic acid (70mL) was added dropwise to the suspension over 15 
minutes with stirring.  Once addition was complete the reaction was heated from 22°C to 80°C in 
10°C increments.  Stirring was maintained at 80°C for 12 hours.  The reaction was allowed to cool 
to room temperature, forming a fine yellow precipitate.  The precipitate was collected via suction 
filtration and washed with ether to give 16.28g of the product (73%). 1H NMR (DMSO-d6) δ (ppm) 
= 7.39 (dd, 3J1 = 6.9 Hz 
3J2 = 8.7 Hz, 1H) 6.66 (dd, 
3J1 = 1.8 Hz 
3J2 = 9.2 Hz, 1H) 6.60 (dd, 
3J1 = 1.8 
Hz 3J2 = 6.9 Hz, 1H); 
13C NMR (DMSO-d6) δ (ppm) = 162.5, 157.7, 139.4, 137.2, 120.9, 106.7 
 
 
methyl 1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxylate 
(2.25): 2.24 (16.28g, 0.1049mol) was suspended in MeOH (600mL) and allowed to stir at 0°C.  To 
this SOCl2 (20mL, 0.274mol) was added dropwise over 15 minutes, after addition the reaction was 
allowed to stir for 4 days at room temperature.  The reaction was evaporated to dryness and co-
evaporated twice with toluene to yield the product as a brown solid mass = 17.13g (96%).  Mp = 
102-111°C1H NMR (DMSO-d6) δ (ppm) = 7.39 (dd, 3J1 = 6.9 Hz 3J2 = 9.1 Hz, 1H) 6.64 (dd, 3J1 = 
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1.4 Hz 3J2 = 9.1 Hz, 1H) 6.48 (dd, 
3J1 = 1.8 Hz 
3J2 = 6.9 Hz, 1H) 3.82 (s, 3H); 
13C NMR (DMSO-
d6) δ (ppm) = 161.4, 158.1, 138.8, 137.8, 122.6, 105.8, 53.8 
 
 
6-oxo-1-(prop-2-en-1-yloxy)-1,6-dihydropyridine-2-carboxylic acid 
(2.26): To a suspension of methyl 2.25 (17.03g, 0.1007mol) in MeCN (250mL) was added K2CO3 
(30.61g, 0.2215mol).  To this, allyl bromide (20mL, 0.2215mol) was added and the reaction stirred 
at room temperature for 4 days.  The reaction was filtered and the filtrate evaporated under reduced 
pressure.  Co-evaporation with toluene (2 x 100mL) yielded the pure product mass = 20.84g 
(98%).1H NMR (DMSO-d6) δ (ppm) = 7.26 (m, 1H) 6.75 (dt, 3J1 = 1.8 Hz 3J2 = 9.1 Hz, 1H) 6.47 
(dt, 3J1 = 1.4 Hz 
3J2 = 6.9 Hz, 1H) 6.03 (m, 1H) 5.41 (dt, 
3J1 = 1.4 Hz 
3J2 = 17.4 Hz, 1H) 5.32 (d, 
3J 
= 10.1 Hz, 1H) 4.85 (d, 3J = 6.4 Hz, 2H) 3.89 (s, 3H)   13C NMR (DMSO-d6) δ (ppm) = 160.4, 
158.8, 138.7, 137.2, 130.6, 125.9, 121.9, 107.9, 78.0, 53.3 
 
6-(hydroxymethyl)-1-(prop-2-en-1-yloxy)-1,2-dihydropyridin-2-one 
(2.27): 2.26 (18.8g, 0.0898mol) was suspended in THF (500mL), to which, NaBH4 (25.5g, 
0.674mol) was added and the mixture brought to reflux for 15 minutes.  At reflux MeOH (150mL) 
was added portionwise (CAUTION! VIOLENT BUBBLING) over six hours.  The reaction was 
allowed to stir at reflux for a further hour and after was allowed to cool to room temperature before 
being placed in an ice-water bath and cooled to 0°C.  Slow addition of saturated ammonium acetate 
solution was used to quench the reaction and the THF was mostly removed by rotary evaporation.  
The aqueous solution was extracted with DCM (5 x 200mL), the extracts dried (MgSO4) and 
evaporated to dryness to yield the crude product.  The pure product was obtained after purification 
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via silica gel column chromatography DCM:MeOH (0-4%) to give a white solid of mass = 7.49g 
(41%). Mp = 100-103°C1H NMR (CDCl3) δ (ppm) = 7.28 (dd, 3J1 = 6.9 Hz 3J2 = 9.2 Hz, 1H) 6.56 
(dd, 3J1 = 1.8 Hz 
3J2 = 9.2 Hz, 1H) 6.24 (dd, 
3J1 = 0.9 Hz 
3J2 = 6.9 Hz, 1H) 6.03 (m, 1H) 5.42 (dd, 
3J1 = 0.9 Hz 
3J2 = 16.9 Hz, 1H) 5.36 (dd, 
3J1 = 1.4 Hz 
3J2 = 10.1 Hz, 1H) 4.8 (d, 
3J = 6.4, 2H) 4.66 
(d, 3J = 6.4, 2H) 2.99 (t, 3J = 6.9 Hz, 1H); 13C NMR (CDCl3) δ (ppm) = 159.4, 148.4, 138.4, 130.2, 
122.3, 120.8, 103.3, 59.7 
 
6-(chloromethyl)-1-(prop-2-en-1-yloxy)-1,2-dihydropyridin-2-one 
(2.28): 2.27 (5.00g, 0.02759mol) was dissolved in DCM (150mL) and cooled to 0°C in an ice-
water bath.  SOCl2 (12mL, 0.16557mol) was added dropwise to the solution and the reaction 
allowed to reflux for 18 hours.  After which time a further addition of SOCl2 (1mL, 0.0138mol) 
was made and reflux continued for a further three hours.  The reaction was quenched with ice water 
at 0°C and then partitioned between DCM (100mL) and H2O (100mL).  The aqueous phase was 
extracted with DCM (2 x 100mL) and the DCM washed with H2O (50mL) and brine (50mL), dried 
(MgSO4) and evaporated to dryness.  The product was dissolved in boiling DCM with activated 
charcoal and filtered hot.  The DCM dried (MgSO4) and evaporated to dryness to yield the pure 
product as an orange solid mass = 4.49g (81%).  Mp = 61-65°C.  1H NMR (CDCl3) δ (ppm) = 7.25 
(dd, 3J1 = 6.9 Hz 
3J2 = 9.2 Hz, 1H) 6.65 (dd, 
3J1 = 1.8 Hz 
3J2 = 9.6 Hz, 1H) 6.23 (dd, 
3J1 = 1.4 Hz 
3J2 
= 6.9 Hz, 1H) 6.09 (m, 1H) 5.48 (dd, 3J1 = 1.4 Hz 
3J2 = 17.4 Hz, 1H) 5.39 (d, 
3J = 10.1 Hz, 1H) 4.90 
(d, 3J = 6.9 Hz, 2H) 4.55 (s, 2H); 13C NMR (CDCl3) δ (ppm) = 159.3, 144.3, 137.8, 130.3, 123.1, 
122.5, 106.3, 77.5, 39.5 
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Tris-allyl-CTG-1,2-HOPO 
(2.29): CTG (0.20g, 4.896 x 10-4mol) was suspended in MeCN (20mL) under N2(g) atmosphere at 
room temperature.   To this Cs2CO3 (0.16g, 4.91 x 10
-4mol) was added and the two stirred at room 
temperature for 15 minutes.  After which time, 6-(chloromethyl)-1-(prop-2-en-1-yloxy)-1,2-
dihydropyridin-2-one (0.29, 1.469 x 10-3mol) was dissolved in MeCN (10mL) and added under 
N2(g) to the stirring solution.  The reaction was stirred at reflux for 72 hours and then allowed to 
cool to room temperature, filtered and the filtrate evaporated to dryness.  The residue was taken up 
in DCM (25mL) and then washed with distilled H2O (4 x 25mL), dried MgSO4 and the organic 
phase evaporated to dryness.  Purification completed on a Isolera automated column, Biotage 
SNAP 50g silica cartridge DCM:MeOH (0-5%).  To yield a light brown solid mass = 0.35g (79%) 
after purification (Rf = 0.6 DCM:MeOH 10%).   Mp =  95-102° C; 
1H NMR (CDCl3) δ (ppm) = 
7.22 (m, 3H) 6.81 (s, 3H) 6.73 (s, 3H) 6.58 (d, 3J = 9.1Hz, 3H) 6.22 (d, 3J = 6.87Hz, 3H) 5.98 (m, 
3H) 5.33 (m, 6H) 5.05 (dd, 3J1 = 40.3Hz 
3J2 = 10.9Hz, 6H) 4.83 (m, 6H) 4.17 (d, 
3J = 13.7Hz, 3H) 
3.73 (s, 9H) 3.49 (d, 3J = 13.7 Hz, 3H); 13C NMR (CDCl3) δ (ppm) = 159.3, 148.8, 146.1, 144.8, 
138.2, 133.9, 131.7, 130.4, 122.6, 121.5, 116.8, 113.8, 104.2, 77.2, 66.1, 56.1, 36.5; HRMS (ESI) 
m/z [M+H]+: calcd for C51H52N3O12
+, 898.3551; found, 898.3543.   
 
CTG-Bn3-3,2-HOPO 
(2.18): CTG (0.25g, 6.12 x 10-4 mol) and iminium salt (0.61g, 323.3613mol) along with Cs2CO3 
(1.0g, 3.06mmol) were added to dry MeCN (40mL) under N2(g) and the reaction allowed to reflux 
for 24 hours.   After which time a further addition of iminium salt (80mg, 2.45 x 10-4mol) was 
made under N2(g) and the reaction stirred again for 24 hours.  The reaction was filtered and the 
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filtrate evaporated to dryness.  Purification was performed on an Isolera automated column 100g 
SNAP silica cartridge DCM:MeOH (0-10%).  To yield a yellow solid mass = 0.62g (93%) after 
purification.  Mp = 82-94°C.  1H NMR (CDCl3) δ (ppm) = 7.35-7.26 (m, 15H) 7.02 (dd, 3J1 = 
1.8Hz, 3J2 = 6.9Hz, 3H) 6.98 (s, 3H) 6.92 (s, 3H) 6.63 (dd, 
3J1 = 1.8Hz, 
3J2 = 7.8Hz, 3H) 5.97 (t, 
3J 
= 6.9Hz, 3H) 5.09 (s, 6H) 4.68 (d, 3J = 13.7Hz, 3H) 4.30 (m, 12H) 3.75 (s, 9H) 3.52 (d, 3J = 
13.7Hz, 3H)13C NMR (CDCl3) δ (ppm) = 158.2, 148.8, 148.2, 146.3, 136.5, 132.9, 131.9, 130.4, 
128.7, 128.1, 127.6, 115.6, 115.3, 113.9, 104.3, 70.8, 66.7, 56.4, 49.3, 36.4; HRMS (ESI) m/z 
[M+H]+: calcd for C66H64N3O12+, 1090.4490; found, 1090.4486.   
 
 
 
CTG-3,2-HOPO 
(2.22): 2.18 (120mg, 1.1x10-4mol) was hydrogenated over Pd/C (15% wt) with HCl (cat.) in 
dioxane:H2O (4:1, 5mL) for 18 hours at 40°C.  After filtration of the catalyst and evaporation of the 
solvent the residue was stirred in HCl:AcOH (1:1, 10mL) for 4 days at room temperature.  The 
reaction was evaporated to dryness to yield the product in 12% yield (11mg).   1H NMR (DMSO) δ 
(ppm) = 7.12 (m, 6H) 7.06 (s, 3H) 6.67 (dd, 3J1 = 1.37Hz, 
3J2 = 7.33Hz, 3H) 6.04 (t, 
3J = 6.87Hz, 
3H) 4.62 (d, 3J = 13.28Hz, 3H) 3.59 (s, 9H) 3.42 (d, 3J = 13.28Hz, 3H) 13C NMR (DMSO) δ (ppm) 
= 158.37, 148.05, 147.19, 146.51, 133.26, 132.59, 129.47, 115.69, 115.47, 114.72, 105.56, 66.72, 
56.53, 49.10, 48.59, 35.51; HRMS (ESI) m/z [M+Na]+: calcd for C45H45N3NaO12+, 842.2901; 
found, 842.2899. 
199 
 
 
CTG-1,2-HOPO 
(2.30): 2.29 (105mg, 1.169 x10-4mol) was stirred in dioxane:H2O (4:1, 8mL) with TFA (0.15M) in 
solution.  Pd/C (15% wt) was added and the reaction allowed to stir at reflux for 18 hours.  After 
which time the catalyst was filtered and washed with dioxane.  The filtrate was evaporated to 
dryness to yield a solid mass = 80mg (87%).  1H NMR (DMSO) δ (ppm) = 7.29 (dd,3J1 = 6.87Hz, 
3J2 = 8.7Hz, 3H) 7.16 (s, 3H) 7.03 (s, 3H) 6.13 (d, 
3J = 7.79, 3H) 6.21 ( d, 3J = 6.41Hz, 3H) 5.06 
(m, 6H) 13C NMR (DMSO) δ (ppm) = 161.31, 146.28, 137.66, 117.57, 116.01, 114.46, 103.04, 
64.99, 64.45, 56.44, 35.49; HRMS (ESI) m/z [M+Na]+: calcd for C42H39N3NaO12
+, 800.2431; 
found, 800.2391 
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8.3.2 Experimental 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene molecules 
 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene 
(3.8): To a mixture of paraformaldehyde (8.40g, 0.279mol) and 1,3,5-triethylbenzene (5mL, 
26.55mmol) in HBr:Acetic acid (~33% w/v),  ZnBr2 (10.0g, 0.044mol) was added portionwise at 
room temperature.  The mixture was heated to 90°C for 18 hours, during which time a white 
crystalline precipitate formed.  The reaction was allowed to cool to room temperature before the 
precipitate was collected via suction filtration and washed with distilled H2O.  The solid was dried 
in a desiccator to yield a pink solid mass = 8.78g (74%).  Mp = 169-173°C 1H NMR (CDCl3) δ 
(ppm) = 4.57 (s, 6H) 2.95 (q, 3J = 7.79 Hz, 6H) 1.34 (t, 3J = 7.79 Hz, 9H) 13C NMR (CDCl3) δ 
(ppm) = 145.28, 132.73, 28.66, 22.84, 15.72 
 
1,3,5-tris(azidomethyl)-2,4,6-triethylbenzene 
(3.10): 1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (6.0g, 0.0136mol) was dissolved in DMF 
(100mL)under an atmosphere of N2(g), to which NaN3 (4.0g, 0.0612mol) was added and the 
reaction portion-wise over 10 minutes.  The reaction was allowed to stir at room temperature for 
three days after which time DCM (500mL) was added and the resultant solution washed with 
distilled H2O (5 x 500mL).  The DCM portion was dried (MgSO4), filtered and evaporated to 
dryness to yield a viscous oil of mass = 2.06g (45%).1H NMR (CDCl3) δ (ppm) = 4.48 (s, 6H) 2.86 
(q, 3J = 7.79 Hz, 6H) 1.24 (t, 3J = 7.79 Hz, 9H) 13C NMR (CDCl3) δ (ppm) =145.05,130.07, 48.01, 
23.26, 15.85 
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1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene 
(3.11): To 1,3,5-tris(azidomethyl)-2,4,6-triethylbenzene (2.06g, 6.292mmol) and Ph3P (11.08g, 
0.0422mol) in THF (50mL) was added distilled H2O (2mL).  Stirring was continued overnight at 
room temperature.  The THF was removed by rotary evaporation and the aqueous solution 
partitioned between DCM (100mL) and HCl(aq) (6m, 100mL).  The organic portion was extracted 
with HCl(aq) (3 x 100mL).  The aqueous extracts were combined and brought to pH 14 with 
NaOH(s) pellets.  The basic solution was then extracted with DCM (3 x 200mL), the DCM dried 
(MgSO4) and then evaporated by rotary evaporation giving a brown solid.  Mp = 131-136°C.
1H 
NMR (CDCl3) δ (ppm) = 3.86 (s, 6H) 2.82 (q, 3J = 7.79 Hz, 6H) 1.23 (t, 3J = 7.33 Hz, 9H) 13C 
NMR (CDCl3) δ (ppm) = 141.45, 135.94, 38.54, 22.62, 16.29 
 
 
ethyl 3-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate (15) 
(3.12): Sodium diethyloxy acetate (10.0g, 0.0475mol) was dissolved in THF (170mL).  
Chloroacetone (4.4g, 0.0475mol) was added at room temperature and the reaction stirred for 15 
mins.  Ammonium acetate (10.0, 0.129mol) was added and AlCl3 (0.64g) was added in portions to 
the stirring solution.  Stirring was maintained at room temperature for 12 days, after which time a 
brown-yellow precipitate was collected via suction filtration.  The precipitate was then stirred in 
HClaq (1M) pH ~2 for 1.5 hours and the solid collected via suction filtration.  The product was 
isolated as a bright yellow solid in 43% yield (4.10g).  Mp = 230-233°C.  1H NMR (DMSO-d6) δ 
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(ppm) = 6.05 (s, 1H) 4.21 (q, 3J = 7.3 Hz, 2H) 2.05 (s, 3H) 1.24 (t, 3J = 7.3 Hz, 3H). 13C NMR 
(DMSO-d6) δ (ppm) = 166.54, 159.16, 147.75, 132.70, 116.29, 102.10, 61.49, 18.56, 14.52 
 
 
ethyl 3-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridine-4-carboxylate (16) 
(3.13): To 3.12  (0.157g, 0.792mmol) in DMF (10mL) was added K2CO3 (0.274g, 1.98mmol) and 
iodomethane (1.12g, 7.89mmol), the mixture was stirred at room temperature for 24 hours, after 
which time the reaction was concentrated under vacuum and partitioned between DCM (20mL) and 
H2O (20mL).  The aqueous phase was extracted with DCM (5 x 20mL), the organic extracts were 
combined, dried (MgSO4) and evaporated to dryness to give the crude product.  
1H NMR (CDCl3) δ 
(ppm) = 6.14 (s, 1H) 4.29 (q, 3J = 6.9 Hz, 2H) 3.90 (s, 3H) 3.49 (s, 3H) 2.28 (s, 3H) 1.32 (t, 3J = 6.8 
Hz, 2H)  
 
 
3-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid (17) 
(3.14): Crude 3.13 was dissolved in MeOH (120mL), NaOHaq (4M, 120mL) was added and the 
reaction was allowed to stir at reflux for 48 hours.  The MeOH was reduced under reduced pressure 
and HClaq (3M) was used to adjust the pH to 1.  The solution was extracted with EtOAc (2 x 
100mL), dried (MgSO4) and the solvent removed under reduced pressure to give a crude product 
which was recrystallised from EtOAc to yield a tan solid (1.68g, 50%) mp = 206-211°C. 1H NMR 
(DMSO-d6) δ (ppm) = 6.32 (s, 1H) 3.83 (s, 3H) 3.54 (s, 3H) 2.37 (s, 3H)   
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1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid 
(3.15): 2.24 (2.45g, 0.0158mol) and K2CO3 (4.36g, 0.0315mol) were added with benzyl bromide 
(3.24g, 0.01895mol) into MeOH (100mL).  The reagents were refluxed for three days (colour 
change from white-green-brown).  The reaction was allowed to cool to room temperature and 
evaporated to dryness.  The residue was taken into H2O (100mL), the aqueous solution brought to 
pH 2 with 37% HCl(aq).  Upon acidification a white precipitate formed which was collected via 
suction filtration and washed with distilled H2O.  The wet product was dried overnight in a 
desiccator to yield a beige solid of mass = 3.42g (88%). Mp = 180-183°C1H NMR (DMSO-d6) δ 
(ppm) = 7.41 (m, 6H) 6.70 (dd, 3J1 = 0.9 Hz 
3J2 = 9.2 Hz, 1H) 6.52 (dd, 
3J1 = 1.4 Hz 
3J2 = 6.9 Hz, 
1H) 5.24 (s, 2H). 13C NMR (DMSO-d6) δ (ppm) = 162.3, 158.2, 141.0, 139.2, 134.3, 130.1, 129.6, 
129.0, 124.6, 106.6, 78.3 
 
 
3-(benzyloxy)-2-methyl-4H-pyran-4-one 
(3.17): Maltol (40g, 0.317mol) was added to MeOH (400mL) with stirring, to which NaOHaq (16g 
in 50mL H2O) was added whereupon addition the maltol dissolved.  The solution was brought to 
reflux before BnBr (54.25g, 0.317mol) was added drop wise over 15 mins.  Reflux was continued 
overnight before the solution was cooled, the MeOH removed by rotary evaporation and H2O 
(200mL) added.  The aqueous solution was extracted with DCM (3 x 200mL) and the extracts 
washed with 5% NaOHaq (2 x 250mL), H2O (2 x 300mL) and brine (200mL).  The organic phase 
was dried (MgSO4) and the solvent evaporated to leave an orange oil mass = 59.30g (86.5%).  
1H 
NMR (CDCl3) δ (ppm) = 7.57 (d, 3J = 5.5Hz, 1H) 7.33 (m, 5H) 6.34 (d, 3J = 5.5Hz, 1H) 5.14 (s, 
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2H) 2.06 (s, 3H).  13C NMR (CDCl3) δ (ppm) = 175.16, 159.80, 153.53, 143.85, 136.95, 129.11, 
128.51, 128.40, 117.25, 73.62, 14.88.   
 
2-[3-(benzyloxy)-2-methyl-4-oxo-1,4-dihydropyridin-1-yl]acetic acid 
(3.18) 3.17 (4.10g, 0.01896mol) was suspended in EtOH:H2O 1:1 (34mL) to which sodium 
glycinate (4.15g, 0.03602mol) was added and the solution brought to reflux for 18hours.  The 
reaction was acidified with 37% HClaq to pH~1 and stored at 0°C overnight.  The solid formed was 
filtered and stirred in boiling H2O to which MeOH was added until cloudy.  The solution was 
cooled to 0°C and the precipitate filtered to yield a solid mass = 3.21g, 65%. 1H NMR (MeOD-d4) 
δ (ppm) = 7.88 (d, 3J = 7.33Hz, 1H) 7.49 (m, 5H) 6.47 (d, 3J = 7.33Hz, 1H) 5.20 (s, 2H) 4.95 (s, 
2H) 2.27 (s, 3H).  13C NMR (MeOD-d4) δ (ppm) = 172.23, 169.30, 145.83, 145.26, 141.49, 137.02, 
128.97, 115.21, 73.85, 55.49, 11.82 
 
 
 
 
Tris-benzyl-TEB-SC-3,2-HOPO 
(3.19): 2.11 (0.31g, 1.20mmol) and TBTU (0.39g, 1.20mmol) were dissolved under N2(g) in dry 
DMF (10mL).  N-methyl morpholine (0.20g, 1.97mmol) was added to the solution under N2(g) and 
the reaction stirred at room temperature for 30 minutes.  After which time, [3,5-bis(aminomethyl)-
2,4,6-triethylphenyl]methanamine (100mg, 0.38mmol) was added under N2(g), the reaction was 
stirred at room temperature for 2 hours and then at 60°C for 24 hours.  The DMF was mostly 
removed under vacuum and the residue taken into DCM (50mL).  The organic solution was washed 
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~5% HClaq (2 x 50mL), NaOHaq (5% w/v, 2 x 50mL), distilled H2O (50mL) and brine (50mL).  
The organic portion was dried (MgSO4), filtered and evaporated to dryness.  The crude product was 
purified using Isolera automated column 100g SNAP silica cartridge DCM:MeOH (3-12%) to yield 
a light yellow solid mass =144mg,  Rf = 0.53 DCM:MeOH (10%);  
1H NMR (CDCl3) δ (ppm) = 
7.30 (m, 15H) 6.94 (br d 3J = 6.41Hz, 3H) 6.67 (br d, 3J = 7.33Hz, 3H) 6.08 (3J = 6.87Hz, 3H) 5.04 
(s, 6H) 4.42 (br s, 6H) 4.37 (br s, 6H) 2.59 (br q, 3J = 6.87Hz, 6H) 1.07 (br t, 3J = 6.87Hz, 9H); 13C 
NMR (CDCl3) δ (ppm) = 166.75, 158.30, 148.68, 144.21, 136.11, 131.60, 129.83, 128.70, 128.22, 
127.55, 116.22, 105.48, 77.32, 70.89, 38.14, 23.09, 16.35; HRMS (ESI) m/z [M+H]+: calcd for 
C57H61N6O9
+, 973.4500; found, 973.4491 
 
 
 
 
Tris-benzyl-TEB-LC-3,2-HOPO 
 (3.20): 2.15 (0.32g, 1.20mmol) and TBTU (0.39g, 1.20mmol) were dissolved under N2(g) in dry 
DMF (10mL).  N-methyl morpholine (0.20g, 1.97mmol) was added to the solution under N2(g) and 
the reaction stirred at room temperature for 30 minutes.  After which time, 1,3,5-tris(aminomethyl)-
2,4,6-triethyl benzene (100mg, 0.38mmol) was added under N2(g), the reaction was stirred at room 
temperature for 2 hours and then at 60°C for 24 hours.  The DMF was mostly removed under 
vacuum and the residue taken into DCM (50mL).  The organic solution was washed ~5% HClaq (2 
x 50mL), NaOHaq (5% w/v, 2 x 50mL), distilled H2O (50mL) and brine (50mL).  The organic 
portion was dried (MgSO4), filtered and evaporated to dryness.  The crude product was purified 
using Isolera automated column 100g SNAP silica cartridge DCM:MeOH (2-20%), to yield a 
yellow solid mass = 169mg.  1H NMR (CDCl3) δ (ppm) = 7.31 (m, 15H) 7.01 (br d, 3J = 5.95Hz, 
3H) 6.63 (d, 3J = 6.41Hz, 6H)  6.00 (t, 3J = 7.33Hz, 3H) 4.99 (s, 6H) 4.26 (d, 3J = 3.21Hz, 6H) 4.04 
(t, 3J = 5.95Hz, 6H) 2.57 (t, 3J =  5.95Hz, 6H) 2.45 (br q, 3J = 7.33Hz, 6H) 1.00 (t, 3J = 7.33Hz, 
9H); 13C NMR (CDCl3) δ (ppm) = 169.73, 158.13, 148.64, 143.74, 136.12, 131.74, 130.08, 128.67, 
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128.20, 127.49, 115.98, 105.03, 70.85, 46.36, 37.90, 35.08, 23.08, 16.39; HRMS (ESI) m/z 
[M+H]+: calcd for C60H67N6O9+, 1015.4969; found, 1015.4958. 
 
 
 
 
 
Tris-methoxy-TEB-R-3,2-HOPO 
(3.21): 3.14 (0.23g, 1.155mmol) was added with TBTU (0.40g, 1.245mmol) and N-
methylmorpholine (0.23g, 1.245mmol) to dry DMF (10mL) under N2(g).  The reaction was stirred at 
room temperature for 20 minutes before 1,3,5-tris(aminomethyl)-2,4,6-triethyl benzene (0.10g, 
3.85 x 10-4mol) was added under N2(g) and the reaction allowed to stir at 60°C for 18 hours.  The 
DMF was mostly removed via rotary evaporation and the residue was taken up into DCM (50mL).  
The organic solution was washed ~5% HClaq (2 x 50mL), NaOHaq (5% w/v, 2 x 50mL), distilled 
H2O (50mL) and brine (50mL).  The organic portion was dried (MgSO4), filtered and evaporated to 
dryness.  The crude product was purified using Isolera automated column 100g SNAP silica 
cartridge DCM:MeOH (2-20%), to yield a beige solid mass = 187mg (61%).   1H NMR (CDCl3) δ 
(ppm) = 7.87 (br t, 3J = 3.66Hz, 3H) 6.61 (s, 3H) 4.64 (d, 3J = 4.12Hz, 6H) 3.80 (s, 9H) 3.48 (s, 9H) 
2.76 (p, 3J = 4.12Hz, 6H) 2.32 (s, 9H) 1.20 (t, 3J = 7.33Hz, 9H); 13C NMR (CDCl3) δ (ppm) = 
163.28, 160.01, 144.91, 144.04, 140.46, 132.10, 129.20, 104.26, 59.95, 38.40, 31.86, 23.02, 20.70, 
16.46; HRMS (ESI) m/z [M+H]+: calcd for C42H55N6O9
+, 987.3031; found, 987.4020  
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Tris-benzyl-TEB-3,4-HOPO 
(3.22): 3.18 (0.66g, 2.41mmol) and TBTU (0.78g, 2.41mmol) were dissolved under N2(g) in dry 
DMF (20mL).  N-methyl morpholine (0.41g, 4.01mmol) was added to the solution under N2(g) and 
the reaction stirred at room temperature for 30 minutes.  After which time, 1,3,5-tris(aminomethyl)-
2,4,6-triethyl benzene (200mg, 8.02mmol) was added under N2(g), the reaction was stirred at room 
temperature for 2 hours and then at 60°C for 24 hours.  The DMF was mostly removed under 
vacuum and the residue taken into DCM (50mL).  A solid was recovered which precipitated from 
DCM to yield the pure product in 82% yield (0.82g).  1H NMR (DMSO-d6) δ (ppm) = 8.50 (br s, 
3H) 7.92 (d, 3J = 6.87Hz, 3H) 7.40 (m, 15H) 6.69 (d, 3J = 7.33Hz, 3H) 5.06 (s, 6H) 4.84 (s, 6H) 
4.37 (s, 6H) 2.68 (br s, 6H) 2.17 (s, 9H) 1.11 (t, 3J = 7.33Hz, 9H); 13C NMR (DMSO-d6) δ (ppm) = 
165.71, 145.44, 144.11, 144.02, 142.60, 137.42, 131.92, 128.85, 128.70, 128.45, 114.44, 73.42, 
56.48, 37.81, 22.83, 16.50, 12.94  
 
 
 
Tris-benzyl-TEB-1,2-HOPO 
(3.23): 3.15 (0.29g, 1.20mmol) and TBTU (0.39g, 1.20mmol) were dissolved under N2(g) in dry 
DMF (10mL).  N-methyl morpholine (0.20g, 1.97mmol) was added to the solution under N2(g) and 
the reaction stirred at room temperature for 30 minutes.  After which time, 1,3,5-tris(aminomethyl)-
2,4,6-triethyl benzene (100mg, 0.38mmol) was added under N2(g), the reaction was stirred at room 
temperature for 2 hours and then at 60°C for 24 hours.  The DMF was mostly removed under 
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vacuum and the residue taken into DCM (50mL).  The organic solution was washed ~5% HClaq (2 
x 50mL), NaOHaq (5% w/v, 2 x 50mL), distilled H2O (50mL) and brine (50mL).  The organic 
portion was dried (MgSO4), filtered and evaporated to dryness.  The crude product was purified 
using Isolera automated column 100g SNAP silica cartridge DCM:MeOH (2-20%), to yield a solid 
mass = 222mg, Rf = 0.5 DCM:MeOH (10%). 
1H NMR (CDCl3) δ (ppm) = 7.30 (m, 15H) 7.16 (dd, 
3J1 = 9.16Hz 
3J2 = 6.41Hz, 3H) 6.53 (d, 
3J = 1.83Hz, 3H) 6.50 (d, 3J = 1.37Hz, 3H) 6.28 (dd, 3J1 = 
6.87Hz 3J2 = 1.83Hz, 3H) 5.16 (s, 6H) 4.49 (d, 
3J = 4.12Hz, 6H) 2.45 (q, 3J = 7.79Hz, 6H) 1.06 (t, 
3J = 7.33Hz, 9H); 13C NMR (CDCl3) δ (ppm) = 159.69, 158.34, 144.43, 141.90, 138.04, 133.10, 
131.32, 130.30, 129.65, 128.61, 124.37, 106.33, 79.54, 38.35, 23.12, 16.38; HRMS (ESI) m/z 
[M+H]+: calcd for C54H55N6O9
+, 931.4031; found, 931.4023 
 
 
TEB-SC-3,2-HOPO 
(3.24): 3.19 (144mg, 0.148mmol) was stirred at room temperature for 4 days and then 60°C for 4 
days in 37% HCl:glacial acetic acid (1:1).  The acids were removed by rotary evaporation and the 
product was precipitated from MeOH with diethyl ether to yield a hygroscopic solid mass = 65mg 
(35%).  mp = >260°C  1H NMR (DMSO-d6) δ (ppm) = 8.36 (s, 3H)7.13 (td, 3J1 = 6.87Hz, 3J2 = 
1.83Hz, 3H) 6.72 (td, 3J1 = 7.33Hz, 
3J2 = 1.83Hz, 3H) (dt, 
3J1 = 10.53Hz, 
3J2 = 6.87Hz, 3H) 4.04 (d, 
3J = 5.04Hz, 6H) 3.68 (s, 6H) 2.78 (q, 3J = 7.19Hz, 6H) 1.12 (t, 3J = 7.33Hz, 9H); 13C NMR 
(DMSO-d6) δ (ppm) = 169.83, 169.12, 158.56, 147.27, 146.17, 129.53, 129.48, 129.37, 115.93, 
115.67, 105.76, 105.49, 52.63, 50.73, 36.44, 23.85, 16.33; HRMS (ESI) m/z [M+H]+: calcd for 
C36H43N6O9
+, 703.3092; found, 703.3086 
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TEB-LC-3,2-HOPO 
(3.25): 3.20  (169mg, 0.166mmol) was stirred at room temperature for 4 days and then 60°C for 4 
days in 37% HCl:glacial acetic acid (1:1).  The acids were removed by rotary evaporation and the 
product was precipitated from MeOH with diethyl ether to yield a hygroscopic solid mass = 124mg 
(40%). mp = 220-227°C  1H NMR (DMSO-d6) δ (ppm) = 7.88 (t, 3J = 4.58Hz, 3H) 7.04 (dd, 3J1 = 
7.33Hz, 3J2 = 1.83Hz, 3H) 6.63 (dd, 
3J1 = 7.33Hz, 
3J2 = 1.83Hz, 3H) 6.02 (t, 
3J = 6.87Hz, 3H) 4.26 
(d, 3J = 4.12Hz, 6H) 4.11 (t, 3J = 6.87Hz, 6H) 1.01 (m, 3J = 7.10Hz, 9H) 13C NMR (DMSO-d6) δ 
(ppm) = 169.91, 157.35, 147.19, 146.23, 129.53, 115.77, 105.59, 50.99, 36.58, 23.83, 21.55, 16.31; 
HRMS (ESI) m/z [M+H]+: calcd for C39H49N6O9
+, 745.3561; found, 745.3554    
 
 
TEB-3,4-HOPO 
(3.26): 3.22 (384mg, 0.378mmol) was stirred at room temperature for 4 days and then 60°C for 4 
days in 37% HCl:glacial acetic acid (1:1).  The acids were removed by rotary evaporation and the 
product was precipitated from MeOH with diethyl ether to yield a hygroscopic solid mass = 248mg 
(88%). 1H NMR (DMSO) δ (ppm) = 7.96 (br d, 3J = 6.87Hz, 3H) 6.95 (d, 3J = 6.87Hz, 3H) 5.11-
5.05 (s, br m, 6H) 4.41 (s, 3H) 4.12 (s, 3H) 6.69 (br m, 6H) 2.39 (s, 9H) 1.07 (br m, 9H) 13C NMR 
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(DMSO) δ (ppm) = 140.17, 139.79, 110.97, 110.86, 58.21, 57.19, 23.58, 16.00, 15.83, 12.40, 
12.11; HRMS (ESI) m/z [M+H]+: calcd for C39H49N6O9
+, 745.3561; found, 745.3551 
 
TEB-1,2-HOPO 
(3.27):  3.23 (304mg, 3.27x10-4mol) was stirred at 60°C for 4 days in 37% Hcl:glacial acetic acid 
(1:1).  The acids were removed by rotary evaporation and the product was precipitated from MeOH 
with diethyl ether to yield a hygroscopic solid mass = 201mg (93%). mp = 255-260°C. 1H NMR 
(DMSO) δ (ppm) = 9.02 (t, 3J = 4.02, 3H) 7.38 (m, 3H) 6.60 (dd, 3J1 = 8.70Hz, 3J2 = 1.37Hz, 3H) 
6.35 (dd, 3J1 = 6.87, 
3J2 = 1.83Hz, 3H) 4.50 (t, 
3J = 4.58, 6H) 2.77 (br m, 6H) 1.16 (t, 3J = 7.79Hz, 
9H) 13C NMR (DMSO) δ (ppm) = 160.49, 157.83, 144.38, 142.18, 137.25, 131.81, 119.37, 105.31, 
38.02, 23.02, 16.61; HRMS (ESI) m/z [M+H]+: calcd for C33H37N6O9
+, 661.2622; found, 661.2616    
 
 
TEB-R-3,2-HOPO 
(3.28): 3.21 (110mg, 0.139mmol) was dissolvd in dry DCM (10mL) and cooled under N2(g) in a 
ice-water bath.  Once cool, BCl3(1M in heptane, 1mL) was added and the reaction allowed to stir at 
room temperature for 4 days.  The reaction was quenched with drop wise addition of MeOH, the 
solvent evaporated and the re-evaporation of additions of MeOH (6 x 20mL) yielded the pure 
product in 60% yield (63mg).   1H NMR (DMSO-d6) δ (ppm) = 8.26 (t, 3J = 3.66Hz, 3H) 6.54 (s, 
3H) 4.56 (d, 3J = 3.81Hz, 6H) 3.42 (s, 9H) 2.72 (q, 3J = 7.33Hz, 6H) 2.29 (s, 9H) 1.13 (t, 3J = 
7.33Hz, 9H) 13C NMR (DMSO-d6) δ (ppm) = 167.21, 164.77, 157.75, 142.09, 133.43, 123.15, 
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111.54, 105.20, 36.74, 31.27, 22.76, 19.57, 16.30; HRMS (ESI) m/z [M+H]+: calcd for 
C39H49N6O9
+, 745.3561; found, 745.3560    
 
2,3-bis(benzyloxy)benzoic acid 
(3.32): To a solution of 2,3-dihydroxybenzoic acid (2g, 12.98mmol), BnBr (13.32g, 77.85mmol) in 
acetone (100mL)was added K2CO3 (10.76g, 77.85mmol) and the reaction allowed to stir at 100°C 
overnight.  The solution was cooled, filtered and the residue taken into MeOH (120mL) and 
NaOHaq (5M, 30mL) added.  The mixture was refluxed for 4 hours, cooled, the MeOH evaporated 
and diluted with H2O until homogenous.  The aqueous solution was extracted with hexane (2 x 
50mL) and the aqueous portion acidified with 37% HClaq upon which a precipitate could be 
isolated by filtration and was used without further purification mass = 5.35g    1H NMR (CDCl3) δ 
(ppm) = 7.48-7.15 (m, 13H) 5.18 (s, 2H) 5.25 (s, 2H) 13C  NMR (CDCl3) δ (ppm) = 165.20, 151.37, 
147.14, 135.92, 134.68, 129.41, 128.96, 128.92, 128.65, 127.88, 125.15, 124.55, 123.06, 119.06, 
77.24, 71.63                 
 
 
Bn6EMECAM 
(3.33): 2,3-dibenzyloxybenzoic acid (49) (0.38g, 1.16mmol) and TBTU (0.39g, 1.20mmol) were 
dissolved under N2(g) in dry DMF (10mL).  N-methyl morpholine (0.23g, 1.97mmol) was added to 
the solution under N2(g) and the reaction stirred at room temperature for 30 minutes.  After which 
time, 1,3,5-tris(aminomethyl)-2,4,6-triethyl benzene (100mg, 0.38mmol) was added under N2(g), the 
reaction was stirred at room temperature for 2 hours and then at 60°C for 24 hours.  The DMF was 
mostly removed under vacuum and the residue taken into DCM (50mL).  The organic solution was 
212 
 
washed ~5% HClaq (2 x 50mL), NaOHaq (5% w/v, 2 x 50mL), distilled H2O (50mL) and brine 
(50mL).  The organic portion was dried (MgSO4), filtered and evaporated to dryness.  The crude 
product was purified using Isolera automated column 100g SNAP silica cartridge DCM:MeOH (3-
12%) to yield a solid mass = 462mg (52%). 35g    1H NMR (CDCl3) δ (ppm) = 7.69 (dd, 3J1 = 
7.79Hz, 3J2 = 1.83Hz, 3H) 7.63 (br t, 
3J = 4.58Hz, 3H) 7.40-7.30 (m, 18H) 7.16-6.82 (m, 21H) 5.04 
(s, 6H) 4.80 (s, 6H) 4.54 (d, 3J = 4.58Hz, 6H) 2.47 (q, 3J = 7.79Hz, 6H) 1.03 (t, 3J = 7.33Hz, 9H)  
 
 
EMECAM 
(1.32): 3.33 (522mg, 0.432mmol) was hydrogenated over Pd/C in EtOH:H2O with an acid catalyst 
for 8 hours at room temperature.  The reaction TLC showed incomplete.  The catalyst was filtered, 
solvents evaporated and the solid taken into dry DCM.  To which BCl3 (1M in heptane, 2.6mL) 
was added under N2(g) and the reaction stirred for 18 hours before quenching with drop wise 
addition of MeOH.  Evaporation to dryness and repeated MeOH evaporations (5 x 20mL) yielded 
the pure product mass = 243mg (85%) as a solid. Mp = 119-127°C.  1H NMR (DMSO-d6) δ (ppm) 
= 8.68 (br s, 3H) 7.40 (dd, 3J1 = 8.24Hz, 
3J2 = 1.37Hz, 3H) 6.90 (dd, 
3J1 = 7.79Hz, 
3J2 = 1.37Hz, 
3H) 4.60 (d, 3J = 3.66Hz, 6H) 2.82 (br q, 3J = 7.33Hz, 6H) 1.13 (t, 3J = 7.33Hz, 9H) 13C NMR 
(DMSO-d6) δ (ppm) =  168.32, 148.44, 145.95, 144.05, 131.67, 118.61, 118.38, 118.05, 115.85, 
37.53, 22.72, 16.07   
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8.3.3 Experimental tris(piperazin-1-yl)-1,3,5-triazine molecules 
 
 
tert-butyl piperazine-1-carboxylate (49) 
(4.6): To a solution of pipirazine (15.0g, 0.174mol) in DCM (300mL) was added di-tert-butyl 
carbonate (19.2g, 0.0871mol) as a solution in DCM (70mL) at 0°C.  The resulting solution was 
stirred at 0°C for 2 hours, during which time a white precipitate formed.  The reaction was filtered 
and the filtrate evaporated to dryness.  H2O (30mL) was added and the reaction was filtered again.  
The filtrate was saturated with K2CO3 and then extracted with ether (3 x 100mL), the ether dried 
(MgSO4) and evaporated to dryness to yield 10.0g of the product (61%).  1H NMR (CDCl3) δ/ppm 
= 3.36 (t, 3J = 4.1Hz, 4H) 2.78 (t, 3J = 4.6Hz, 4H) 1.44 (d, 3J = 1.4Hz, 9H).  13C NMR (CDCl3) δ 
(ppm) = 154.92, 79.60, 46.00, 28.50 
 
 
tert-butyl-4-[bis({4-[(tert-butoxy)carbonyl]piperazin-1-yl})-1,3,5-triazin-2-yl]piperazine-1-carboxylate 
(50) 
(4.7): Cyanuric chloride (3.10g, 16.8mmol), 4.6 (10g, 50.4mmol) and K2CO3 (20g, 144mmol) were 
suspended in THF (50mL) and refluxed at 80°C overnight.  The solution was cooled and the 
solvent evaporated to leave a residue which was taken into DCM and washed with H2O and brine.  
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Evaporation of the DCM gave the product in 58% yield (6.22g).  1H NMR (CDCl3) δ (ppm) = 3.73 
(br t, 3J = 5.04Hz, 12H) 3.44 (br t,3J = 5.50Hz, ) 1.48 (s, 27H) 13C NMR (CDCl3) δ (ppm) = 165.39, 
164.54, 80.32, 43.36, 43.06, 28.49 
 
tris(piperazin-1-yl)-1,3,5-triazine  
(4.2): 4.7 (1.48g, 2.33mmol) was dissolved in DCM:TFA 1:1 (25mL) and allowed to stir at room 
temperature for 6 hours.  After which time the solution was evaporated to give a viscous residue 
which was brought to pH 14 with NaOHaq (6M).  The basic solution was extracted with DCM (3 x 
50mL), dried (MgSO4) and the solvent evaporated to yield the product in 58% yield (450mg).  mp 
= >260°C.  1H NMR (MeOD-d4) δ (ppm)  = 3.75-3.60 (br m, 12H) 3.24-3.21 (m, 3H) 2.76-2.64 (m, 
9H) 13C NMR (MeOD-d4) δ (ppm)  = 165.30, 45.05, 43.53 
 
 
Tris-allyl-triazine-1,2-HOPO 
(4.8): 4.2 (0.25g, 7.497 x 10-4 mol) and Et3N (0.47g, 4.648 x 10
-3mol) were added under N2(g) to 
MeCN (10mL).  To this 2.28 (0.46g, 2.342 x 10-3 mol) was added under N2(g) and the reaction 
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allowed to stir at room temperature for 72 hours and a further 48 hours at reflux.  The reaction was 
evaporated to dryness, taken into DCM (100mL) washed NaHCO3(sat) (3 x 100mL) and purified 
using Isolera automated column 100g SNAP silica cartridge DCM:MeOH (3-12%).  To yield a 
viscous oil mass = 105mg (17%).  1H NMR (CDCl3) δ (ppm) = 7.25 (dd, 3J1 = 6.4Hz, 3J2 = 9.2Hz, 
3H) 6.57 (dd, 3J1 = 1.8Hz, 
3J2 = 9.2Hz, 3H) 6.14 (dd, 
3J1 = 1.4Hz, 
3J2 = 6.9Hz, 3H) 6.04 (m, 3H) 
5.42 (dd, 3J1 = 1.4Hz, 
3J2 = 17.4Hz, 3H) 5.32 (dd, 
3J1 = 0.9Hz, 
3J2 = 10.1Hz, 3H) 3.74 (br s, 12H) 
3.70 (s, 6H) 2.50 (t, 3J = 4.6Hz, 12H)13C NMR (CDCl3) δ (ppm) = 165.3, 160.0, 145.9, 137.9, 
130.9, 121.3, 121.1, 105.9, 57.4, 53.2, 50.8, 43.1; HRMS (ESI) m/z [M+H]+: calcd for 
C42H55N12O6
+, 823.4368; found, 823.4358 
 
Triazine-1,2-HOPO 
(4.9): 4.8 (87mg, 0.106mmol) was dissolved in dioxane:H2O (4:1, 10mL) to which Pd/C (10mg) 
was added and TFA was added to give a 0.15M solution.  The reaction was refluxed overnight, the 
catalyst filtered and washed with dioxane and water (5mL) and the solvents evaporated.  Repeated 
evaporations from MeOH yielded the pure product in 79% yield (59mg).  mp = 122-130°C. 1H 
NMR (DMSO-d6) δ (ppm) = 7.45 (dd, 3J1 = 9.16Hz, 3J2 = 6.87Hz, 3H) 6.64 (dd, 3J1 = 9.16Hz, 3J2 = 
1.37Hz, 3H) 6.47 (dd (3J1 = 6.87Hz, 
3J2 = 1.37Hz, 3H) 4.31 (s, 6H) 3.92 (br s, 12H) 3.12 (br s, 
12H) 13C NMR (DMSO-d6) δ (ppm) = 165.05, 158.39, 139.78, 137.40, 119.44, 108.40, 54.63, 
52.17, 43.22; HRMS (ESI) m/z [M+H]+: calcd for C33H43N12O6
+, 703.3429: found, 703.3426  
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Tris-benzyl-triazine-3,2-HOPO 
(4.10): To 4.2 (0.23g, 6.897 x 10-4mol) was added dry MeCN (15mL) under N2(g), Et3N ( 0.41g, 
4.138 x 10-3mol) was added to the reaction.  After 10 minutes, 2.21 (0.70g, 2.165 x 10-3mol) was 
added and the reaction stirred under N2(g) for three days at room temperature.  After which time, the 
reaction was allowed to reflux for 24 hours.  The reaction was evaporated to dryness, taken into 
DCM (50mL), washed NaHCO3(sat) (3 x 50mL), dried (MgSO4) and evaporated to dryness.  
Purification via silica gel column chromatography DCM:MeOH (1-8%) yielded 203mg (29%).  1H 
NMR (CDCl3) δ (ppm) = 7.50-7.20 (m, 15H) 6.93 (dd, 3J1 = 1.4Hz, 3J2 = 6.9Hz, 3H) 6.31 (dd, 3J1 = 
1.4Hz, 3J2 = 7.3Hz, 3H) 6.00 (t, 
3J = 7.3Hz, 3H) 5.08 (s, 6H) 4.08 (t, 3J = 6.5Hz, 6H) 3.7 (br m, 
12H) 2.71 (t, 3J = 6.9Hz, 6H) 2.48 (br m, 12H) 13C NMR (CDCl3) δ (ppm) = 165.3, 158.2, 148.8, 
136.4, 129.7, 128.6, 128.6, 128.0, 127.4, 115.6, 104.4, 70.8, 56.7, 53.3, 47.2, 43.2, 29.8; HRMS 
(ESI) m/z [M+H]+: calcd for C57H67N12O6
+, 1015.5307; found, 1015.5295 
 
Triazine-3,2-HOPO 
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(4.11): (4.10) (201mg, 5.02 x 10-5mol) was dissolved in HCl:AcOH (1:1, 10mL) and allowed to stir 
at room temperature for 4 days and at 50-70°C for 16 days.  The reaction was evaporated to 
dryness, dissolved in methanol and a solid was collected by precipitation with diethyl ether mass = 
43mg. mp = 221-225°C. 1H NMR (DMSO-d6) δ (ppm) = 7.26 (dd, 3J1 = 6.87Hz, 3J2 = 1.37Hz, 3H) 
6.76 (dd, 3J1 = 7.33Hz, 
3J2 = 1.37Hz, 3H) 6.20 (t, 
3J = 6.87Hz, 3H) 4.40 (br t, 6H); HRMS (ESI) m/z 
[M+H]+: calcd for C36H49N12O6
+, 745.3898; found, 745.3891 
8.4 Experimental cholic acid  
Methyl cholate  
(5.2): A 50mL 3n-round bottomed flask was charged with cholic acid (2.00g, 4.89mmol) and 
MeOH (15mL).  The flask was equipped with a reflux condenser and the mixture brought to reflux 
for 1 hour 15 mins.  H2SO4 (5-6 drops) was added till pH ~ 1-2 determined via indicator paper.  
The solution was allowed to cool to room temperature and stirred for one day.  Saturated 
Na2CO3(aq) (20mL) was added to the reaction and upon addition a white precipitate was filtered 
after 10 mins of stirring.  The solid was recrystallized in toluene and stored at 4°C for 24 hours.  
The solid was filtered to yield a white powder mass = 1.36g (66%).  mp = 155-158°C 1H NMR 
(CDCl3) δ (ppm) = 3.97 (s, 1H) 3.63 (s, 3H) 3.14 (m, 1H) 1.18 (d, 3J = 6.19Hz, 3H) 1.01 (s, 3H) 
0.81 (s, 3H)   
 
Methyl cholate- Bn6-3,2-HOPO 
(5.3) To methyl cholate (100mg, 2.37 x 10-4mol) was added in dry toluene to a dry 3-necked round bottomed 
flask under N2(g).  Calcium hydride (60mg, 1.43mmol) was added to this before 2.21 was added drop wise as 
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a solution in dry toluene.  The reaction was brought to reflux for 2 days after which time, the reaction was 
filtered and the solvent evaporated.  The crude residue was purified via Isolera automated column 50g 
SNAP silica cartridge DCM:MeOH (3-12%). 13C NMR (CDCl3) δ (ppm) = 174.8, 158.2, 148.8, 
148.6, 136.5, 136.4, 130.3, 128.6, 128.0, 127.4, 116.0, 115.7, 104.0, 103.9, 80.0, 72.9, 70.8, 68.7, 
68.3, 65.8, 51.6, 50.4, 49.6, 47.2, 46.6, 42.1, 41.4, 39.6, 36.21, 35.21, 35.12, 35.0, 34.6, 31.1, 30.9, 
28.5, 27.5, 27.1, 26.8, 23.2, 22.7, 17.4, 12.6.  HRMS (ESI) m/z [M+Na+H2O]
+: calcd for 
C67H83N3O12 , 1144.5869; found, 1144.5864. 
 
Methyl cholate-3,2-HOPO 
(5.4) The isolated residue 5.3 was the subject to hydrogenation with a H-Cube® Continuous-flow 
Hydrogenation Reactor (ThalesNano) in methanol, using a Pd/C cartridge (full H2(g) mode).  The 
product was isolated via evaporation of the methanol to yield a solid 90mg. 13C NMR (CD3OD) δ 
(ppm) = 175.8, 159.3, 147.4, 129.9, 129.5, 116.3, 106.8, 80.8, 73.4, 68.9, 38.4, 65.8, 51.3, 50.8, 
50.0, 49.2, 47.3, 46.8, 42.4, 42.3, 40.3, 36.8, 36.1, 35.6, 35.5, 35.2, 31.6, 31.2, 28.9, 28.0, 27.4, 
27.2, 23.6, 22.5, 16.9, 12.3.  (+) ESI-MS found 873.86  = [M+Na+H2O] 
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8.4.1 Experimental TREN core scaffold 
 
 
2,5-dioxopyrrolidin-1-yl 2-[3-(benzyloxy)-2-oxo-1,2-dihydropyridin-1-yl]acetate 
(6.6): 2.11 (0.30g, 1.16mmol) in DMF (20mL) was added NHS (0.14g, 1.12mmol) and DCC 
(0.25g, 1.21mmol) each as a solution in DMF (5mL).  The solution was stirred in the dark for 4 
days after which time glacial AcOH (0.5mL) was added and the solution stirred for 1 hour.  The 
precipitate was filtered and the DMF evaporated to give a residue which was recrystallized from 
EtOAc to yield a pink powder mass = 0.18g (43%).   
 
 
 Bn-CP130 
 (6.7): TREN (133mg, 9.12 x 10-4 mol) was added with stirring to a solution of 2,5-dioxopyrrolidin-
1-yl 2-[3-(benzyloxy)-2-oxo-1,2-dihydropyridin-1-yl]acetate (976mg, 2.73mmol) in DMF (30mL).  
After 24 hours the solution was evaporated to dryness, the residue dissolved in DCM (50mL).  The 
organic solution was washed Na2CO3 (0.05M, 3 x 10mL) and H2O (2 x 20mL).  The organic phase 
was dried (MgSO4), filtered and evaporated to dryness.  The resulting residue was recrystallized in 
EtOH/H2O and the precipitate collected after 4 days at 4°C as a white solid mass =0.51g (64%).  
1H 
NMR (CDCl3) δ (ppm) = 8.38 (t, 3J = 5.50Hz, 3H) 7.41-7.27 (m, 15H) 6.68 (d, 3J1 = 7.79Hz, 3H) 
6.67 (d, 3J = 6.87 Hz, 3H) 6.01 (td, 3J1 = 7.33Hz, 
3J2 = 1.37Hz, 3H) 4.97 (s, 6H) 4.48 (s, 6H) 3.20 
(br q, 3J = 4.12Hz, 6H) 2.51 (br t, 3J = 5.04Hz, 6H)     
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CP130 
(1.6): 6.7 (454mg, 0.512mmol) was dissolved in EtOH and H2O (10:1) with glacial AcOH (1mL) 
and Pd/C (140mg).  The mixture was hydrogenated overnight at room temperature and the solution 
the filtered and evaporated after the catalyst was washed with EtOH.  The crude solid was 
recrystallized from EtOH to yield a powder mass = 80mg (25%). mp = 145-153°C.  1H NMR 
(DMSO-d6) δ (ppm) = 8.54 (br s, 3H) 7.09 (d, 3J = 6.41Hz, 3H) 6.74 (d, 3J = 6.87Hz, 3H) 6.10 (t, 3J 
= 6.87Hz, 3H) 4.59 (s, 6H) 3.51 (s, 6H) 3.31 (s, 6H) .  13C NMR (DMSO-d6) δ (ppm) = 168.35, 
158.45, 147.11, 129.98, 115.86, 105.56, 52.00, 34.13       
 
 
 Bn-LC-CP130 
(6.8): 2.15 (0.56g, 2.0519mmol) and TBTU (0.705g, 2.19mmol) were dissolved under N2(g) in dry 
DMF (20mL).  N-methyl morpholine (0.42g, 4.1mmol) was added to the solution under N2(g) and 
the reaction stirred at room temperature for 30 minutes.  After which time, TREN (0.10g, 6.84 x 10-
4mol) was added under N2(g), the reaction was stirred at room temperature for 2 hours and then at 
60°C for 24 hours.  The DMF was mostly removed under vacuum and the residue taken into DCM 
(50mL).  The organic solution was washed ~5% HClaq (2 x 50mL), NaOHaq (5% w/v, 2 x 50mL), 
distilled H2O (50mL) and brine (50mL).  The organic portion was dried (MgSO4), filtered and 
evaporated to dryness.  The crude product was purified using Isolera automated column 100g 
SNAP silica cartridge DCM:MeOH (2-20%), to yield a brown solid mass = 191mg (30%) 1H NMR 
(CDCl3) δ (ppm) = 7.83 (t, 3J = 5.04Hz, 3H) 7.33 (m, 15H) 7.03 (dd, 3J1 = 6.92Hz, 3J2 = 1.37Hz, 
3H) 6.34 (dd, 3J1 = 7.33Hz, 
3J2 = 1.37Hz, 3H) 5.99 (t, 
3J = 7.33Hz, 3H) 4.98 (s, 6H) 4.12 (t, 3J = 
5.95Hz, 6H) 3.05 (br q, 3J = 3.66Hz, 6H) 2.57 (t, 3J = 5.95Hz, 6H) 2.37 (br t, 6H) 13C NMR 
221 
 
(CDCl3) δ (ppm) = 170.57, 158.10, 148.51, 136.20, 130.22, 128.61, 128.15, 127.55, 115.56, 
105.10, 70.58, 54.91, 46.50, 37.73, 35.42      
  
 
LC-CP130 
(6.9): 6.8 (283mg) was hydrogenated over Pd/C (30mg) for 8 hours in a solvent mixture of 
EtOH:H2O (9:1).  The solution was filtered and the catalyst washed.  The solvent and washings 
were combined and were evaporated to dryness to yield the product in 68% yield (135mg).  mp = 
90-95°C. 1H NMR (MeOD-d4) δ (ppm) = 6.99 (d, 3J = 6.41Hz, 3H) 6.71 (d, 3J = 7.33Hz, 3H) 6.11 
(t, 3J = 6.87Hz, 3H) 4.18 (t, 3J = 6.41Hz, 6H) 3.08 (t, 3J = 5.50Hz, 6H) 2.62 (t, 3J = 5.95, 6H) 2.48 
(t, 3J = 5.04Hz, 6H) 13C NMR (MeOD-d4) δ (ppm) = 173.02, 159.95, 148.39, 129.64, 117.10, 
108.11, 54.86, 47.88, 38.22, 36.06; (+)-ESI-MS m/z calcd for C30H40N7O9+, 642.29; found, 642.20: 
HRMS (ESI) m/z [M+H]+: calcd for C30H40N7O9
+, 642.2882: found, 642.2878 
 
2,5-dioxopyrrolidin-1-yl 3-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridine-4-carboxylate  
(6.10): 3.14 (1.00g, 5.02mmol) in DCM (100mL) was added N-hydroxysuccinimide (0.79g, 
6.84x10-3mol) and EDAC (1.285g, 6.7x10-3mol) and the resulting mixture stirred at room 
temperature for three days.  The reaction was washed with HClaq (0.1M (2x100mL), organic phase 
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was dried (MgSO4) and evaporated to dryness to yield a yellow-orange solid, 1.30g (88%).  Mp = 
110-113°C. 1H NMR (CDCl3) δ (ppm) = 6.28 (s, 1H) 3.96 (s, 3H) 3.49 (s, 3H) 2.83 (s, 4H) 2.30 (s, 
3H). 13C NMR (CDCl3) δ (ppm) = 169.05, 160.27, 159.96, 148.80, 140.65, 122.85, 103.01, 60.77, 
32.06, 25.75, 20.66 
 
 
Me6-TREN-R-3,2-HOPO 
(6.11): To 6.10 (0.60g, 2.05mmol) in DCM (15mL) was added TREN (0.10g, 0.684mmol) as a 
solution in DCM (5mL).  The reagents were allowed to stir at room temperature for 2 days.  The 
evaporation of the solvent gave a residue which solidified on standing to provide the pure 
compound in 92% yield (0.43g).  1H NMR (CDCl3) δ (ppm) = 8.30 (t, 3J = 5.5Hz, 3H) 6.57 (s, 3H) 
3.98 (s, 9H) 3.62 (q, 3J = 6.41Hz, 6H) 3.54 (s, 9H) 2.36 (s, 9H) 2.97 (t, 3J = 6.41Hz, 6H)    
 
TREN-R-3,2-HOPO 
(6.12): 6.11 (0.20g, 0.293mmol) was added to a clean, dry, 3n round-bottomed flask under N2(g) as 
a solution in dry DCM (20mL).  The solution was cooled in an ice-water bath for 15 minutes before 
BCl3 (1M in heptane, 1.70mL) was added via gas tight syringe under N2(g).  The reaction was stirred 
at room temperature for 2 days before MeOH (50mL) was added drop wise at 0°C.  The solvents 
were evaporated and the residue precipitated from suspension in MeOH.  The solid was collected 
after storage for 2 days at 4°C to give the pure product in 23% yield (43mg).     
1H NMR (DMSO) δ 
(ppm) = 8.57 (br t, 3H) 6.29 (s, 3H) 3.66 (br s, 6H) 2.19 (s, 9H) 13C NMR (DMSO) δ (ppm) = 
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166.34, 159.26, 144.86, 134.99, 117.02, 102.96, 52.41, 34.70, 32.01, 20.01; HRMS (ESI) m/z 
[M+H]+: calcd for C30H40N7O9+, 642.2888; found, 642.2886 
 
Bn6-TRENCAM 
(6.17): 3.32 (686mg, 2.05mmol) and TBTU (702mg, 2.19mmol) were dissolved under N2(g) in dry 
DMF (20mL).  N-methyl morpholine (0.42g, 4.1mmol) was added to the solution under N2(g) and 
the reaction stirred at room temperature for 30 minutes.  After which time, TREN (100mg, 
0.684mmol) was added under N2(g), the reaction was stirred at room temperature for 2 hours and 
then at 60°C for 24 hours.  The DMF was mostly removed under vacuum and the residue taken into 
DCM (50mL).  The organic solution was washed ~5% HClaq (2 x 50mL), NaOHaq (5% w/v, 2 x 
50mL), distilled H2O (50mL) and brine (50mL).  The organic portion was dried (MgSO4), filtered 
and evaporated to dryness.  The crude product was purified using Isolera automated column 100g 
SNAP silica cartridge DCM:MeOH (2-20%), to yield a brown solid mass = 310mg (41%).  1H 
NMR (CDCl3) δ (ppm) = 7.46-7.21 (m, 33H) 7.16-7.04 (m, 6H) 5.17-5.06 (m, 12H) 3.56 (br s, 6H) 
3.17 (br s, 6H) %); 13C NMR (CDCl3) δ (ppm) = 165.31, 151.75, 146.79, 136.62, 136.56, 128.73, 
128.69, 128.26, 127.88, 127.68, 124.38, 123.14, 116.79, 76.33, 71.23, 52.57, 38.70, 37.35 
 
 
 
 
TRENCAM 
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(6.16): 6.17 (310mg, 0.283mmol) was stirred in 37% HCl:glacial AcOH (1:1) at room temperature 
for 7 days.  The acids were evaporated and the residue was repeatedly evaporated from MeOH (6 x 
20mL) the pure product was obtained in 77% yield (120mg).  1H NMR (DMSO-d6) δ (ppm) = 6.77 
(dd, 3J1 = 7.79Hz, 
3J2 = 1.37Hz, 3H) 6.57 (dd, 
3J1 = 7.79Hz, 
3J2 = 1.37Hz, 3H) 6.31 (t, 
3J = 7.79Hz, 
3H) 3.52 (br t, 3J = 5.50Hz, 6H) 3.34 (br t, 3J = 5.04Hz, 6H); 13C NMR (DMSO-d6) δ (ppm) = 
170.08, 149.25, 146.15, 119.03, 118.12, 117.66, 115.03, 51.31, 38.22, 33.71         
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9 Appendix 
9.1 OD630 Kinetic assay data E. coli  
-  
Appendix Figure 9.1  Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
CTG-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM).        
 
Appendix Figure 9.2 Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
TRENCAM at concentrations given in legend, reported in micromolar.  Control contained no ligand (0µM).        
 
Appendix Figure 9.3 Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
EMECAM at concentrations given in legend, reported in micromolar.  Control contained no ligand (0µM).        
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Appendix Figure 9.4 Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
triazine-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM).        
 
Appendix Figure 9.5 Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
triazine-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM).        
 
 
Appendix Figure 9.6 Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
TEB-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM).        
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Appendix Figure 9.7 Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
TEB-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM).        
 
Appendix Figure 9.8 Development of OD630 over 24 hours for E. coli in BHI broth at 37°C.  Containing 
TREN-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
9.2 OD630 Kinetic assay data K. pneumoniae 
 
Appendix Figure 9.9 Development of OD630 over 24 hours for K. pneumoniae in BHI broth at 37°C.  
Containing CTG-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
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Appendix Figure 9.10 Development of OD630 over 24 hours for K. pneumoniae in BHI broth at 37°C.  
Containing CTG-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
Appendix Figure 9.11 Development of OD630 over 24 hours for K. pneumoniae in BHI broth at 37°C.  
Containing triazine-1,2-HOPO  at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
 
Appendix Figure 9.12 Development of OD630 over 24 hours for K. pneumoniae in BHI broth at 37°C.  
Containing TEB-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
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Appendix Figure 9.13 Development of OD630 over 24 hours for K. pneumoniae in BHI broth at 37°C.  
Containing TEB-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
 
Appendix Figure 9.14 Development of OD630 over 24 hours for K. pneumoniae in BHI broth at 37°C.  
Containing TRENCAM at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
Appendix Figure 9.15 Development of OD630 over 24 hours for K. pneumoniae in BHI broth at 37°C.  
Containing EMECAM at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
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9.3 OD630 Kinetic assay data P. aeruginosa 
 
Appendix Figure 9.16 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing CTG-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
Appendix Figure 9.17 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing triazine-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM).  
 
 
Appendix Figure 9.18 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing CTG-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
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Appendix Figure 9.19 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing TEB-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
 
Appendix Figure 9.20 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing TEB-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
 
 
Appendix Figure 9.21 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing TREN-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control 
contained no ligand (0µM). 
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Appendix Figure 9.22 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing TRENCAM at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
 
Appendix Figure 9.23 Development of OD630 over 24 hours for P. aeruginosa in BHI broth at 37°C.  
Containing EMECAM at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
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9.4 OD630 Kinetic assay data A. baumannii 
 
Appendix Figure 9.24 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing CTG-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
Appendix Figure 9.25 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing CTG-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
 
Appendix Figure 9.26 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing triazine-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
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Appendix Figure 9.27 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing TEB-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
Appendix Figure 9.28 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing TEB-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
 
 
Appendix Figure 9.29 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing TREN-R-3,2-HOPO  at concentrations given in legend, reported in micromolar.  Control 
contained no ligand (0µM). 
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Appendix Figure 9.30 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing TRENCAM at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
Appendix Figure 9.31 Development of OD630 over 24 hours for A. baumannii in BHI broth at 37°C.  
Containing EMECAM at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
 
Appendix Figure 9.32 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
CTG-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
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9.5 OD630 Kinetic assay data S. aureus 
 
Appendix Figure 9.33 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
CTG-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
 
Appendix Figure 9.34 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
triazine-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
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Appendix Figure 9.35 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
TEB-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
 
 
Appendix Figure 9.36 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
TEB-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
 
Appendix Figure 9.37 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
TREN-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
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Appendix Figure 9.38 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
TRENCAM at concentrations given in legend, reported in micromolar.  Control contained no ligand (0µM). 
 
 
Appendix Figure 9.39 Development of OD630 over 24 hours for S. aureus in BHI broth at 37°C.  Containing 
EMECAM at concentrations given in legend, reported in micromolar.  Control contained no ligand (0µM). 
 
9.6 OD630 Kinetic assay data B. subtilis 
 
Appendix Figure 9.40 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
CTG-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
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Appendix Figure 9.41 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
CTG-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
 
Appendix Figure 9.42 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
triazine-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
 
 
Appendix Figure 9.43 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
TEB-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
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Appendix Figure 9.44 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
TEB-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
 
Appendix Figure 9.45 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
TREN-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no ligand 
(0µM). 
 
 
Appendix Figure 9.46 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
TRENCAM at concentrations given in legend, reported in micromolar.  Control contained no ligand (0µM). 
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Appendix Figure 9.47 Development of OD630 over 24 hours for B. subtilis in BHI broth at 37°C.  Containing 
EMECAM at concentrations given in legend, reported in micromolar.  Control contained no ligand (0µM). 
9.7 OD630 Kinetic assay data C. albicans 
 
Appendix Figure 9.48 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing CTG-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
Appendix Figure 9.49 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing CTG-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
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Appendix Figure 9.50 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing triazine-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
 
 
Appendix Figure 9.51 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing triaizne-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
 
Appendix Figure 9.52 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing TEB-LC-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control 
contained no ligand (0µM). 
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Appendix Figure 9.53 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing TEB-1,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained no 
ligand (0µM). 
 
 
Appendix Figure 9.54 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing TEB-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control contained 
no ligand (0µM). 
 
Appendix Figure 9.55 Development of OD630 over 18 hours for C. albicans in BHI broth at 37°C.  
Containing TREN-R-3,2-HOPO at concentrations given in legend, reported in micromolar.  Control 
contained no ligand (0µM). 
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